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Abstract 
 
Calreticulin (CALR) is an endoplasmic reticulum (ER) protein that plays an important role as a 
calcium (Ca2+) buffering chaperone. Mutations in CALR exon 9 have been identified in 
essential thrombocythemia and primary myelofibrosis, two myeloproliferative neoplasms 
(MPNs) characterised by megakaryocyte hyperplasia. Despite the large body of research built 
around CALR mutations, many aspects of the oncogenic mechanisms of CALR in MPNs remain 
unanswered. This investigation aims to investigate whether CALR mutations affect the nature 
of the C-terminal domain of this protein, its sub-cellular compartmentalisation and its Ca2+ 
buffering activity during megakaryocyte hyperplasia.  Additionally, this study establishes a 
new cellular model to investigate megakaryocyte differentiation in presence of CALR 
mutations.  
In silico analysis of the structural characteristics of CALR mutant C-terminal domain revealed 
that CALR mutations lead to changes in its secondary structure, its protein binding properties 
and changes the acidity of CALR mutant´s C-terminal domain. These physical alterations could 
affect CALR cellular behaviour by leading to inefficient ER Ca2+ buffering activity and lead to a 
novel oncogenic network of protein interactions. 
This study revealed that MARIMO leukemic cell line, which harbours a CALR mutation, has in 
vitro megakaryocyte differentiation potential. Importantly, this discovery was useful for 
further studies aiming to analyse CALR mutant cells during megakaryocyte commitment. 
Moreover, study of CALR mutant cellular localisation showed that this protein is localised 
within the ER, but it is also mislocalised within the cytoplasm and cell membrane, where it co-
localised with thrombopoietin receptor. Interestingly, CALR cell surface expression increased 
during megakaryocyte commitment in CALR mutant cells, showing a dynamic process of CALR 
compartmentalisation during megakaryocyte differentiation.   
One of the more significant findings shown in this study is the emergence of intracellular Ca2+ 
concentrations ([Ca2+I]) as an important element during megakaryopoiesis. Importantly, CALR 
mutations impaired the cellular ER Ca2+ buffering activity and led to changes in the [Ca2+I] 
during the process of megakaryocyte differentiation. In addition, initial experiments revealed 
17 
 
that physical manipulation of [Ca2+I] leads to the emergence of a megakaryocyte phenotype 
in leukemic cells, showing the relevance of this factor during megakaryocyte commitment.  
All together, these findings elucidate novel effects of CALR mutations into the physical and 
functional characteristics of CALR mutant in MPNs, describing new aspects of this driver 
mutation during the oncogenesis of these diseases. Finally, the current data highlight the 
importance of studying the effects of CALR mutations during the process of megakaryocyte 
differentiation, as CALR mutant sub-cellular compartmentalisation and ER Ca2+ buffering 
activity variate during the process of megakaryopoiesis.  
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CHAPTER 1: General background 
 
 
1.1. Overview of normal and malignant megakaryopoiesis  
 
Megakaryocytes are bone marrow cells characterised by a multilobulated or polyploid 
nucleus and a large cytoplasmic diameter (100-150 µm). These cells are the precursors of 
platelets, of which approximately 1x1011 are released daily into the blood stream by a highly 
dynamic process (Wen et al., 2011).  Megakaryocytes are infrequent within the bone marrow, 
as there are only 1 in 103 nucleated cells. Megakaryopoiesis is the complex process of 
megakaryocyte formation which is highly regulated by external factors such as the bone 
marrow stroma, cytokines or hormones (Wen et al., 2011; Machlus et al., 2014).  
During megakaryopoiesis, megakaryocytes derive from haematopoietic stem cells (HSCs) 
through several sequential commitment steps. HSCs are a rare population of cells that reside 
in the bone marrow maintaining the hematopoietic lineage (Ogawa, 1993). These pluripotent 
embryonic cells can differentiate into hematopoietic progenitor cells (HPCs) which will 
subsequently commit into either of two different lineages, the common lymphoid progenitors 
(CLPs) (Kondo et al., 1997) or common myeloid progenitors (CMPs) (Akashi et al., 2000). CLP 
has the capacity to differentiate into lymphoid cells, whereas CMP leads to the development 
of the myeloid cell linage. Firstly, CMP differentiate into more differentiated progenitors, 
known as granulocyte/monocyte progenitors (GMPs) and megakaryocyte/erythroid 
progenitors (MEPs) (Debili et al., 1996). Finally, MEP generates single lineage progenitor cells 
which will finally become mature erythroid or megakaryocyte cells (Figure 1). The proportion 
of each blood cell type is strictly regulated in the bone marrow and therefore, a controlled 
balance between self-renewal and cell differentiation establishes a healthy blood cell 
composition.  
After megakaryocyte differentiation, cell maturation starts with the expression of platelet 
specific genes, increase cell size and an increase in cell ploidy (Bianchi et al., 2016; Zimmet 
and Ravid, 2000). Megakaryocytes ploidy is acquired by a process known as endomitosis, 
where DNA is replicated but there is a lack of cytoplasmic division. During maturation, 
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megakaryocytes migrate close to the vasculature within the bone marrow in response to 
Stromal-derived factor-1α (SDF-1α) (Avecilla et al., 2004). Here, megakaryocytes produce long 
and branched cytoplasmic projections known as demarcation membrane system (DMS) (Junt 
et al., 2007; Schulze et al., 2006). These projections are extended into the bone marrow 
sinusoids lumen and become fragmented, releasing platelets into the circulatory system (Junt 
et al., 2007) (Figure 1).  
Cytokines are produced within the bone marrow microenvironment and these directly 
support megakaryocyte terminal differentiation (Yu and Cantor, 2012).  Thrombopoietin 
(TPO) is known to be the most important cytokine during megakaryopoiesis. TPO and its 
receptor myeloproliferative leukemia protein (MPL) are critical for megakaryopoiesis as seen 
in mouse models where knock down of any of both genes leads to thrombocytopenia (Gurney 
et al., 1994; Bunting et al., 1997). 
 
 
 
 
Megakaryocyte proliferation and apoptosis are highly balanced during megakaryopoiesis to 
reach a tight control of cell production. Nevertheless, when a genetic mutation occurs, this 
balance might be altered leading to an uncontrolled production of megakaryocytes within the 
bone marrow. Megakaryocyte hyperplasia can be described in benign diseases such as 
Figure 1. Megakaryopoiesis.  
Representative diagram of megakaryocyte formation and platelet release within the bone marrow 
(BM). HSC: haematopoietic stem cell, CMP: common myeloid progenitor, MEP: megakaryocyte 
erythrocyte progenitor, TPO: thrombopoietin.  
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idiopathic thrombocytopenia (Ganguly and Cunningham, 2004), however it is mostly 
associated to malignant or clonal disorders such as chronic myelogenous leukaemia 
(Carbonell et al., 1982), acute megakaryocytic leukemia (Hahn et al., 2016) or 
myeloproliferative neoplasms (MPNs).  
 
1.2. Myeloproliferative Neoplasms  
 
Myeloid Neoplasms are a heterogeneous group of stem cell clonal diseases characterised by 
an overproduction of myeloid cells. The 2016 World Health Organisation (WHO) classification 
system for haematopoietic tumours establishes three main categories of neoplasms: Acute 
myeloid leukemia (AML), Myelodysplastic syndromes (MDS) and MPNs (Arber et al., 2016) 
(Table 1).  
AML is a disease characterised by an uncontrolled neoplastic proliferation of myeloid blasts 
cells in the bone marrow. This production of blast cells leads to a disruption of normal 
haematopoiesis and consequently haematopoietic insufficiency and bone marrow failure (De 
Kouchkovsky and Abdul-Hay, 2016). In contrast, MDS are clonal disorders characterised by an 
ineffective haematopoietic process which could transform into AML. Additionally, cytopenias 
and dysmorphogenesis of myeloid cells with dysplastic features are hallmarks of MDS (Gangat 
et al., 2016). On the other hand, MPN display overproduction of functional mature myeloid 
cells, such as erythrocytes or megakaryocytes, within the bone marrow. Additionally, MPN 
patients display risk of AML transformation (Tefferi, 2016a). 
Nevertheless, this classification is not entirely precise, as patients could display symptoms of 
MDS and MPNs. This group of patients are assigned to a category of overlap of MDS/MPN. 
Additionally, the 2016 WHO classification includes myeloid neoplasms associated with 
eosinophilia and abnormalities of PDGFRA, PDGFRB, FGFR1 or PCM1-JAK2, mastocytosis and 
myeloid neoplasms with germ line predisposition as separate categories (Arber et al., 2016).  
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Table 1. The 2016 WHO classification scheme for Myeloid Neoplasms and subcategorisation of 
Myeloproliferative Neoplasms (Arber et al., 2016). 
MYELOID NEOPLASMS 
1) Acute myeloid leukemia (AML) and related neoplasms  
2)Myelodysplastic syndromes (MDS) 
3) Myeloproliferative Neoplasms (MPN)  
          i. Chronic myeloid leukemia (CML), BCR-ABL1+ 
i i. Polycythemia vera (PV)  
          iii. Essential thrombocythemia (ET) 
          iv. Primary myelofibrosis (PMF) 
               PMF, prefibrotic/early stage 
               PMF, overt fibrotic stage 
           v.  Chronic neutrophilic leukemia (CNL) 
           vi. Chronic eosinophilic leukemia, not otherwise specified (NOS) 
           vii. MPNs, unclassifiable 
4) MDS/MPN 
5) Mastocytosis 
5) Myeloid neoplasms associated with eosinophilia and abnormalities of PDGFRA, PDGFRB, or FGFR1, or 
with PCM1-JAK2 
6) Myeloid neoplasms with germ line predisposition 
 
 
1.2.1. Myeloproliferative neoplasms, the emergence of key clonal markers 
The first classification of MPN was registered in 1951 by William Dameshek as 
myeloproliferative disorders (MPDs), which grouped polycythemia vera (PV), essential 
thrombocythemia (ET), erythroleukemia, chronic myelogenous leukaemia (CML) and primary 
myelofibrosis (PMF) based on their clinical and histologic characteristics (Dameshek, 1951). 
Over the years important discoveries based on the molecular pathology of MPNs have led to 
a better understanding of the molecular basis of this heterogeneous group of diseases. The 
latest WHO classification includes seven subcategories in the group of MPNs:  CML BCR-ABL1+, 
Chronic neutrophilic leukaemia (CNL), PV, PMF, ET, Chronic eosinophilic leukaemia (CEL) and 
MPNs-unclassifiable. This classification is based on the molecular and cellular pathology of 
the diseases (Table 1) (Arber et al., 2016).  
The importance of using molecular markers in the classification of MPNs was firstly confirmed 
with the discovery of Philadelphia chromosome (Ph), characteristic of CML. Ph is an aberrant 
chromosomal translocation, t(9;22)(q34;q11), which results in the formation of BCR-ABL 
fusion protein (Nowell, 2007; Quintas-Cardama and Cortes, 2009).  According to molecular 
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characteristics, ET, PMF and PV are categorised as Ph-negative MPN. During recent years, the 
understanding of the molecular basis of these three diseases has increased greatly.  
The discovery in 2005 by four different research groups of a mutation in exon 14 of Janus 
Kinase 2 (JAK2) gene present in a high proportion of PV, ET and PMF patients opened a new 
molecular diagnostic approach of Ph-negative MPNs (Baxter et al., 2005; James et al., 2005; 
Kralovics et al., 2005; Levine et al., 2005). The majority of PV patients (up to 95%) carry this 
mutation, whereas in ET and PMF patients it is found in 50-60% of cases. Further research 
described a gain-of-function mutation in c-MPL gene, which encodes for thrombopoietin  
receptor, in ET and PMF JAK2 negative patients (Pikman et al., 2006). These mutations were 
described as MPN’s driver mutations and were included as clonal markers in the 2008 revision 
of the WHO document for better classification and diagnosis of these diseases (Tefferi and 
Vardiman, 2008). 
Additional studies have described less common mutations including EZH2 or TET2 in MPN 
patients (Delhommeau et al., 2009; Ernst et al., 2010). Although, these somatic mutations 
affect only a small fraction of JAK2 and c-MPL negative MPN patients and therefore they are 
not valuable to use as molecular diagnostic markers of MPNs. However, in 2013 two research 
groups identified a high incidence mutation in the Calreticulin (CALR) gene in MPN patients 
with non-mutated JAK2 and c-MPL, greatly improving the diagnostic approach for these 
pathologies (Klampfl et al., 2013; Nangalia et al., 2013). The 2016 WHO diagnostic criteria of 
ET and PMF included the presence of CALR mutations as a major criterion for a correct 
diagnosis of these diseases (Arber et al., 2016) (Table 2).  
 
1.3. Classic Ph-negative MPNs 
 
ET, PV and PMF are considered as stem cell-derived haematological diseases (Beer et al., 
2009; Tefferi, 2010).  The presence of mutational pathogenic events in Ph-negative MPNs 
occurs in early stages of the hematopoietic process. This has been demonstrated with the 
identification of JAK2 and CALR somatic mutations in hematopoietic progenitor cells 
(Kralovics et al., 2005, Nangalia et al., 2013). Interestingly, these two independent driver 
mutations and c-MPL mutations lead to the emergence of three different clinical phenotypes. 
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However, CALR mutations have only been described in ET and PMF, the two MPNs 
characterised by megakaryocyte neoplasia (Figure 2).  
 
 
 
 
 
 
 
 
 
 
 
1.3.1. Essential thrombocythemia 
ET is a disease characterised by a neoplastic proliferation of megakaryocytes and platelets 
within the bone marrow and the blood stream. Platelets characteristic of this disease are 
functionally and morphologically altered and therefore ET patients display a higher risk of 
bleeding and thrombosis (Klco et al., 2010; Wilkins et al., 2008). 
It is estimated that ET prevalence is about 38-57 per 100,000 individuals (Mehta et al., 2014). 
Approximately the median age range of ET patients at diagnosis is between 50-60 years old 
Figure 2. Schematic diagram of MPNs classification. 
The 2016 WHO latest classification divides MPNs in three major categories: rare MPN, classic MPN and unclassifiable 
MPN.  Classic MPN are classified as Philadelphia chromosome (Ph) positive or Ph negative. Ph negative includes 
Polycythemia Vera (PV) which major molecular pathological feature is JAK2 mutations or Essential thrombocythemia 
(ET) and primary myelofibrosis (PMF) characterised by JAK2, CALR of MPL mutations. Purple shades identify the MPNs 
affected by CALR mutations.  
 
    ET PMF 
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and the incidence of ET has higher prevalence in females (Aruch and Mascarenhas, 2016). 
Clinically, ET is characterised by thrombosis, erythromelalgia, transient ischemic attacks and 
splenomegaly. However, some cases of ET are diagnosed in symptom-free patients during 
routine blood tests (Sanchez and Ewton, 2006).  
The major feature of ET is a platelet count greater than 450,000 x109/L, in addition to further 
diagnostic criteria as listed in Table 2.  JAK2 mutation is the major molecular pathological 
feature, affecting about 50-60% of ET patients. CALR mutation is present in approximately 
30%, followed by c-MPL mutation which affects 5% of patients (Klampfl et al., 2013). 
Nevertheless, the molecular pathogeny of the remaining group of patients with non-mutated 
JAK2, CALR or c-MPL remains elusive.  
Evolution of ET to myelofibrosis varies in the disease duration from the onset of diagnosis. In 
the first decade of diagnosis 3-10% of cases evolve to myelofibrosis and in the second decade 
it increases greatly, to 6-30%. Additionally, ET could progress to AML in a small percentage of 
patients, from 1-2.5% during the first decade of the disease, increasing to 5-8% in the next 
decade (Beer et al., 2011; Sanchez and Ewton, 2006; Wolanskyj et al., 2006). ET patients are 
considered to be at high risk of thrombotic events. However, it is important to note that 
recent investigations have shown a differing risk of thrombosis dependent on the driver 
mutation, as CALR mutated patients show a lower risk of thrombosis than JAK2 and c-MPL 
mutated patients (Rotunno et al., 2014). 
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Table 2. 2016 Who Diagnostic Criteria for PV, ET and PMF 
 
 
 
 
 
 PV ET prePMF Overt PMF 
 
Major 
criteria 
1.  Hgb>16.5 g/dL 
(men) 
> 16.0 g/dL (women) 
Or 
Hematocrit >49% 
(men) 
Hematocrit >48% 
(women) 
Or 
Increased in cell mass 
1.  Platelet count ≥ 450 x 
109/L 
1. Megakaryocytic 
proliferation and atypia, 
without reticulin fibrosis 
grade 1, accompanied by 
increased age-adjusted 
BM cellularity, 
granulocytic proliferation, 
and often 
decreased erythropoiesis 
1. Presence of 
megakaryocytic 
proliferation and 
atypia, 
accompanied by 
either reticulin 
and/or collagen 
fibrosis grades 2 
or 3 
2. BM biopsy showing 
hypercellularity for 
age with 
trilineage growth 
including 
prominent erythroid, 
granulocytic, and 
megakaryocytic 
proliferation with 
pleomorphic, 
mature 
megakaryocytes 
(differences in size) 
2.  Megakaryocyte 
proliferation with large 
and mature 
morphology. No 
significant increase in 
neutrophil 
granulopoiesis or 
erythropoiesis and 
minor increase in 
reticulin fibres 
 
 
 
2.  Not meeting WHO criteria for CML, PV, 
MDS, or other myeloid neoplasm 
3.  Presence of 
JAK2V617F or 
JAK2 exon 12 
mutation 
3.   Not meeting WHO 
criteria for CML BCR-
ABL+, PV, PMF, MDS, or 
other 
myeloid neoplasm 
3.   Presence of JAK2, CALR or c-MPL mutation 
or in the absence of these mutations, 
presence of another clonal marker or absence 
of minor reactive BM reticulin fibrosis 
4. Presence of JAK2, 
CALR or c-MPL mutation 
 
Minor 
criteria 
1.  BM 
trilineage 
myeloproliferation 
1. Presence of a clonal 
marker or absence of 
evidence for reactive 
thrombocytosis 
 
1.  Leukocytosis  ≤11x 109/L 
2. Subnormal serum 
Epo level 
2.  Increased serum LDH level 
3. EEC growth 3.  Anemia 
4.  Palpable splenomegaly 
5. Leukoerythroblastosis 
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1.3.2. Primary myelofibrosis  
 
PMF is a myeloproliferative disorder associated with a neoplastic proliferation of 
megakaryocytes, abnormal cytokine expression and reactive bone marrow fibrosis (Tefferi, 
2016b). Increased bone marrow fibrosis leads to ineffective erythropoiesis and consequently 
severe anemia. Additional clinical manifestations in PMF include hepatosplenomegaly, 
thrombosis, bone pain and bleeding, among others (Tefferi and Nagorney, 2000). 
The prevalence of PMF is lower than ET, being 4-6 per 100,000 individuals and prevalence of 
MF post-ET and post-PV varies between 0.5-1.1 and 0.3-0.7 per 100,000 respectively (Mehta 
et al., 2014). It is estimated that median age at PMF diagnosis is approximately 65 years old 
and there are not significant differences between sex (Tefferi and Nagorney, 2000).  
The revised 2016 WHO criteria distinguished two new subcategories within PMF, known as 
prefibrotic (prePMF) and overtly fibrotic PMF (Arber et al., 2016). Pre and overt PMF 
diagnostic criteria are listed in Table 2. Careful diagnosis must be done in prePMF, as it shares 
a similar mutation profile with ET (60% JAK2 mutation, 35% CALR mutation, 10% c-MPL 
mutation approximately) (Tefferi and Pardanani, 2014). Therefore, cautious analysis of 
megakaryocyte characteristics is recommended to distinguish between the two diseases 
(Tefferi, 2016b). PMF has the worst survival rates of Ph-negative MPNs and has the higher risk 
to develop into AML (5-30%) (Mesa et al., 2005; Klco et al., 2010).  
 
1.4. JAK-STAT signalling, a key cellular pathway in megakaryopoiesis and MPNs 
pathogenesis 
 
The JAK/STAT pathway is a conserved cell signalling cascade involved in development and 
present in a diverse range of species from flies to humans. This signalling pathway is an 
important cellular mechanism to transduce cytokine and growth factor signals, being involved 
in central cellular processes such as cell differentiation and proliferation, as well as playing 
important roles in the haematopoietic and immune system development (Rawlings et al., 
2004). 
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JAK/STAT signal transduction is mediated by two main protein families: JAKs (JAK1-3 and Tyr) 
and signal transducer and activator of transcription (STATs) (STAT1-4, STAT5a, STAT5b and 
STAT6).  Intracellular JAK/STAT cascade activation occurs when cytokine ligands bind and 
stimulate a conformational change of the receptor, inducing the multimerization of the 
receptor subunits (Rawlings et al., 2004). Receptors involved in JAK/STAT signalling lack 
intrinsic kinase activity. Receptor dimerization or oligomerization brings JAK kinases 
associated to the receptor subunits into proximity. This allows the trans-phosphorylation of 
JAK kinases and consequently an increase in their enzymatic activity (Ihle and Gilliland, 2007). 
As a result, the active receptor complex recruits dormant cytoplasmic transcription factors, 
known as STATS. Phosphorylated STAT proteins dimerize and translocate from the cytoplasm 
to the cellular nucleus. STAT dimers bind to specific DNA regions known as Gamma-interferon 
activated sequences (GAS) and Interferon-Stimulated Response Element (ISRE), activating or 
repressing gene transcription (Lim and Cao, 2006). JAK-STAT pathway displays a negative 
feedback loop in order to control its own signalling.  There are three major protein families 
involved in the negative regulation of this pathway: protein inhibitor of activated stats (PIAS), 
suppressors of cytokine signalling (SOCS) and protein tyrosine phosphatases (PTPs) 
(Greenhalgh and Hilton, 2001) (Figure 3).  
In theory, JAK/STAT signalling is a simple cellular pathway; however, this cascade cross-talks 
with more complex signalling pathways such as the mitogen-activated protein kinase (MAPK) 
pathway (Rawlings et al., 2004).  For example, SOCS-3 binds and inhibits RasGAP, a negative 
regulator of Ras protein, leading to Ras activation (Cacalano et al., 2001). Moreover, MAPK 
pathway can promote the activation of JAK/STAT pathway by different mechanisms. It has 
been shown that activation of epidermal growth factor receptor (EGFR) results in an 
activation of STATs without the interaction of JAK proteins (Park et al., 1996).  In addition to 
MAPK, other signalling pathways have been shown to interact with JAK/STAT signalling, such 
as phosphoinositide 3-kinase (PI3K) pathway (Abell and Watson, 2005).   
The JAK/STAT pathway plays a key role during megakaryopoiesis by transducing signals from 
TPO, an essential cytokine during this process (Geddis, 2010). Altered TPO signalling is 
characteristic of PMF, ET and PV. Interestingly, two of the most common driver mutations 
described in these diseases affect two key components of this pathway, MPL and JAK2, 
leading to a deregulated JAK/STAT signalling. Thus, strong efforts are being made for the 
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development of therapies targeting the inhibition of JAK/STAT cascade for the treatment of 
MPNs. For example, Ruxolitinib is a selective inhibitor of JAK1/2 approved for myelofibrosis 
treatment (Quintas-Cardama et al., 2010) which shows reductions in myelofibrotic symptoms 
and improved quality of life in ET and PMF patients (Harrison et al., 2012). Importantly, a 
previous study revealed a high correlation between the mutation profile in PMF patients and 
the response rate to Ruxolitinib (Patel et al., 2015). This highlights the importance of 
enhancing our understanding of the pathology of MPN driver mutations (JAK2, CALR and c-
MPL) for a correct treatment of these neoplasms based on the molecular profile of MPN 
patients.  
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Figure 3. JAK-STAT signalling pathway. 
Cytokines ligands bind to the hematopoietin receptors leading to the activation of JAK proteins. These 
proteins phosphorylate the intracellular domain of the receptor, leading to the formation of docking 
sites for downstream signalling proteins, such as STATS. Active STATS translocate into the nucleus and 
active the transcription of target genes. SOCS gene expression is dependent on this signalling pathway 
and act as a negative feedback loop of this cytokine dependent pathway. 
Ruxolitinib 
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1.5. Classic mutations in Ph-negative MPNs  
 
1.5.1. JAK2 mutations 
JAK2 protein, member of the JAK family proteins, is a known non-receptor tyrosine kinase 
involved in signal transduction of JAK-STAT pathway.  JAK2 gene is located in chromosome 
9p24 and comprises 25 exons.  Oncogenic JAK2V617F mutation is the most frequent mutation 
in Ph-negative MPN patients (Baxter et al., 2005). Additionally, it has been detected in other 
myeloproliferative diseases, such as CML and AML (Hussein et al., 2008; Kiladjian, 2012). The 
JAK2V617F somatic mutation found in hematopoietic cells is characterised by a transversion of 
guanine (G) for thymine (T) leading to a substitution of phenylalanine (F) for valine (V). This 
mutation leads to a constitutively active JAK2 (Kralovics et al., 2005).   
MPN patients carrying JAK2V617F mutations are older than patients negative for these 
mutations. Additionally, JAK2V617F mutation shows a more aggressive clinical phenotype, with 
a higher incidence of complications such as haemorrhage, thrombosis and secondary fibrosis 
(Kralovics et al., 2005).  
 
1.5.2. c-MPL mutations 
After the identification of JAK2 mutations in PV, ET and PMF patients, research was focussed 
on the identification of the molecular pathology of JAK2 negative patients. Shortly after the 
discovery of JAK2V617F, the gain-of-function mutation cMPLW515L was described in ET and PMF 
JAK2 negative patients (Pikman et al., 2006). c-MPL mutation consists in a G to T transition in 
exon 10, leading to a tryptophan to leucine substitution. This oncogenic event results in 
constitutive active JAK/STAT, MAPK and PI3K pathways (Chaligne et al., 2008). Presence of c-
MPL mutation in ET patients is associated with the elderly, low haemoglobin levels, 
thrombocytosis and microvascular symptoms (Vannucchi et al., 2008). 
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1.6. Calreticulin, a novel driver mutation in MPNs 
 
After the identification of JAK2 and c-MPL mutations a big subset of MPN patients were 
considered as c-MPL and JAK2 negative and no driver mutation was known in this group of 
patients. However, in 2013 two different investigations revealed by using whole-exome 
sequencing that CALR was mutated in this group of MPNs patients (Klampfl et al., 201; 
Nangalia et al., 2013). CALR mutations were described as “indels” within exon 9, generating a 
+1 bp frameshift. Several types of CALR mutations have been identified; all leading to a 
mutant protein with an altered C-terminal region. The amino acid sequence of CALR mutants 
described in ET and PMF patients are shown in Table 3, of which two mutations are described 
as the most common mutation variants: a 52-bp deletion, L367fs*46 (type 1), and a 5 bp 
insertion, K385fs*47 (type 2) (Nangalia et al., 2013).  
CALR mutations were identified in patients with ET and PMF and these mutations were 
mutually exclusive with JAK2 and c-MPL mutations. CALR mutations have been described as 
the second most common driver mutations after JAK2 in both diseases. In contrast, no CALR 
mutations were identified in PV patients (Klampfl et al., 2013; Nangalia et al., 2013). However, 
there is strong evidence supporting that CALR and JAK2 mutated disease phenotypes are 
different, suggesting two different facets of these diseases based in the molecular pathology 
(Rumi et al., 2014). JAK2 and CALR mutated ET and PMF are described as distinct disease 
entities with different clinical outcomes (Rumi et al., 2014; Pietra et al., 2015). Moreover, 
recent studies have characterised the link between CALR mutations subtypes and different 
clinical phenotype in MPNs (Cabagnols et al., 2015; Pietra et al., 2015).  CALR type 1 mutations 
have been mainly associated with a myelofibrotic phenotype and this mutation has been 
identified in ET with high risk of myelofibrotic progression (Pietra et al., 2015; Cabagnols et 
al., 2015). In contrast, type 2 mutations are usually associated with ET phenotype. 
Interestingly, patients with type 2 mutations display higher platelet counts and a lower risk of 
thrombosis than JAK2 mutant (Cabagnols et al., 2015; Pietra et al., 2015). Therefore, the 
studies presented thus far provide evidence that molecular profiling is essential for a correct 
diagnosis and for a better selection of therapy for each individualised patient.  
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Table 3. Described CALR mutations in MPN patients. 
Mutant sequences are highlighted in grey (Nangalia et al., 2013) 
 
 
 
 
 
Name Amino acid sequence 
Deletions 
L367fs*46 
E370fs*43 
E370fs*48 
L367fs*48 
L367fs*44 
K368fs*51 
L367fs*52 
R366fs*53 
E371fs*49 
K368fs*43 
E370fs*37 
D373fs*47 
K374fs*53 
E371fs*49 
 
QDEEQRTRRMMRTKMRMRRMRRTRRKMRRKMSPARPRTSCREACLQGWTEA 
QDEEQRLKEVMRTKMRMRRMRRTRRKMRRKMSPARPRTSCREACLQGWTEA 
QDEEQRLKEQRTRMMRTKMRMRRMRRTRRKMRRKMSPARPRTSCREACLQGWTEA 
QDEEQRQRTRRMMRTKMRMRRMRRTRRKMRRKMSPARPRTSCREACLQGWTEA 
QDEERRMMRTKMRMRRMRRTRRKMRRKMSPARPRTSCREACLQGWTEA 
QDEEQRLRRRQRTRRMMRTKMRMRRMRRTRRKMRRKMSPARPRTSCREACLQGWTEA 
QDEEQRRRRRQRTRRMMRTKMRMRRMRRTRRKMRRKMSPARPRTSCREACLQGWTEA 
QDEEQKRRRRQRTRRMMRTKMRMRRMRRTRRKMRRKMSPARPRTSCREACLQGWTEA 
QDEEQRLKEERQRTRRMMRTKMRMRRMRRTRRKMRRKMSPARPRTSCREACLQGWTEA 
QDEEQRLMMRTKMRMRRMRRTRRKMRRKMSPARPRTSCREACLQGWTEA 
QDEEQRLKERMRRMRRTRRKMRRKMSPARPRTSCREACLQGWTEA 
QDEEQRLKEEEERTRRMMRTKMRMRRMRRTRRKMRRKMSPARPRTSCREACLQGWTEA 
QDEEQRLKEEEEDKRRRRQRTRRMMRTKMRMRRMRRTRRKMRRKMSPARPRTSCREACLQGWTEA 
QDEEQRLKEERTRRMMRTKMRMRRMRRTRRKMRRKMSPARPRTSCREACLQGWTEA 
Insertions 
K385fs*47 
K385fs*47 
 
QDEEQRLKEEEEDKKRKEEEEAEDNCRRMMRTKMRMRRMRRTRRKMRRKMSPARPRTSCREACLQGWTEA 
QDEEQRLKEEEEDKKRKEEEEAEDLCRRMMRTKMRMRRMRRTRRKMRRKMSPARPRTSCREACLQGWTEA 
Complex 
R376fs*55 
K385fs*47 
E381fs*48 
 
QDEEQRLKEEEEDKKLCKRRRRQRTRRMMRTKMRMRRMRRTRRKMRRKMSPARPRTSCREACLQGWTEA 
QDEEQRLKEEEEDKKRKEEEEAEDSCRRMMRTKMRMRRMRRTRRKMRRKMSPARPRTSCREACLQGWTEA 
QDEEQRLKEEEEDKKRKEEEDPCRRMMRTKMRMRRMRRTRRKMRRKMSPARPRTSCREACLQGWTEA 
33 
 
Major efforts have been undertaken to improve the molecular diagnosis of MPN patients. 
Identification of CALR mutations in MPN patients is an important step towards a correct 
categorisation of the disease. Recent investigations have been focussed on the development 
of efficient techniques for the detection of CALR mutations. Importantly, 
immunohistochemistry to detect the CALR mutant in MPNs patients’ samples is highly specific 
for these mutations, showing that this technique could be very valuable for routine diagnostic 
tests (Andrici et al., 2016). Furthermore, a novel technique using screening PCR has been 
proved to be satisfactory when detecting CALR mutations in primary bone marrow samples 
(Jeong et al., 2016). Additionally, recent publication revealed the development of a next 
generation sequencing assay that could significantly improve the screening of MPN driver 
mutations during the diagnostic process (Frawley et al., 2018).   
 
In addition to an accurate diagnosis based on the characterisation of the molecular driver 
mutations of the disease, a deep knowledge of the cellular and molecular basis of these 
mutations is essential for a correct understanding of MPN’s biology. As such, analyses of the 
CALR cellular functions and the mechanisms of CALR mutations oncogenicity are essential to 
shed light on its contribution to the pathogenesis and prognosis of MPNs.  
  
 
 
1.6. Calreticulin: a multifunctional cellular protein 
 
CALR is a chaperone and a Ca2+ buffering protein that resides in the lumen of the endoplasmic 
reticulum (ER). CALR gene comprises 5891 bp and is localised on chromosome 19. The 
obtained protein is formed by 417 amino acids and has three functional and structural 
domains (Figure 4). The N-terminal domain includes carbohydrate and polypeptide binding 
sites (Leach et al., 2002). In addition, Zn2+ binding sites have been described to be in this 
domain (Baksh et al., 1995). The proline rich domain also contains carbohydrate and 
polypeptide binding sites and contains a specific binding region to interact with ER 
chaperones, such as ERp57 (Frickel et al., 2002). In vitro analyses have shown that this region 
has high binding affinity and low capacity Ca2+ binding residues (Baksh and Michalak, 1991). 
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The CALR C-terminal domain plays an important role in Ca2+ buffering as it binds to over 50% 
of ER Ca2+ due to the presence of a high number of negatively charge amino acids (Nakamura 
et al., 2001b). These residues have low Ca2+ binding affinity and high capacity.  Finally, CALR 
C-terminal domain contains the ER retention/retrieval motif, known as KDEL (Lys-Asp-Glu-
Leu). This motif ensures the retrieval of this protein from the Golgi apparatus to the ER (Figure 
4) (Sonnichsen et al., 1994). 
 
 
 
 
 
 
 
 
1.6.1. CALR chaperone activity 
 
ER is a key cellular organelle essential for protein synthesis and folding. CALR resides mostly 
within the lumen of the ER where it functions as a chaperone of nascent glycoproteins, 
ensuring appropriate protein folding (Figure 5).  Once glycoprotein chains are synthesised 
within the ER, two terminal glucose residues are removed in a sequential manner from the 
oligosaccharide region of these proteins by glucosidase I and II. This ensures the exposure of 
a Glc1Man9GlcNAc2 epitope that is recognised by CALR and calnexin (CNX) (Caramelo and 
Parodi, 2008). These two lectin chaperones work together to cover a broader range of 
substrates depending on the topology of the nascent glycoproteins. CNX will bind to proteins 
next to the ER membrane and CALR will bind to soluble glycans (Hebert et al., 1997). 
Figure 4. Calreticulin protein and its functional domains. 
CALR is formed by 417 amino acids and it comprises three domains: N-terminal domain, Proline-rich domain 
and C-terminal domain. Each domain is essential for CALR functions within the cell. Importantly, KDEL region 
(ER retention motif) is located at the end of the C-terminal domain.  
 
      N-domain Pro rich-domain C-domain 
      
Chaperone activity 
Zn
2+
 binding 
Chaperone activity 
Ca
2+
 binding 
Proline rich 
ERP57 binding 
ER retrieval signal 
Ca
2+
 binding and buffering 
activity 
KDEL 
1 187 307 417 
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Intermediated folded glycoproteins interact with CALR/CNX for final protein folding. Then, 
folded proteins are rapidly deglucosylated and finally are secreted out of the ER. However, 
glycoproteins for which folding is not complete enter into the “CNX/CALR cycle”. Once final 
deglucosylation is completed they are returned to the cycle by glucosidase I, which adds a 
glucose residue to the chain. Then, glycan interacts again with CALR/CNX upon correct protein 
folding (Hebert and Molinari, 2007). CALR depletion leads to a decline of glycoprotein quality 
control (Molinari et al., 2004). 
 
1.6.2. CALR calcium buffering activity 
 
The ER is the main Ca2+ storing organelle within the cell. Reticular Ca2+ is essential for a variety 
of cellular processes, such as gene expression, cell signalling and protein synthesis (Sammels 
et al., 2010).  CALR is one of the most important Ca2+ chaperones within the ER, binding to 
50% of total ER luminal Ca2+ stores (Figure 5).  In its C-terminal acidic domain there are high 
capacity Ca2+ binding residues that bind to 25 mole of Ca2+ per mole of CALR with low Ca2+  
binding affinity (Kd= 2 mM) (Baksh and Michalak, 1991, Nakamura et al., 2001b). Mutations 
affecting this protein domain decrease its Ca2+ buffering activity (Breier and Michalak, 1994). 
Additionally, CALR contains high affinity binding residues (Kd = 10 µM) with low Ca2+   binding 
capacity, equivalent to 1 mole of Ca2+ per mole of protein (Baksh and Michalak, 1991; 
Nakamura et al., 2001b). CALR overexpressing cells show an increase in intracellular Ca2+   
storage and a reduced amount of Ca2+   influx within the ER lumen (Mery et al., 1996). In 
contrast, cells without CALR show a decrease in Ca2+ storage capacity, however, free luminal 
Ca2+  remains the same (Nakamura et al., 2001b).  
 
CALR Ca2+ homeostatic activity could have a key role during cardiac development. CALR null 
mice are not viable due to altered cardiac development and CALR gene is highly expressed 
during early stages of cardiac development (Mesaeli et al., 1999).  Additionally, mice 
transiently over-expressing CALR leads to arrhythmia and death induced by heart block 
(Hattori et al., 2007; Nakamura et al., 2001a). These results suggest a critical role of CALR 
during embryonic heart development and in the pathogenesis of cardiac cycle. Moreover, 
CALR and its Ca2+ homeostasis activity is associated with adipocyte cell differentiation (Szabo 
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et al., 2008) and osmotic stress in cells within the ascending limb of Henle’s loop (Bibi et al., 
2011).   
 
 
 
 
 
 
 
 
 
 
Figure 5. Schematic representation of CALR cellular functions. 
CALR is involved in several cellular functions. Within the endoplasmic reticulum (ER) CALR is involved in calcium 
homeostasis and protein folding. CALR population in the cytoplasm is involved in cell adhesion by integrin 
interactions and it also interacts with hormone receptors. Within the cell membrane, CALR induces immunogenic 
cell death and the in extracellular matrix it is involved in wound healing.  
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1.6.3. CALR functions out of the ER 
 
CALR functions in the cytoplasm 
 
CALR is also compartmentalised in the cytoplasm although the cytoplasmic levels of CALR are 
minor compared with CALR population in the ER lumen (Shaffer et al., 2005).  Here CALR has 
been associated with several cellular processes, such as cell adhesion (Figure 5). CALR 
specifically binds to the KXGFFKR sequence of the cytoplasmic tail of α-integrins mediating 
integrin activation (Coppolino et al., 1997) and transducing Ca2+ signalling between integrins 
and Ca2+ channels such as IP3R (Kwon et al., 2000).  
 
Further studies suggested that CALR interacts with hormone receptors, such as glucocorticoid 
receptors (GR) (Figure 5). Nuclear hormone receptors contain in their DNA binding domain a 
homologous protein sequence of the cytoplasmic tail of integrins, KXFFKR. CALR interacts with 
this sequence and inhibits the direct binding of nuclear hormone receptors to the DNA 
hormone response elements (Dedhar et al., 1994). Additionally, CALR induces the nuclear 
export of GR (Holaska et al., 2001). Therefore, CALR directly regulates the transcriptional 
activity of these receptors.  
 
 
CALR functions in the cell surface 
 
CALR cell surface expression is a relevant process for immunogenic cell death (Figure 5). CALR 
exposure on the plasma membrane is induced by anthracyclines, radiotherapy and Ca2+ 
depletion ER stores (Tufi et al., 2008; Wemeau et al., 2010). Apoptotic and cancer cells express 
CALR within the cell surface and this is recognised by dendritic cells as an “eat me” signal 
(Wijeyesakere et al., 2016). Inhibition of CALR cell surface expression in anthracycline treated 
cells leads to depletion of immunogenic cell death (Obeid et al., 2007). Investigations 
targeting CALR translocation to the cell surface are revealing important information for cancer 
research. For example, in AML patients, CALR cell surface expression facilitates immunogenic 
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cell death in response to chemotherapy (Wemeau et al., 2010). However, the molecular 
mechanisms of cell death driven by CALR cell surface expression remain to be clarified.  
 
CALR functions in the extracellular matrix  
 
Extracellular CALR is involved in wound healing and tissue remodelling (Figure 5). CALR 
significantly increases wound repair by upregulating the expression of certain growth factors 
such as transforming growth factor-β3, an important regulator of cutaneous repair (Nanney 
et al., 2008). Additionally, in vitro analyses show that CALR in the extracellular matrix induces 
cell proliferation and migration of fibroblasts, vascular endothelial cells and keratinocytes 
(Nanney et al., 2008). The importance of CALR for tissue repair and healing is being 
investigated for its potential use as a potent therapeutic agent to treat diabetic wound healing 
and chronic wounds (Greives et al., 2012).  
 
 
 
1.7. Oncogenicity of CALR mutations in MPNs 
 
Since 2013, several major efforts have been made to increase the understanding of CALR 
mutant cellular behaviour and its role as a MPN driver mutation. All the CALR mutations 
described in ET and PMF affect a highly conserved amino acid sequence at the end of the C-
terminal domain of this protein (Klampfl et al., 2013; Nangalia et al., 2013) (Figure 6). As 
previously mentioned, this domain plays an important role in the correct functioning of CALR, 
as it contains the major Ca2+ binding sites within the protein. Additionally, CALR C-terminal 
domain is characteristic of its highly structural instability and it has been proposed that its 
spatial conformation might be in close relationship with its Ca2+ buffering activity and its 
protein binding functions (Migliaccio and Uversky, 2017). CALR mutations are thought to 
change the nature of this domain, by altering its chemical and physical characteristics 
(Shivarov et al., 2014; Eder-Azanza et al., 2014), possibly leading to abnormal CALR behaviour 
within the cell.  
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When CALR was described as a novel MPN driver mutation, there was an initial surprise 
regarding the finding of an ER chaperone to be involved in the development of ET and PMF.  
CALR mutations did not, apparently, have a direct link with a deregulated JAK/STAT signalling 
pathway, as previously described in JAK2 and c-MPL mutations. Therefore, investigating the 
link between CALR mutations, deregulated signalling network and MPNs progression has 
been a continuous concern within the field.  
Recent in vivo studies have been focused in elucidating the role of mutant CALR in the 
development of MPN.  Retroviral (Marty et al., 2015) and transgenic (Shide et al., 2017) 
studies demonstrated that CALR mutations are sufficient to generate specific MPN phenotype 
in mice. These studies showed that CALR type 1 mutant expressing mice developed high levels 
of myelofibrosis accompanied with splenomegaly and thrombocytosis (Marty et al., 2015). In 
contrast CALR type 2 mutation expressing mice showed ET-like phenotype. Both mutant mice 
showed increased platelet counts and an amplified megakaryocyte lineage (Marty et al., 2015; 
Shide et al., 2017).  Moreover, CALR mutant mice harbouring a deleted CALR exon 9 did not 
show any disease phenotype, demonstrating that the novel C-terminal domain of CALR 
mutants is essential for disease induction (Marty et al., 2016).   
Figure 6. Schematic representation of the CALR conserved sequence affected by mutations found in 
MPN. 
CALR mutations affect a highly conserved sequence within CALR C-terminal domain, which includes high 
capacity and low affinity Ca2+ binding sites and KDEL region. The amino acid conservation rate within the 
affected C-terminal domain is represented by shading. Blue displaying highly conserved residues and light 
grey indicates less conserved regions. Purple circles represent Ca2+ binding motifs. 
      N-domain Pro rich-domain C-domain KDEL 
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Drosophila 
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Further studies have been foccussed on elucidating the direct link between CALR mutation 
and JAK/STAT signalling pathway. It is now known that MPL receptor is essential for CALR 
mutant MPN progression, as CALR mutants directly interact with this receptor leading to its 
activation (Chachoua et al., 2016; Elf et al., 2016; Araki et al., 2016). Activation of MPL 
receptor by CALR mutant binding is dependent on the N-glycosylation residues located in the 
extracellular domain of this receptor and the glycan binding site of the N-terminal domain of 
CALR mutant (Chachoua et al., 2016; Araki et al., 2016). FLAG-tagged CALR mutants used for 
immunoprecipitation studies showed that mutant CALR physically interacts with MPL 
receptor and that the positively charged amino acids localised within the novel C-terminal 
domain are essential for this direct interaction (Elf et al., 2016).  
 
Despite the described interaction between CALR mutants and MPL receptor, the 
understanding of the consecutive deregulated signalling cascade leading to CALR oncogenicity 
remains an intense debate within the field. RNA sequencing of Ba/F3 murine cells co-
expressing CALR mutant and MPL receptor revealed an enrichment of STAT5/3 gene 
signatures and additional western blot analysis corroborated the activation of JAK/STAT 
signalling cascade in these cells (Elf et al., 2016; Marty et al., 2016). Moreover UT-7 cells 
expressing CALR mutations displayed high levels of JAK2, ERK1/2 and STAT5 phosphorylation 
in the absence of TPO within the media (Araki et al., 2016). Additionally, the CALR-MPL 
downstream pathway was blocked by JAK2 inhibitors in these cells (Araki et al., 2016; Elf et 
al., 2016).  On the other hand, a novel study revealed that megakaryopoiesis in CALR driven 
MPNs might be mediated by MAPK pathway, together with JAK/STAT signalling (Kollmann et 
al., 2016). Moreover, analysis of ET primary megakaryocytes revealed that STAT5/3 target 
genes are highly expressed in JAK2 ET patients, compared with the CALR mutant group (Lau 
et al., 2015).  Overall, these studies suggest further complexity in the cellular signalling of 
CALR mutant MPNs and highlight the need for additional analyses to decipher the molecular 
pathogenesis of these diseases (Figure 7).  
CALR mutations have been described only in MPNs characterised by megakaryocyte 
hyperplasia. Of note, previous research has linked the presence of CALR mutants with 
induction of megakaryocyte differentiation. Interestingly, CALR mutants drive the expression 
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of specific megakaryocytic genes, such as CD41 and c-MPL (Han et al., 2016), however, the 
molecular mechanism linking CALR mutations and the mechanism of induction of 
megakaryopoiesis remains unclear (Figure 7).  
Despite the intense work performed in the last few years characterising CALR mutations in ET 
and PMF, there are many aspects of this novel mutation that remain to be studied. CALR is a 
multifunctional protein, which plays important roles within the ER, cytoplasm, cell membrane 
and ECM. Therefore, mutant CALR might show an alteration in its normal cellular functions 
during disease. For instance, very little is known about the effects of CALR mutations on its 
Ca2+ buffering activity. One recent study demonstrated that CALR mutant primary 
megakaryocytes displayed an abnormal Ca2+ buffering capacity (Pietra et al., 2015). However, 
further investigation is needed to analyse the consequences of altered Ca2+ buffering activity 
in megakaryocyte hyperplasia during MPNs.  
Recent publication revealed that a previously established cell line, known as MARIMO, 
harbours CALR mutation (Kollmann et al., 2015). This cell line was established from a 
secondary AML patient that evolved from ET treatment (Yoshida et al., 1998). The discovery 
of CALR mutation within a common cultured cell line facilitated the analysis of the pathogenic 
role of this mutation. However, MARIMO cells are leukemic blast cells and therefore are not 
committed into the megakaryocytic lineage, hence their differentiation stage is important to 
bear in mind when using this cell line to analyse the effects of CALR mutations in ET and PMF. 
Interestingly, analysis of JAK/STAT signalling pathway using MARIMO cells revealed that these 
cells are not dependent on this cascade (Kollmann et al., 2015) and in contrast show an 
overactivated MAPK pathway (Kollmann et al., 2016). 
 
 
 
 
 
 
42 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. CALR mutant oncogenic activity. 
CALR mutant has been shown to interact with MPL receptor, leading to an aberrant cell 
signalling. However, the exact mechanism of CALR mutant oncogenicity remains unclear.  ER: 
Endoplasmic reticulum, ET: essential thrombocythemia, PMF: primary myelofibrosis 
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1.8. General hypothesis and aims of this study 
 
Despite the large body of research built around CALR mutations in MPNs during recent years, 
many aspects of its oncogenic mechanisms remain unanswered. This investigation has 
worked under the hypothesis that CALR mutations affect the nature of the C-terminal domain 
of this protein and this not only leads to deregulated signalling cascades, but there is also a 
modification of CALR normal cellular behaviour, such as its cellular compartmentalisation and 
its Ca2+ buffering activity.  
CALR C-terminal domain is a highly important region for CALR protein binding and Ca2+ 
buffering and its structural and physical properties have been directly linked to its biological 
functions (Migliaccio and Uversky, 2017). A key question is whether CALR novel C-terminal 
domain in MPNs leads to changes in the structure of this region, and therefore affects CALR 
cellular functions. Thus, this thesis seeks to examine the structural properties of CALR 
mutants’ C-terminal domain and identify potential novel protein binding regions within this 
domain.  
CALR mutations lead to the deletion of the KDEL region, an ER retention motif described 
within the C-terminal domain (Klampfl et al., 2013; Nangalia et al., 2013). Changes in the sub-
cellular compartmentalisation of this mutant protein could lead to major effects within the 
cell. Therefore, the second aim of this study was to investigate the possible changes of CALR 
mutant sub-cellular localisation.  
Differences in the physical characteristics of CALR C-terminal domain and in the 
compartmentalisation of this protein could lead to alterations in the Ca2+ buffering activity of 
the cell. However, little is known about the importance of Ca2+ during megakaryopoiesis in 
physiological condition and disease (Di Buduo et al., 2016). Therefore, this research aims to 
characterise the importance of Ca2+ during normal megakaryocyte differentiation conditions 
and the possible effects of CALR mutations in the Ca2+ buffering activity of CALR mutant cells 
during megakaryocyte differentiation.  
Finally, the limited available cellular models harbouring CALR mutations hinder the study of 
the pathogenic role of CALR mutations during megakaryocyte hyperplasia. The recent 
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characterisation of CALR mutation in MARIMO leukemic cell line allowed the study of CALR 
mutation in vitro using routine cell culture techniques without the use of transduction or 
transfection techniques (Kollmann et al., 2015). However, the best cellular model used to 
study CALR mutation would be the use of a cell line committed into the megakaryocyte 
lineage to mimic ET and PMF pathological cellular conditions. Thus, this investigation aims to 
analyse the possible megakaryocyte differentiation potential of MARIMO cells which could be 
useful for the understanding of CALR oncogenicity during megakaryocyte proliferation in ET 
and PMF harbouring CALR mutations.  
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CHAPTER 2: Material and Methods 
 
 
2.1. Computational methods 
 
2.1.1. Input sequences 
The sequence of 417 amino acids of Homo Sapiens Calreticulin (CALR) was retrieved from 
Swiss Prot database (http://www.uniprot.org/uniprot/P27797) (Table 4). CALR mutant 
sequences of type 1 mutation (L367fs*46) and type 2 mutation (K385fs*47) were obtained 
from previous literature (Nangalia et al., 2013).  
Table 4. CALR amino acid sequences used in this study. 
 C-terminal domain sequence is in bold and mutant sequences are underlined.  
 
 
Name Amino acid  sequence 
 
CALR WT 
MLLSVPLLLGLLGLAVAEPAVYFKEQFLDGDGWTSRWIESKHKSDFGKFVLSSGKFYGDEE
KDKGLQTSQDARFYALSASFEPFSNKGQTLVVQFTVKHEQNIDCGGGYVKLFPNSLDQTD
MHGDSEYNIMFGPDICGPGTKKVHVIFNYKGKNVLINKDIRCKDDEFTHLYTLIVRPDNTYE
VKIDNSQVESGSLEDDWDFLPPKKIKDPDASKPEDWDERAKIDDPTDSKPEDWDKPEHIP
DPDAKKPEDWDEEMDGEWEPPVIQNPEYKGEWKPRQIDNPDYKGTWIHPEIDNPEYSP
DPSIYAYDNFGVLGLDLWQVKSGTIFDNFLITNDEAYAEEFGNETWGVTKAAEKQMKDK
QDEEQRLKEEEEDKKRKEEEEAEDKEDDEDKDEDEEDEEDKEEDEEEDVPGQAKDEL 
CALR type 1 
mutation 
(L367fs*46) 
 
MLLSVPLLLGLLGLAVAEPAVYFKEQFLDGDGWTSRWIESKHKSDFGKFVLSSGKFYGDEE
KDKGLQTSQDARFYALSASFEPFSNKGQTLVVQFTVKHEQNIDCGGGYVKLFPNSLDQTD
MHGDSEYNIMFGPDICGPGTKKVHVIFNYKGKNVLINKDIRCKDDEFTHLYTLIVRPDNTYE
VKIDNSQVESGSLEDDWDFLPPKKIKDPDASKPEDWDERAKIDDPTDSKPEDWDKPEHIP
DPDAKKPEDWDEEMDGEWEPPVIQPEYKGEWKPRQIDNPDYKGTWIHPEIDNPEYSPD
PSIYAYDNFGVLGLDLWQVKSGTIFDNFLITNDEAYAEEFGNETWGVTKAAEKQMKDK
QDEEQRTRRMMRTKMRMRRMRRTRRKMRRKMSPARPRTSCREACLQGWTEA 
CALR type 2 
mutation 
(K385fs*47) 
 
MLLSVPLLLGLLGLAVAEPAVYFKEQFLDGDGWTSRWIESKHKSDFGKFVLSSGKFYGDEE
KDKGLQTSQDARFYALSASFEPFSNKGQTLVVQFTVKHEQNIDCGGGYVKLFPNSLDQTD
MHGDSEYNIMFGPDICGPGTKKVHVIFNYKGKNVLINKDIRCKDDEFTHLYTLIVRPDNTYE
VKIDNSQVESGSLEDDWDFLPPKKIKDPDASKPEDWDERAKIDDPTDSKPEDWDKPEHIP
DPDAKKPEDWDEEMDGEWEPPVIQNPEYKGEWKPRQIDNPDYKGTWIHPEIDNPEYSP
DPSIYAYDNFGVLGLDLWQVKSGTIFDNFLITNDEAYAEEFGNETWGVTKAAEKQMKDK
QDEEQRLKEEEEDKKRKEEEEAEDRRMMRTKMRMRRMRRTRRKMRRKMSPARPRTS
CREACLQGWTEA 
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2.1.2. Computational analysis of the intrinsic disorder predisposition of the C-
terminal domain of CALR wt and type1/2 mutants 
Evaluation of the residue disorder propensity within the C-terminal domain of CALR wt, type 
1 and type 2 mutants were evaluated by using different disorder predictors. From the PONDR 
family, PONDR® VLXT and PONDR-FIT (Xue et al., 2010) were used as well as RONN-FIT (Yang 
et al., 2005), IUPRED (Dosztanyi et al., 2005) and PSIPRED (McGuffin et al., 2000) web servers.   
PONDR-FIT is a metapredictor, assembled by combining six different predictors: PONDR® 
VLXT/ VSL2/VL3, FoldIndex, IUpred and TopIDP. This predictor shows a relatively improved 
prediction capacity than each of the components alone and it has been described as one of 
the best available disorder predictors (Xue et al., 2010; Migliaccio and Uversky, 2017). PONDR 
® VLXT was separately used due to its accuracy to predict short sequences disorder 
propensity associated with molecular recognition features (MoRFs) regions (Dunker et al., 
2001). Moreover IUPRED uses an accurate algorithm to predict the disorder propensity of 
amino acid sequences based in their pair-wise energy (Dosztanyi et al., 2005), whereas 
PSIPRED and RONN-FIT use neural networks to estimate the coil-coil propensity.  
These predictors were used to analyse the primary amino acid sequence of CALR wt, CALR 
type 1 and type 2 mutants C-terminal domains (highlighted in bold in Table 4) and gave scores 
for each amino acid of the input sequence showing the individual disorder or structure 
probability.  Finally, the outputs of each individual disorder predictor were averaged, 
obtaining a consensus to evaluate the CALR C-terminal domain disorder propensity.  This 
approach has been shown to increase the reliability of the results compared to using a single 
disorder predictor (Fan and Kurgan, 2014; Migliaccio and Uversky, 2017) 
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2.1.3. Computational analysis of the secondary structure of CALR wt and mutants C-
terminal domain  
Initial analysis of crystal structure of CALR globular domain was performed by Visual 
Molecular Dynamics (VMD) using the available CALR PDB code 3O0V (Wijeyesakere et al., 
2011) in collaboration with Dr. Farooq A Kiani at IWR, University of Heidelberg (Germany).  
In order to predict the secondary structure of CALR C-terminal domain two different servers 
were used, the Iterative Threading Assembly Refinement (I-TASSER) (Yang et al., 2015) and 
S2D method (Vendrusco Lab- Software, University of Cambridge) (Sormanni et al., 2015). Both 
online servers were used to perform a comparative analysis between the estimated structure 
of CALR wt, and CALR type 1 and type 2 mutants. 
 I-TASSER software matches structure predictions with functional properties. The obtained 3D 
protein structures are accompanied with C-scores, known as the confidence value to estimate 
the quality of the predicted model and it ranges between -5 to 2. High C-score values indicate 
better accuracy of the predicted model.  Moreover, S2D method server predicts secondary 
structure together with intrinsic disorder predisposition of the protein regions. S2D software 
gave scores for each amino acid of the input sequences (CALR wt and type1 and type 2 
mutations) showing the individual amino acid secondary structure population.  
 
2.1.4. Validation of predicted CALR wt and mutants structural models 
PROCHECK (Laskowski et al., 1996) was used to validate the best predicted structures of CALR 
wt, type 1 and type 2 mutations C-terminal domains obtained in the I-TASSER server analysis. 
PROCHECK analyses the phi (Φ) and psi (Ψ) torsion angles of the predicted models.  Obtained 
plots show a good quality model when 90% of the residues are located in the favoured regions 
within the obtained Ramachandran plots.  
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 2.1.5. Computational analysis of the presence of MORFs regions within the CALR wt 
and mutants C-terminal domain  
The presence of protein binding sites within disorder protein regions was analysed by 
MoRFpred (Disfani et al., 2012) and ANCHOR algorithms (Dosztanyi et al., 2009).  MoRFpred 
detects potential Molecular Recognition Features (MoRFs) based in the hallmarks of these 
regions, such as solvent accessibility or physiochemical characteristics. ANCHOR server uses 
the pair-wise energy estimation method as previously described by IUPred server (Dosztanyi 
et al., 2005). 
Both predictors were used to analyse the presence of MoRFs within the CALR wt, CALR type 
1 and type 2 mutants C-terminal domains and gave scores for each amino acid of the input 
sequence showing the individual score for MoRFs probability. Finally, the outputs of each 
individual disorder predictor were averaged, obtaining a consensus to evaluate the CALR C-
terminal domain MoRFs propensity.  
 
2.1.6. Analysis of amino acid charge within the CALR wt and mutants C-terminal 
domain  
Isoelectric points (pI) of CALR wt, CALR type 1 and type 2 C-terminal domains were obtained 
using the Scripps Institute’s on-line Protein Calculator v.3.3 
(http://www.scripps.edu/Bcdputnam/protcalc.html). Furthermore, visualization of acidic vs 
basic amino acids within the sequence of interest was performed using the obtained best 
predictive 3D secondary structures from I-TASSER analysis as scaffolds (see section 2.1.3).  
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2.2. Laboratory techniques  
 
2.2.1. Cell culture and cell lines 
Three myelogenous leukemia cell lines have been used throughout this investigation. K562 
cells, originally established from bone marrow blasts cells obtained from a patient with CML 
in a blast crisis (Lozzio and Lozzio, 1975). MARIMO cell line, established from a patient with 
secondary AML developed during treatment of ET (Yoshida et al., 1998) and DAMI cells, 
established from a patient with megakaryoblastic leukemia (Greenberg et al., 1988). 
Additionally, a human embryonic kidney cell line was used, known as HEK-293T (Graham et 
al., 1977). 
HEK-293T cells were grown in Dulbecco’s modified Eagle´s medium (DMEM, Invitrogen) 
supplemented with 10% Fetal bovine serum (FBS) (Invitrogen), 1% Penicillin and Streptomycin 
(Gibco), and 1% Sodium pyruvate (Gibco). MARIMO cell line, kindly provided by Dr Hitoshi 
Kioyi at University of Japan, and K562 cells were grown in Roswell Park Memorial Institute 
medium 1640 (RPMI, Invitrogen) supplemented with 10% Fetal Calf Serum, 1% Penicillin and 
Streptomycin and 1% Sodium pyruvate. Clones of DAMI cells overexpressing GFP, CALR wt, 
CALR type1 and CALR type 2 mutations kindly provided by Dr. Petros Papadopoulos from the 
Hospital Clinico San Carlos in Madrid, were grown in Iscove’s Modified Medium (IMDM, 
Invitrogen) supplemented with 10% Horse Serum (Invitrogen), 1% Penicillin and 
Streptomycin, 1% Sodium pyruvate. CALR wt, CALR type 1 and CALR type 2 clones were 
selected with 2 µg/ml Puromycin (Apollo Scientific).  
All cell lines were incubated at 37oC and 5% CO2 and cells were passed upon confluency every 
2-3 days. 
 
2.2.2. Subculture of cell lines 
Confluent cells were collected in a sterile 15ml falcon tube and centrifuged at 1200 rpm for 5 
minutes in order to pellet the living cells. The supernatant was then discarded and the cell 
pellet was resuspended in 5 ml of pre-warmed cell culture media. For general subculturing 
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conditions, 0.5 ml of cells was transferred to a new sterile cell culture flask or plate containing 
9.5 ml of fresh media (1:10 dilution from the original culture). Cells were subsequently 
cultured in optimal conditions. 
 
2.2.3. Freezing and thawing cells 
For freezing, cells were centrifuged at 1200 rpm for 5 minutes and cell pellet was resuspended 
in 1 mL of 10% dimethyl sulfoxide (DMSO) FBS. Cell suspension was transferred into cryovials 
and stored initially at -80 oC and for long term storage in liquid nitrogen.  
For cell thawing, cryovials were thawed in a water bath at 37 oC and cells were rapidly 
resuspended into 10 ml of pre-warmed media. Then, samples were centrifuged at 1200 rpm 
for 5 minutes. Supernatant was discarded and the cell pellet was resuspended in 10 ml of 
fresh media and transferred to a new cell culture flask. Subsequently, cells were cultured in 
optimal conditions. 
 
2.2.4. Cell counting and trypan blue exclusion 
In order to plate the required number of cells during the experiments, viable cells were 
counted using haemocytometers (Labtech) and the trypan blue exclusion assay was 
performed. Trypan Blue is used to calculate a dead:viable cell ratio within the cell suspension. 
Under light microscopy dead cells are recognised due to trypan blue staining being 
internalised in dead cells. To perform cell counting and trypan blue exclusion assay 10 µl of 
cell dilution were resuspended in 50 µl of Phosphate buffered saline (PBS) and 40 µl of trypan 
blue.  Then 10 µl of the final solution was loaded into the haemocytometer. Number of living 
cells in each square corner of the haemocytometer chamber (Figure 8) were counted and 
averaged. Subsequently, calculations were performed to obtain the number of living cells per 
µl and the dilutions needed to seed the number of live cells required for following 
experiments.  
51 
 
 
 
 
 
 
 
 
2.2.5. Extraction of DNA plasmids from Whatman paper 
CALR-WT -FLAG and CALR-K385fs*477Ins-FLAG plasmids (Table 5) were kindly provided by Dr. 
Tony Green at Cambridge University (UK) in Whatman® paper. In order to extract the plasmids 
of interest, the paper containing the DNA was introduced into an eppendorf tube. Then 50 µl 
of 10 mM Tris (pH: 7.6) was added to the paper, vortexed and subsequently incubated for 15 
minutes at room temperature. DNA concentration was measured using NanoDrop 1000 
Spectrophotometer (Thermo Scientific) and samples were kept at – 20 0C until plasmid were 
finally amplified for further experiments.  
 
2.2.6. Plasmids amplification 
For DNA plasmid amplification 1 µg of DNA vector of interest was added to 25 µl of DH5α 
E.coli competent cells (Thermo Fisher Scientific). Cells were gently mixed and were kept on 
ice for 30 minutes. After incubation, samples were heat-pulsed in a 420C water bath for 45 
seconds and immediately transferred to ice for 2 minutes. 250 µl of sterile Luria-Bertani (LB) 
media was added to the bacteria and samples were incubated for 1 hour at 37oC whilst 
shaking. Cells were plated on LB agar plates (100 µg/ml ampicillin) and were incubated 
aerobically overnight at 37oC for selection of the transformed cells.  
Figure 8. Typical haemocytometer chamber.  
10 µl of cell/trypan blue solution were loaded into the chamber. Number of live cells are counted within the 
4 square corners using light microscopy.  
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The following day, colonies were picked and inoculated into 3 ml of LB (100 µg/ml ampicillin) 
for selection. Then, samples were incubated overnight at 37oC whilst shaking for further 
bacteria growth.  
Following growth of selective bacteria containing the plasmid of interest, QIApre Spin 
Midiprep kit (Qiagen) was used as per manufacturer’s guidelines to isolate the DNA plasmid. 
Finally, DNA concentration was measured using NanoDrop Spectrophotometer and samples 
were kept at –20 0C until use in further experiments. Amplified plasmids were sequenced by 
Source Bioscience (Rochdale).  
 
2.2.7. PolyFect transfection 
A day before transfection 6 x105 of HEK 293T cells per well were plated in 6-well plates 
(Sigma). The following day 2 µg of the DNA plasmids of interest (Table 5) were diluted in cell 
growth media containing no serum proteins or antibiotics in a total volume 100 µl in a sterile 
Eppendorf tube. Afterwards 15 µl of PolyFect Transfection Reagent (Quiagen) were added to 
the DNA solution. Samples were mixed by vortexing 10 seconds before incubation at room 
temperature for 10 minutes.    
While DNA incubation was taking place, cell growth medium was removed from the plates 
and cells were washed twice with PBS. Then 1.5 ml of pre-warmed complete cell growth 
media was added to the cells. Once DNA samples were incubated, 600 µl of growth media 
were added to the samples. This final solution was added drop by drop over the cell plates. 
The following day cell media was removed, and cells were washed twice with PBS in order to 
avoid cytotoxicity from the PolyFect reagent. Finally, 2 ml of fresh media was added to the 
cells and were incubated for another 24 hours for further experiments. 
Additionally, an empty GFP vector (Table 5) was used in all cell transfection assays as a control 
for transfection efficiency. GFP expression was detected after 48 hours using fluorescent 
microscopy. 
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Table 5. List of plasmids used in this study. 
Plasmids used for cell transfection Source 
pLKO-3G-3V-GFP  
 
 
Gift from Dr Tony Green laboratory 
(Cambridge University) 
 
pCDNA5_FRT_CALR-NonMutant-FLAG 
pCDNA5_FRT_CALR-K385fs*477Ins -FLAG 
pCDF1-MSC2-EF2- CALR-NonMutant-copGFP 
pCDF1-MSC2-EF2-CALR- K385fs*477Ins-copGFP 
pCMV-10-TPOR-HA 
 
 
 
2.2.8. Immunostaining 
Sterile coverslips were washed twice with sterile PBS and incubated with fibronectin (Sigma) 
(25µg/ml in PBS) to improve cell adhesion and expansion on top of the coverslip surface. 
Fibronectin was incubated for one hour at room temperature under sterile conditions. Then, 
coverslips were washed again twice with PBS and placed in 6 well plates.  
A day prior to transfection HEK 293T cells were seeded at a concentration of 2 x105 cells and 
were plated in 6-well plates containing a previously treated coverslip. The following day cells 
were subjected to transfection as described in section 2.2.7 with the vectors of interest.  
Two days after transfection cells were washed twice with PBS and 4% paraformaldehyde 
(PFA) was added into the well. After 15 minutes of incubation at room temperature, PFA was 
removed and cells were washed twice with PBS.  Then, cells were incubated with PBS 
containing 1% triton for 5 minutes at room temperature.  
Before blocking, cells were washed twice with PBS. Then cells were incubated with PBS + 1% 
bovine serum albumin (BSA) for one hour at room temperature. Afterwards, cells were 
incubated with the primary antibody (1:200 dilution) (see antibodies in Table 6) for 1 hour 
and then samples were washed three times with PBS for 5 minutes each. Cells were incubated 
with the secondary antibody (1:200 dilution) for 1 hour at room temperature (see antibodies 
in Table 6). Finally, samples were washed again three times in PBS and once in dH2O. Then, 
coverslips were left to air-dry overnight at room temperature.  
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The following day coverslips were transferred to a glass slide and mounted with mounting 
media (Vectashield). Slides were stored at 4oC in dark until microscopy.  
 
Table 6. List of antibodies used in this study. 
Primary antibodies Source Secondary 
antibodies 
Source 
Mouse-Flag  
Sigma 
 
Anti-mouse 647  
Gift from Dr Patrick 
Caswell laboratory 
(Manchester University) 
 
Rabbit-Flag Anti-rabbit Cys3 
Mouse-ERP57 Anti-mouse Cys3 
Mouse-HA Abcam 
 
 
2.2.9. High-resolution imaging  
High-resolution imaging was performed in collaboration with the laboratory of Dr Patrick 
Caswell at The University of Manchester (UK). Fixed cells were imaged using a Leica TCS SP8 
STED 3X microscope with an HC PL APO 100X/1.40 oil objective and further 3.0x or 4.0x 
confocal zoom. A pinhole with 0.7 airy units was used to further improve resolution. White 
light laser (WLL) was used for imaging captures using the following emission wavelengths: 
488, 550 and 653. Then, appropriate acceptance spectrum for GFP, cys3 and far red were 
used. Z-slide images were taken from the bottom of the cell to the top. Images were 
deconvolved using Huygens Professional software with default settings and were analysed 
using LAS X Leica Software. 
 
2.2.10. Lentiviral transduction of DAMI cells 
Lentivirus was produced according to previous published protocols (Borg et al., 2010). DAMI 
cells were transduced in 6 well plates using between 5 to 10 µl of concentrated lentivirus. 
Puromycin (2 µl/ml final concentration) was added to the cells for selection. At day 7 after 
transduction, cells were harvested and were used for serial dilution within a 96 well plate to 
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obtain single clones. pRRLsin.PPTs.hCMV.Wpre vector was used as a backbone for CALR-WT, 
CALR-type1 and CALR-type2 gene insertion.  
 
2.2.11. Protein extraction 
To decrease loss of protein during the extraction protocol, protein extraction was carried out 
on ice. Cells were pelleted by centrifugation at 1200 rpm for 5 minutes, supernatant was 
removed and cells were washed twice in ice cold PBS. Then, samples were centrifuged and 
the cell pellet was resuspended in 500 µl of high salt lysis buffer (HSLB) (45mM HEPES pH 7.5, 
400 mM NaCl, 1mM EDTA, 0.5% NP40 (Igepal) 10% Glycerol). 1mM DTT, 1mM PMSF, 5 µl 
Protease inhibitors (PI), 2 mM Sodium orthovanadate (Na3VO4) 10 mM BGP and 5 mM NaPPI 
were added to activate the lysis buffer before use. Lysates were transferred to a 1.5 ml 
microcentrifuge tube and were subsequently rotated for 20 minutes at 4 oC and followed by 
15 minutes centrifugation at 12000 rpm at 4 oC.  The obtained supernatant was transferred 
to another tube and kept as protein extract. Finally, in order to quantify protein levels within 
the extracts, the Bradford assay was performed (see section 2.2.12) to ensure the use of equal 
amounts between samples in subsequent experiments.  
 
2.2.12. Bradford assay 
The Bradford assay is a commonly used technique to determinate protein concentration 
within samples.  Initial working solution was prepared diluting 200 µl of Protein assay dye 
reagent concentrate (Bio-Rad) into 800 µl of distilled water. 2 µl of protein sample was added 
into 1 ml of working solution in semi-micro cuvettes. As a control, 2 µl of HSLB was used for 
spectrophotometer calibration.  Duplicates of each protein sample were prepared in order to 
obtain a final average of protein concentration.  Using the spectrophotometer cuvettes were 
read at 595 nm (Lu et al., 2010).  
Use of even amounts of protein was necessary for experiments such as Western blotting. 
Therefore, calculations based on the results obtained from the Bradford assay quantification 
were performed.  A value of 40 µl was given to the sample with the lowest reading of 
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absorbance (maximal loading volume allowed during electrophoresis). Appropriate relative 
amount of protein concentration was then calculated for the other samples using the 
following formula:  
 𝑙𝑜𝑤𝑒𝑠𝑡 𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑥 40
𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑐𝑢𝑟𝑟𝑒𝑛𝑡 𝑠𝑎𝑚𝑝𝑙𝑒
 
Finally, based on previous calculation, appropriate aliquots with the corresponding volume 
were prepared. Then 3XSDS buffer (see Table 7) was added to the samples (half the volume 
of the corresponding sample) and samples were kept at – 80 oC until use.  
 
2.2.13. Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
10% Ready Gel® Tris-HCl Gel (Bio-Rad) was used for protein electrophoresis. The gel was 
placed in the running chamber filled with 1XSDS running buffer (see Table 7).  Then, protein 
samples were denatured at 95oC for three minutes and were loaded on the gel alongside 
Hyperpage protein molecular weight marker (Bio-Rad) using a Hamilton microlitre glass 
syringe. The gel was set to run at 80 V, which was increased to 110 V once the samples entered 
the resolving gel.   
 
2.2.14. Western blotting 
After SDS electrophoresis, western blot was performed to detect the proteins of interest. 
Firstly, a polyvinylsise fluoride (PVDF) membrane (Millipore) was activated in 100% methanol 
for five minutes and washed in 1 X Western Transfer Buffer (see Table 7). Then, transfer 
cassettes were prepared in the following order: sponge, 2 x filter paper, SDS gel, PVDF 
membrane, 2 x filter paper and sponge. Finally, cassettes were transferred into a Mini Trans-
Blot® Cell (Bio-Rad) filled with 1 x Western Transfer buffer. Transfer was performed at 0.4 mA 
for 2 hours at 4 oC.   
PVDF membrane was washed once with PBS and blocked with skimmed milk (SM) PBS (PBS 
and 5% SM) for one hour at room temperature. Then, membrane was incubated with the 
corresponding primary antibodies overnight rotating at 4oC (primary antibodies were diluted 
in 2.5% SM-PBST following manufacturers guidelines for appropriate concentration). The 
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following day, using a shaking incubator the membrane was washed three times with PBST 
for 10 minutes, after which was incubated with the correspondent secondary antibody for 1 
hour at room temperature while shaking (secondary antibodies were diluted in 2.5% SM-PBST 
following manufacturers guidelines for appropriate concentration). After incubation, the 
membrane was washed again three times with PBST for 10 minutes and finally developed.   
The membrane was incubated with SuperSignal West Femto Chemiluminescent Substrate 
(Thermo Scientific). The working solution of the developer reagent was prepared following 
manufacture’s guidelines.  Signal was detected with CL-XPosure™ Film (Life-technologies) in 
a Photon Ecomax Automatic X-Ray Film Processor. 
Antibodies used for western blot were purchased as follows: mouse anti-human CALR 
(AbCam), anti-mouse (GE Healthcare Life Sciences), rabbit anti-human actin (AbCam), anti-
rabbit (GE Healthcare Life Sciences).  
 
Table 7. List of buffers used for western blot analysis. 
Buffer name Composition 
 
0.1% PBS/Tween (PBST) 
 
 
100ml 1xPBS, 900ml dH2O, 1ml Tween-20 
 
 
10X SDS Running Buffer 
 
 
1.9M Glycine, 247.7mM Tris, 35mM SDS 
 
 
10X Western Transfer Buffer 
 
 
1.5M Glycine, 272.4mM Tris 
 
 
1XWestern Transfer Buffer 
 
 
100 ml 10xWTB, 200 ml Methanol, 700 ml dH2O 
 
 
3XSDS Loading Buffer 
 
 
0.01% bromophenol blue, 187mM Tris, 30% Glycerol, 15% 2-
mercaptoethanol, 6% SDS,  
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2.2.15. RNA extraction and cDNA synthesis  
Cells were collected and centrifuged at 1200 rpm for 5 minutes. Then, cells were washed twice 
with ice cold-PBS. After this, RNA of cell pellet was extracted using Isolate II Mini Kit (Bioline) 
following the manufacturers guidelines. Finally, RNA concentration was determined using 
NanoDrop spectrophotometer and was stored at - 80oC until use.  
Following cell RNA extraction, mRNA was converted into stable complementary DNA (cDNA) 
by using Tetro cDNA Synthesis Kit (Bioline). To avoid RNA degradation, all reactions were 
prepared on ice. Samples were prepared as followed: RNA (up to 5 µg), 1 µl of Oligo (dT)18, 1 
µl of 10 mM dNTP mix, 4 µl of 5x RT Buffer, 1 µl of RiboSafe RNase inhibitor, 1 µl of Tetro 
Reverse Transcriptase (200 u/µl), dH2O up to 20 µl. Samples were vortexed and incubated at 
45oC for 30 minutes before increasing temperature to 85oC for an incubation of 5 minutes. 
Afterwards samples were incubated on ice until use. 
After cDNA synthesis, cDNA concentration was determined using NanoDrop 
spectrophotometer. Then, cDNA was diluted to an end concentration of 50 ng/ µl and samples 
were stored at - 20oC until used.  
 
2.2.16. Taq polymerase chain reaction 
Optimal temperature of primer annealing was tested by taq PCR. For DNA amplification, DNA 
Taq polymerase recombinant (Invitrogen) samples were prepared using 2.5 µl of 10x PCR 
Reaction Buffer, 0.5 µl of 10 mM dNTP mix, 0.2 µl of Taq DNA polymerase, 1 µl of primer mix 
(10 mM of forward and reverse primers), 2 µl of template cDNA and 18.05 µl of dH2O.   Verity 
96-well Thermal Cycler was used for the PCR amplification and the samples were subjected 
to the conditions as described in Table 8.  
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Table 8. Taq PCR cycles. 
Step Temperature (0C) Time Number of cycles 
Denature 94 2 minutes 1 
Denature 94 45 seconds  
35 Anneal 54-60 30 seconds 
Extend 72 20 seconds 
Final Extension 72 10 minutes 1 
 
PCR products were analysed by gel electrophoresis. For gels, 2% agarose (Bioline) was diluted 
in 1x Tris/Borate/EDTA running buffer (Severn Biotech) containing 1x gel red (Cambridge 
Bioscience). Samples were mixed with 5x loading buffer (Bioline) and a total volume of 20 µl 
was loaded into the gel. For reference a 50 bp Hyperladder (Bioline) was loaded into the first 
well. Electrophoresis was performed at 110 V for 1 hour. Finally, DNA samples were visualised 
using a Box transilluminator with GeneSnap version 7.12.06 (Syngene).  
 
2.2.17. Quantitative real-time Polymerase Chain Reaction (qRT-PCR) 
qRT-PCR is a technique commonly used to analyse and quantify gene expression using 
fluorescent DNA dyes. In this study SYBR green fluorescent dye was used, which binds 
specifically to double stranded DNA and emits light upon excitation (VanGuilder et al., 2008).  
qRT-PCR samples were performed using the SensiFast SYBR No-Rox mix (Bioline). Samples 
were prepared on ice as follows: 10 µl of SensiFast SYBR No-Rox mix, 0.75 µl of primer mix of 
gene of interest (Table 10), 2 µl cDNA and 7.25 µl of dH2o. For every run a non-template 
control sample was included. During this study, human GAPDH gene was used as a 
housekeeping gene.  
Reactions were run on a QIAGEN Rotor-Gene Q Thermocycler.  Parameters of the PCR are 
shown in Table 9.  A final dissociation melting curve was performed between 72oC and 95oC 
at 0.5oC increments with intervals of 5 seconds holds. Fluorescence was acquired in the green 
channel. Melting curves were performed to corroborate the amplification of a single DNA 
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product within the samples and to ensure no contamination within the non-template 
controls. 
Table 9.  qRT-PCR cycles 
 
 
 
 
 
 
QIAGEN Rotor-Gene Q Series Analysis Software was used to determinate the Threshold cycle 
(CT) values for each sample. Samples were run in triplicate and an average was taken. Only 
samples with standard deviation of ≤ 1 CT were used for analysis. Samples were normalised 
against human GAPDH CT values and subsequently presented relative to the respective 
controls following comparative Ct method.  
 
 
 
 
 
 
 
 
 
Step Temperature 
(0C) 
Time Number of 
cycles 
Denature 95 2 minutes 1 
Denature 95 5 seconds  
40 Annealing 59 10 seconds 
Extend 72 20 seconds 
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Table 10. Primers used in this study. 
 
 
2.2.18. Comparative Ct method (2- ΔΔCT) 
In order to present the quantitative gene expression analysis obtained in the qRT-PCR 
experiment, the 2-ΔΔCT method was used (Schmittgen and Livak, 2008). Firstly, ΔCt was 
calculated by the subtraction of the average Ct value of the housekeeping gene from the 
average Ct value of the target gene. This calculation normalises the results to allow 
comparisons between different samples.  
 
 
 
Gene name Primer sequence Reference 
GAPDH forward 5’-ATGGGGAAGGTGAAGGTCGG -3’ 
 
 
(Hui et al., 2017) 
GAPDH reverse 5’-GACGGTGCCATGGAATTTGC -3’ 
 
CISH forward 5’-AGCCCAGACAGAGAGTGAGC-3’ 
 
 
N/A 
CISH reverse 5’-TGACAGCGTGAACAGGTAGC-3’ 
 
ID1 forward 5’-CCAGAACCGCAAGGTGAG-3’ 
 
 
(Tobin et al., 2011) 
ID1 reverse 5’-GGTCCCTGATGTAGTCGATGA-3’ 
 
PIM1 forward 5’-CGAGCATGACGAAGAGATCAT-3’ 
 
 
(Kim et al., 2005) 
PIM1 reverse 5’-TCGAAGGTTGGCCTATCTGA-3’ 
 
SOCS2 forward 5’-TGCAAGGATAAGCGGACAGG-3’ 
 
(Carvalho et al., 2014) 
SOCS2 reverse 5’-CAGAGATGCTGCAGAGATGG-3’ 
 
C-MPL forward 
 
5’-GCACTGTGATGCTTTATGCAAC-3’ 
 
(Jacquel et al., 2006) 
C-MPL reverse  
 
5’-TGAACGGTTTAGAGGATGAGGA-3’ 
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ΔCt= Ct target gene - Ct Housekeeping gene 
 
Then ΔΔCt value was calculated by subtracting the ΔCt of the treated sample from the ΔCt of 
the control sample. Finally, fold change was used to calculate the quantitative difference of 
gene expression from the control.  
 
ΔΔCt= ΔCt treated cells - ΔCt control cells 
Fold change = 2- ΔΔCT 
 
2.2.19. Propidium Iodide staining and cell cycle analysis 
Analysis of cell cycle was performed by Propidium iodide (PI) staining. PI is a fluorescent 
molecule used to stain DNA, as it intercalates between the DNA bases (Crowley et al., 2016). 
Cells were collected and centrifuged at 1200 rpm for 5 minutes, followed by two washes in 
cold PBS. Then, cold 70 % ethanol was added drop by drop into the cell pellet while vortexing 
and samples were incubated at 4oC for 30 minutes.  
After incubation, cells were washed twice with cold PBS. Cell pellet was resuspended in 50 µl 
of 100 µg/ml Ribonuclease A (RNase A) (Sigma-Aldrich) and incubated at room temperature 
for 15 minutes. Then, 200 µl of 50 µg/ml PI (Sigma-Aldrich) was added. Cells were incubated 
at room temperature for 15 minutes and were kept in dark until flow cytometry analysis.  
PI fluorescence is directly proportional to the amount of DNA within the cell. Three cell phases 
of cell cycle (G0/G1, S and G2/M phase) were identified by flow cytometry based on the DNA 
content of cells (Crowley et al., 2016).  
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2.2.20. Protein cell surface immunostaining 
Cells were collected and centrifuged at 1200 rpm for 5 minutes. After two washes in cold PBS, 
cells were incubated with the primary antibody diluted in PBS + 1% FBS (1:1000 dilution) for 
30 minutes at room temperature (see Table 11). Then cells were washed twice with PBS. 
When staining was performed with primary antibody containing a fluorescent marker, cells 
were then resuspended in 500 µl of PBS and were analysed by flow cytometry.  
When CALR cell surface staining was performed, cells were subsequently incubated with 
secondary antibody (see Table 11) diluted in PBS + 1% FBS (1:500 dilution) for 30 minutes at 
room temperature and were washed twice with PBS. Then, cells were incubated with PE 
streptavidin (Biolegend) diluted in PBS + 1% FBS (1:500 dilution) for another 30 minutes at 
room temperature in the dark. Finally, cells were washed twice with PBS and were subjected 
to flow cytometry analysis.  
 
Table 11. List of antibodies used in this study. 
 
2.2.21. Free intracellular calcium staining 
Fluo-8 AM (Abcam) chemical intracellular Ca2+ indicator was used for staining of intracellular 
free Ca2+. Fluo-8 AM stock was prepared using pluronic DMSO to improve cell loading 
efficiency (Hamad et al., 2015).  
Antibody Source 
Anti-human CALR AbCam 
Anti-human CD235a APC  
eBioscience Anti-human CD41a APC 
Anti-mouse CD41a PE 
Anti-mouse CD117 Alexa Fluor 700 
Anti-human CD110 APC BD 
Anti-mouse Biotinylated DAKO 
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For Ca2+ staining cells were pelleted by centrifugation at 1200 rpm for 5 minutes. Supernatant 
was removed and cells were washed with PBS and centrifuged again. Cell pellet was 
resuspended in 1 ml of PBS and 5 µl of Fluo-8 AM (final concentration of 5 μM). After 30 
minutes of incubation at room temperature, samples were diluted to a final volume of 10 ml 
with PBS and were then centrifuged at 1200 rpm for 5 minutes. Then cells were washed with 
PBS and finally resuspended in 500 µl of PBS. Samples were analysed using flow cytometry.   
2.2.22. Flow-cytometry analysis 
Samples were analysed using a FACS Verse flow cytometry (BD Bioscience, USA). Forward 
scatter (FSC) and side scatter (SSC) were used to gate the cell population of interest. Cells 
were subjected to the detection of specific fluorescent signal using different fluorescent 
parameters. The following three fluorescent parameters were used during the analysis: 
phycoerythrin (PE), FITC and allophycocyanin (APC). Data was analysed using FACS Suite 
software (BD).  
2.2.23. ER calcium release assay 
ER Ca2+ flux into the cytoplasm was quantified in MARIMO, K562 and DAMI cells. Firstly, 
intracellular Ca2+ was stained with Fluo-8-AM as previously described (see section 2.2.22). 
Then cells were pelleted and were diluted in 1 ml of PBS.  
Ca2+ cytoplasmic levels were quantified by using flow-cytometry. Samples were recorded each 
60 seconds during 18 minutes. Firstly, initial basal intracellular Ca2+ levels of the cell 
population were recorded for two minutes. Afterwards, Thapsigargin (Abcam) was added to 
the cells in a final concentration of 1 μM. Cells were vortexed and immediately recorded. After 
Thapsigargin addition, samples were recorded for another 15 minutes each 60 seconds. 
Ca2+ fluorescent readings were expressed relative to the initial Ca2+ cytoplasmic levels. Three 
independent experiments were performed using cells of different culture passages. 
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2.2.24. Cell drug treatment 
Growing MARIMO, K562 and DAMI cells at a concentration of 3 x 105 cells/ml were treated 
with the correspondent drug treatment (see Table 12) diluted in complete RPMI medium, 
unless otherwise stated. Cells were incubated for 72 hours and were subsequently used for 
further analysis.  
 
Table 12. Drug treatments used in this study. 
Drug Source Concentration 
PMA Sigma-Aldrich 5 nM 
Hemin Sigma-Aldrich 50 µM 
BTP-2 Abcam 50 µM 
Fendiline Alfa Aesar 20 µM 
Riluzole Abcam 100 µM 
 
2.2.25. Mouse bone marrow cells megakaryocyte induction 
Bone marrow was harvested from schedule 1 culled C57/Black6 mice from Charles River 
Laboratories. Freshly isolated bone marrow was aliquoted and frozen down in liquid nitrogen 
until used.  
Cryovials containing bone marrow cells were defrosted as previously described in section 
2.2.3. Once the cell pellet was diluted in fresh culture media, 1 x 105 cells per ml were plated 
in a 12 well plate. In order to induce megakaryocyte formation within the culture, cells were 
plated in pre-warmed RPMI medium containing 100 ng/ml of mouse thrombopoietin (R&D 
systems). Cells were subsequently incubated over 10 days at 37oC and 5% CO2.  Samples in day 
0, 5 and 10 cells were further stained to detect Ca2+ concentration and cell surface markers. 
Finally, samples were analysed by flow cytometry.  
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2.2.26. May-Grunwald Giemsa staining  
Analysis of MARIMO cell morphology was performed using May-Grunwald Giemsa staining. 
Undifferentiated MARIMO cells grow in suspension within the culture; therefore cell 
cytospins were performed in order to obtain a circular monolayer of cells onto a glass slide to 
further perform cell staining. 
MARIMO cells in culture were diluted in PBS at a concentration of 1x105 cells/ml in a 
microcentrifuge tube. Then, cytofunnel chambers were prepared as follow: cytoclip, glass 
slide, filter card and cytofunnel, and placed in the cytocentrifuge. 100 µl of cell suspension 
were loaded into the cytofunnels. Then, samples were centrifuged at 500 rpm for 5 minutes 
at minimum acceleration. Finally, slides were removed from the centrifuge and left to air dry 
for 5 minutes.  
Sterile coverslips were washed twice in PBS and placed in 6 well plates used for MARIMO cells 
incubation in PMA. After 72 hrs incubation media was removed from wells and MARIMO 
differentiated cells were adhered to the coverslips. The cells were then washed twice in PBS.  
Cells adhered to the coverslips and within a monolayer in glass slides were fixed by immersion 
in 100% ethanol and left to air dry for 10 minutes. Then, May-Grunwald Giemsa stain solution 
(BDH/VWR international limited UK) was diluted to 10% in Giemsa buffer. Giemsa buffer was 
prepared by diluting one tablet of pH 6.4 (BDH laboratory supplies) in 1 L of dH2O. The slides 
and coverslips were covered in Giemsa working solution for 20 minutes at room temperature. 
After incubation, Giemsa staining was discarded and samples were washed under tap water.  
 
2.2.27. Bright field microscopy 
Images of fixed MARIMO cells stained with May-Grunwald Giemsa were captured using a 
Leica DM 500 compound microscope and 100x oil objective lens (Leica N Plan 1.25). 
For live-cell imaging of cells within the culture plates, images were captured using inverted 
Vert.A1 AXIO (Zeiss) and Zeiss 40X Objective, LD A-Plan (0.5 NA). 
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2.2.28. Cell proliferation Assay  
Cells were plated at 2x104 cells per well in a 96-well plate exposed to the relevant drug 
concentration and incubated for 72 hours. Each drug condition was plated in triplicate. Cell 
proliferation was measured using CellTiter 96® Aqueous Non-Radioactive Cell Proliferation 
Assay (Promega) which is composed of two different solutions: [3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt] (MTS) and 
phenazine methosulfate (PMS), following manufacturers guidelines. MTS working solution 
was prepared as follows: 100 µl of PMS (0.92 mg/ml) for 2 ml of of MTS (2mg/ml). Then, 20 
µl of MTS working solution was added into 100 µl of cells in each well.   
 
Once MTS working solution was added into the wells, cells were incubated for 4 hours at 37 
ºC and 5% CO2. Then, plate absorbance was read on a Thermo Labsystem Multiskan Ascent 
plate reader at 490 nm and 690 nm. Finally, in order to remove background noise from the 
readings, the 690 nm values were subtracted from the 490 nm values. Readings were 
expressed relative to the respective controls. Three independent experiments were 
performed using cells of different culture passages.  
 
2.2.29. Statistical analyses  
Comparisons between groups were carried out using the statistical Student´s t-test. P-values 
less than 0.05 (*) and 0.01 (**) were considered statistically significant. Microsoft excel 
program was used to obtain the statistical data and generate graphs. 
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Chapter 3: Effects of CALR mutations into 
the physical characteristics of CALR C-
terminal domain in MPNs 
 
 
3.1. Introduction 
 
Over the past few decades, structural biologists have intensively characterised protein 
structures, leading to a large body of knowledge linking amino acid primary sequences with 
secondary structure. The three-dimensional (3D) structure of a protein and its cellular 
behaviour are closely related. However, growing evidence suggests that not all the encoded 
proteins are folded spontaneously into stable structures and instead these proteins can reach 
dynamic conformations known as intrinsic disorder states (Wright and Dyson, 1999; van der 
Lee et al., 2014). It is now recognised that the intrinsically disordered proteins (IDPs) or the 
intrinsically disordered protein regions (IDPRs) stability is determined by the amino acids 
sequences of the protein (Oldfield and Dunker, 2014). IDPs/IDPRs are characterised by the 
depletion of specific amino acids. Examples include: Aspartic Acid, Cysteine, Isoleucine, 
Leucine, Phenylalanine, Tryptophan, Tyrosine and Valine and for the presence of the known 
disorder promoting residues like Arginine, Glutamine, Glutamic acid, Glycine, Lysine, Proline 
and Serine (Williams et al., 2001). Correct protein´ order-disorder conformation is essential 
for their optimal biological activity, as it is now recognised that dysfunctional IDPs are linked 
with human diseases, such as cancer, neurodegenerative diseases and diabetes (Uversky et 
al., 2014).  
Interestingly, recent studies have shown that IDPs/IDPRs could change to structured regions 
upon binding with their specific targets (Babu et al., 2011; Migliaccio and Uversky, 2017) and 
this disorder-to-order transition could be essential for the correct cellular function of the 
protein.  Among long IDPRs it is possible to identify disordered protein binding sites, known 
as Molecular Recognition Features (MoRFs), which lead to protein folding as consequence of 
specific binding interaction (Yan et al., 2016). 
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Recent advances in the field of structural biology have helped to design computational 
methods to predict IDPs/IDPRs, identify MoRFs within these regions and even build 3D protein 
structural models. Currently, there are several protein disorder prediction software available, 
such as PONDR-FIT (Xue et al., 2010) or IUpred (Dosztanyi et al., 2005), which are based on 
the average of several disorder databases or the protein energy content respectively.  
Additionally, there are structural and functional protein predictor severs as the interactive 
threading assembly refinement (I-TASSER) (Yang et al., 2015), which helps to structurally 
characterise proteins with known sequences and match structure with protein function (Yang 
et al., 2015). So far, I-TASSER method is one of most accurate server for prediction of protein’s 
secondary structure and during recent years it has been extensively used by many researchers 
to predict the secondary structure of proteins of interest (Jethra et al., 2012; Manochitra and 
Parija, 2017). Moreover, a current server known as S2D method (Sormanni et al., 2015) allows 
an in silico study of protein’s secondary structure and a simultaneous description on the 
intrinsic disorder regions using a combined statistical method. Finally, further bioinformatic 
tools have been designed in order to identify MoRFs within IDPs/IDPRs, such as ANCHOR 
algorithm (Dosztanyi et al., 2009) or MoRFpred (Disfani et al., 2012). 
CALR secondary structure has been an intense focus of study during recent years (Norgaard 
Toft et al., 2008; Giraldo et al., 2010; Kozlov et al., 2010; Wijeyesakere et al., 2011; Migliaccio 
and Uversky, 2017). CALR is formed by three structural and functional domains, the N-
terminal domain, central P-domain and the C-terminal domain.  Previous studies have focused 
on describing CALR secondary structure and its link with CALR cellular functions (Kozlov et al., 
2010). Several investigations based on the structural analysis of CALR attempted to crystallise 
this protein; however, the intrinsic mobility of the P-domain and the highly disordered C-
terminal region affected the crystallisation of CALR.  Recent research work by Kozlov and 
colleagues (2010) depleted the problematic P-domain and C-terminal regions and published 
the crystal structure of mouse CALR (Kozlov et al., 2010). This primary template of CALR has 
being useful for further structural CALR studies (Wijeyesakere et al., 2011). However, the 
precise structure of the C-terminal domain remains unknown.  
CALR C-terminal domain is known to be essential for the Ca2+ buffering activity of the protein, 
due to the presence of a high number of negatively charged amino acids within this residue 
which are known to bind with Ca2+ ions (Nakamura et al., 2001). Recent studies showed by 
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using molecular dynamics simulations and spectroscopic techniques that CALR C-terminal 
region structure fluctuates depending on Ca2+ levels. In low Ca2+ concentrations the domain 
shows a disordered structure, however, in presence of higher Ca2+ concentrations, this region 
becomes compacted and increases the conformational stability of the protein (Giraldo et al., 
2010; Migliaccio and Uversky, 2017). Therefore, it appears likely that the nature of the folded 
structure of this domain is dependent on the Ca2+ buffering activity of the protein within the 
ER. 
Interestingly, the recently identified CALR mutations in MPNs have been described to produce 
a novel C-terminal domain of the protein (Klampfl et al., 2013, Nangalia et al., 2013). These 
mutations are known to change the net charge of the protein from acidic to basic (Shivarov 
et al., 2014). This suggests that the novel mutant C-terminal domain described in MPNs could 
have less Ca2+ binding affinity within the ER and therefore contribute to the malignancy of 
these mutations in disease by changing Ca2+ dynamics in CALR mutant megakaryocytes 
(Shivarov et al., 2014; Eder-Azanza et al., 2014). A relatively recent bioinformatic analysis 
identified the presence of a low-complexity region (LCR) within CALR wild-type (wt) C-
terminal domain (Eder-Azanza et al., 2014). LCR are known to be protein regions with low 
amino acid diversity and their position and size are directly linked with the protein binding 
properties (Coletta et al., 2010). However, CALR mutations lead to changes in the location and 
length of this LCR (Eder-Azanza et al., 2014). In addition, recent study suggested changes in 
the MoRFs regions of CALR mutant´s C-terminal domain (Varricchio et al., 2017). Therefore, 
changes in the LCR together with MoRFs regions within the C-terminal domain could lead to 
changes in the CALR protein binding affinity during disease. Interestingly, CALR type 1 and 
type 2 mutations have been described to interact with MPL receptor in MPNs and this novel 
interaction directly dependent on the novel CALR C-terminal domain (Chachoua et al., 2016; 
Elf et al., 2016), therefore it could be suggested that changes in the protein binding properties 
within mutant CALR C-terminal domain could be the cause of this novel protein interaction. 
However, the understanding of the molecular basis of this novel interaction remains 
unknown.  
Additionally, previous bioinformatic analysis using RaptorX, COILS and PAIRCOILS2 secondary 
structure predictor servers showed that CALR type 1 mutation increases the possibility of non-
coil regions within the C -terminal domain, possibly leading to a more structured region, 
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whereas type 2 maintains similar characteristics to CALR wt (Eder-Azanza et al., 2014). 
Interestingly, previous study using a single disorder predictor known as PONDR-VXLT 
suggested that CALR mutations affect the disorder profile of the C-terminal domain 
(Varricchio et al., 2017). Additionally, further in silico investigations showed the presence of 
phosphorylation sites within the new C-terminal domains in CALR type 1 and type 2 mutants. 
These phosphorylation sites were described to be specific for kinases with important roles in 
cellular signalling, such as PKC or CDK5 (Eder-Azanza et al., 2014). Therefore, the acquisition 
of phosphorylation sites within CALR mutants could lead to changes in cellular signalling 
during disease by establishing new networks of protein interactions. 
 
3.1.1. Aims and hypothesis 
 
Changes in the molecular nature of CALR mutants C-terminal domain could lead to changes 
in the functionally of CALR and consequently to the oncogenic phenotype of MPNs. Previous 
bioinformatic studies have suggested that CALR mutations described in MPNs could change 
the disordered status, the secondary structure and the amino acid charge of the novel C-
terminal domains. However, further analysis need to corroborate and describe in more detail 
the specific molecular nature of these mutant proteins and its consequences for CALR 
functionality. Thus, during this in silico study three major aims will be addressed:  
I. Comparative study the stability and protein secondary structure of CALR novel C-
terminal domain of CALR type 1 and type 2 mutants. 
II. Analysis of the impact of CALR mutations on the appearance of potential novel 
protein binding regions within CALR mutants C-terminal domain.  
III. Analysis of the effects of CALR mutations on the amino acid charge of CALR mutants 
C-terminal domain.  
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3.2. Results 
 
3.2.1. Initial analysis of CALR secondary structure 
In order to gain a better understanding of the CALR 3D structure, the in silico analysis of the 
available PDB file (3O0V) of mouse CALR (Kozlov et al., 2010) was carried out using VMD 
software. This structure is depleted with the high motility arm in the P-domain and the IDPR 
of C-domain (Figure 9 A).  As previously described, CALR mutations in MPNs are located in 
exon 9 (Klampfl et al., 2013; Nangalia et al., 2013). In Figure 9 A, the encoded protein region 
from exon 9 is highlighted in grey and shows an α-helix structure until the IDPR starts after 
residue 362. Interestingly, both CALR type 1 and type 2 mutations appear after residues 365 
and 381 respectively, within the IDPR. Therefore, this preliminary analysis showed that the 
available crystallised structure displays the secondary structure of the C-terminal domain 
until the region where CALR mutations found in MPNs are located; hence these mutations are 
located within the known IDPR described in CALR wt (Figure 9 B).  
Additionally, the distribution of the Ca2+ binding motifs within CALR protein was analysed 
within this model. The location of these amino acids was highlighted in the structure (Figure 
9A). Embed in the globular domain Asp46 and Asp312 (represented in orange) function as high 
Ca2+ binding affinity residues (Ca2+ molecule represented in green). Moreover, low affinity and 
high capacity Ca2+ binding residues (represented in yellow) are located in the C-terminal 
domain. However, only three Ca2+ binding residues (Glu346, Asp345 and Asp342) are within the 
last α-helix of the structure. Hence, the rest of Ca2+ binding motifs are located within the IDPR 
of C-terminal domain (Glu368, Glu369, Glu370, Glu371, Asp372, Glu377, Glu378) and are therefore 
depleted by the CALR mutations.  
Overall, this analysis shows that CALR mutations found in MPN affect the IDPR of CALR C-
terminal domain and therefore this region has not been previously crystallised. Moreover, 
this analysis demonstrates that the IDPR of this C-terminal domain also contains most of the 
Ca2+ binding motifs of CALR. Consequently, the available PDB structure of CALR wt cannot be 
used as a direct template to build models of the CALR mutants’ secondary structure. 
Therefore, further analysis to investigate mutant CALR C-terminal domains will need to rely 
on the use of in silico secondary structure predictors.  
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B. 
 
 
 
 
 
 
 
 
 
 
 
 
 
CALR WT          DEAYAE EFGNETWGVTKAAEKQMKDKQDEEQRLKEEEEDKKRKEEEEAEDKEDDEDKDEDEEDEEDKEEDEEEDVPGQAKDEL 
 
CALR type 1     DEAYAE EFGNETWGVTKAAEKQMKDK QDEEQRTRRMMRTKMRMRRMRRTRRKMRRKMSPARPRTSCREACLQGWTEA  
  
CALR type 2     DEAYAEEFGNETWGVTKAAEKQMKDKQDEEQRLKEEEEDKKRKEEEEAEDRRMMRTKMRMRRMRRTRRKMRRKMSPARPRTS 
                               CREACLQGWTEA 
Disordered region 
Figure 9. Structural characteristics of CALR wt 
A) 3D representation of the mouse CALR depleted of P-domain and the unstructured region of the C-terminal domain 
(PDV 3O0V). Ca2+ high binding affinity residues and low binding affinity residues are represented in orange and yellow 
respectively. Ca2+ binding atom is shown in green. Region encoded by exon 9 is shown in grey. B) C-terminal domain 
sequence alignment of CALR WT and CALR type 1 and Type2 mutants with the analysed crystal structure. Grey square 
represents α-helix structure. Ca2+ low binding affinity residues are shown in yellow.  Figure based on (Wijeyesakere 
et al., 2011) 
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3.2.2. Analysis of CALR mutations effects in the intrinsic disorder state of CALR C-
terminal domain 
To study whether CALR type1 and type2 mutations affect the known disorder state of CALR 
C-terminal domain, a multiparametric in silico analysis of the intrinsic disorder state of the 
CALR mutants’ C-terminal domain was performed by using five different bioinformatic 
servers: PONDR-VLXT, PONDR-FIT, IUPRED, PSIPRED and RONN-FIT (McGuffin et al., 2000; 
Dosztanyi et al., 2005; Yang et al., 2005; Xue et al., 2010). The trend to a disorder state of each 
amino acid was estimated with a score ranging between 0.5 and 1.  
Results showed that CALR wt C-terminal domain is highly disordered after residue 353 (Figure 
10 A) (estimation based in the average of all the obtained outputs). Interestingly, further 
analysis of the C-terminal domain of CALR type 1 and type 2 mutants showed an overall 
decrease in the disorder state in this region (Figure 10 B, C) compared with the CALR wt 
results. After mutation sequence boundary, all the individual predictors, except PONDER-FIT 
outputs, showed an overall decrease in the disorder probability of the new mutant C-terminal 
domain.  However, values below the disorder threshold were only observed at the end of the 
amino acid sequence in both CALR mutations.  
Overall, this computational analysis showed a decrease in the disorder probability of CALR C-
terminal domain in type 1 and type 2 mutants characteristic of MPNs.  This data could suggest 
that the C-terminal domain of CALR mutants could become a more rigid and defined 
structure, however further analysis focussing on the structural characteristics of this domain 
need to be performed in order to reach a better understanding of how CALR mutations affect 
the intrinsic structural characteristics of this novel C-terminal domain.  
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 317         337        357        377         397 
 3 7        337        357        377         397  317         337       357       377      397      417 
A.  
B.  C.  
Figure 10. Protein disorder analysis of CALR wt and CALR mutants' C-terminal domain 
Results obtained from (A) CALR wt sequence, (B) type 1  and  (C) type 2 mutation  C-terminal domains using five 
different disorder predictors : PONDR-VLXT (grey) PONDR-FIT (black), IUPRED (brown), PSIPRED (orange), RONN 
FIT (blue) and mean (read).  
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3.2.3. Three-dimensional structural modelling of CALR WT and CALR mutants  
After previous results showing a decrease of the disorder probability within the C-terminal 
domain of CALR mutants, it was questioned whether these physical alterations could lead to 
changes in the secondary structure of this protein region. As previously described, the 
experimental characterisation of the secondary structure of CALR wt C-terminal domain is not 
available yet and therefore the available PDB file cannot be used as a template to characterise 
and predict CALR mutants C-terminal domain secondary structure. Hence, in order to study 
the physical properties of CALR mutants C-terminal domain, it is necessary to build a model 
based on in silico comparative analysis. During this in silico study, the predicted structural 
models of CALR wt, CALR type 1 and type 2 mutations were obtained using I-TASSER software 
(Yang et al., 2015). The obtained results showed the predicted secondary structure of the 
input sequences. Results were shown as PDB templates and five 3D predicted structures were 
obtained for each input sequence. 
I-TASSER structural modelling starts from identifying structure templates in the PDB library. 
This analysis showed the PBD templates used for the sequence alignment of the input CALR 
sequences (Table 13). In this study, CNX (PDB LjhnA), a CALR structural homologue, was used 
for the alignment. Obtained Z-scored estimates the alignment of the protein sequences. Z-
scores >1 indicate higher confident alignment. 
 
Table 13. Rank1 threading templates for query protein sequence. 
Input sequence Structure template PDB Hit Z-score 
CALR wt  
Crystal structure of 
the luminal domain 
of Calnexin 
 
ljhnA 
3.87 
CALR type 1 
mutation 
2.78 
CALR type 2 
mutation 
2.78 
 
 
Five predicted 3D structural models of each input sequence were obtained by their alignment 
with CNX sequence. However, Figure 11 only shows the CALR wt, CALR type 1 and type 2 
mutant models considered as the best predicted structures. Obtained C-scores for these 
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models were -0.3, -0.21 and -1.09 respectively. For this structural analysis the C-terminal 
region of the proteins was studied in detail. Within the obtained models, the C-terminal 
domain is represented in orange-red and is pointed by white arrows in Figure 11.  
Results showed that after the structured region already predicted to be an α-helix within CALR 
wt C-terminal domain (Figure 11 A) there is a loop of random coil structural state until the 
end of the amino acid sequence where a short α-helix is formed (Figure 11 A). Interestingly, 
I-TASSER predicted changes in the secondary structure within the same protein region of CALR 
mutants. CALR type 1 mutation displayed an α-helix at the beginning of the random coil region 
and possible another small α-helix after. The α-helix predicted to be at the end of the protein 
in CALR wt disappears in this mutant region (Figure 11 B). Moreover, CALR type 2 mutant 
model showed a different structure. CALR type 2 C-terminal domain was formed mostly by 
random coil, except a short α-helix at the beginning of the region (Figure 11 C).  
Overall, the in silico analysis of the 3D structure of CALR C-terminal domain using I-TASSER 
software reveals that CALR type 1 and type 2 mutations could lead to changes within the 
secondary structure of this region. However, further analysis to confirm the fidelity of these 
structures need to be performed, as in silico analysis could have technical limitations.  
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Figure 11. 3D structural modelling of CALR wt, type 1 and type 2 mutants. 
Best predicted structural models of A) CALR wt, B) CALR type 1 and C) Type 2 mutation. Image shows three 
different space orientations of the obtained models by I-TASSER software. White arrows indicate the C-
terminal region of the protein.  
 
79 
 
3.2.4. Assessment of CALR WT and CALR mutants structural predicted models 
In order to assess the reliability of the previous structural CALR models the PROCHECK server 
was used to obtain Psi/Phi Ramachandran plots of the best predicted models by I-TASSER. 
This analysis was focused on the reliability of the C-terminal domains structural models only. 
CALR wt C-terminal domain (residues number 317-417) Psi/Phi Ramachandran plot showed 
89.05% residues in the allowed regions, 6% in the generous region and 4.95% in the 
disallowed region (Appendix 1 A). Overall, 95.05% residues of this model were located in the 
confidence regions, although residues within the generous region should be investigated 
more closely.  
CALR type 1 C-terminal domain (317-410 residues number) Psi/Phi Ramachandran plot 
showed 84% residues in the allowed regions, 12% in the generous region and 4% in the 
disallowed region (Appendix 1 B). Finally, CALR type 2 C-terminal domain (317-428 residues 
number) showed 87.37% residues in the allowed regions, 9% in the generous region and 
3.63% in the disallowed region (Appendix 1 C).  Therefore, 96% and 96.37% of the total 
residues of CALR type 1 and Type 2 mutations C-terminal domain are located within the 
confidence region of the Ramachandran plots.  
PROCHECK results obtained from CALR wt, type 1 and type 2 mutants C-terminal domain 
Psi/Phi Ramachandran plots suggested a high quality of the predicted models by I-TASSER. 
However, it is important to note that some of the amino acids were within the disallowed 
region. This suggests that further analysis should be performed to corroborate these models, 
as less than 90% of the residues were not within the high confidence regions.  
 
3.2.5. Analysis of CALR WT and mutants C-terminal domain secondary structure 
based on s2D method 
As the previous analysis by Ramachandran plots did not show higher than 90% of residues 
within the high confidence regions of the I-TASSER predicted models, further analyses were 
performed using other secondary structure predictor. For that, investigations into CALR wt 
and mutants C-terminal domains by using a novel online server, known as s2D method, were 
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carried out (Sormanni et al., 2015). This method unifies the prediction of the secondary 
structure population and the disorder probability of each amino acid of the given protein 
sequence.  
CALR wt C-terminal domain analysis showed a general low disorder probability and an 
increase of α-helix population until amino acid 345. Afterwards the final region of the C-
terminal domain showed an exponential increase of random coil (Figure 12 A) reaching values 
of 0.9 confidence.  
Results showed that first α-helix populations predicted in CALR wt remains constant in the 
two CALR mutations sequences till residue 345. It is important to note that CALR mutations 
are located after this amino acid sequence, in the IDPR predicted in the previous analysis 
(Figure 10). CALR type 1 mutation showed an overall decrease in the population of random 
coil structure and a small population of α-helix at the end of the structure (residues numbers 
400-404) (Figure 12 B). Moreover, analysis of CALR type 2 mutant C-terminal domain 
displayed two decreases in the population of random coil structure and two rises of α-helix 
populations at the end of the structure (residues numbers 398-403 and 418-423) (Figure 12 
C).  
Together, these results suggested that CALR mutations affecting the C-terminal domain could 
lead to a more stable conformational state within this protein region as seen previously by I-
TASSER and the three disorder predictor servers used in this study.  Overall, s2D analysis 
showed changes in the secondary structure populations within the C-terminal domain of CALR 
mutants, however the localisation of new α-helix populations did not agree with the I-TASSER 
predicted models (Figure 11), as this software predicted two small α-helix structures within 
the mutant region in CALR type 1 mutation and one α-helix in CALR type 2 mutation. However, 
both servers agreed that CALR mutations within this region lead to small changes in the 
secondary structure and there is an overall decrease in the disorder state of this region.  
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Figure 12. Analysis by S2D method of CALR wt, type 1 and type 2 C-terminal domains. 
Representations of A) CALR wt, B) CALR type 1, C) CALR type 2 C-terminal domains analysis performed by S2D 
server.  Graphs show the confidence of α-helix population in blue, β-strands in orange and random coil 
population in a continuous gray line. 
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3.2.6. Localisation of disorder-based protein binding sites within the intrinsically 
disordered CALR WT and CALR mutants C-terminal domain 
To further characterise the effects of type 1 and type 2 mutations in the IDPR within CALR C-
terminal domain, additional analysis aimed to investigate the presence and characteristics of 
MoRFs within these mutant regions.  For this in silico analysis, two different algorithms, 
ANCHOR (Dosztanyi et al., 2009) and MoRFpred (Disfani et al., 2012) as well as the average of 
both obtained inputs were used.  
Initially, both algorithms identified two MoRFs within the C-terminal domain of CALR wt. 
Average of both inputs predicted the location of MoRFs within the residues 319-348 and 409-
417, which suggested that the IDPR of this C-terminal domain could have the potential for 
protein binding (Figure 13).  
Both CALR mutations lead to a reduction of length of the first MoRF identified in this region 
in CALR wt (29 residues). CALR type 1 showed the location of MoRF in the amino acids 319-
333 (15 residues) and CALR type 2 in 319-336 (18 residues).  Second MoRF identified at the 
end of the C-terminal domain within CALR WT (8 residues), increased length in both type 1 
and type 2 mutants, 399-411 and 416-428 (13 residues). Changes in length in both MoRFs 
could lead to changes in the protein binding properties within this region and therefore 
changes in the disorder-to-order transitions of CALR C-terminal domain (Figure 13).  
Surprisingly, MoRFpred identified a potential additional MoRFs within CALR type 1 C-terminal 
domain, residues 374-382. Interestingly, although this MoRF predicted by MoRFpred was not 
identified by ANCHOR, this region displayed higher average scores when these were 
compared with the adjacent amino acids (Figure 13, black arrow). Therefore, this region could 
have a potential for binding proteins. Moreover, CALR type 2 showed an increase in MoRFs 
scores within the same region of the protein, predicted by both, ANCHOR and MoRFpred 
(Figure 13b, black arrow).  Hence, ANCHOR and MoRFpred showed that CALR mutations found 
in MPNs change the nature of MoRFs regions within the C-terminal domain and this could 
potentially affect the range of binding partners of these mutant proteins.  
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3.2.7. Effects of CALR mutations in the amino acid charge within the C-terminal 
domain  
As mentioned previously, CALR C-terminal domain is a highly acidic region and CALR 
mutations found in MPNs lead to changes in the amino acid sequence, increasing the number 
of basic residues within this region. Further analysis using the CALR wt, type 1 and type 2 
mutations structural models by I-TASSER allowed us to visualise independently the acidic and 
the basic amino acids within the 3D structure. The CALR C-terminal domain is represented in 
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 317      337        357       377       397 
 317          337      357       377      397  317     337      357     377     397     417 
A.  
B.  C.  
Figure 13. Computational analysis of MoRFs within the C-terminal domain of CALR wt, type 1 and type 2 
mutants.  
Results obtained from (A) CALR wt sequence, (B) type 1 mutation and (C) type 2 mutation C-terminal domains 
using two different disorder predictors: ANCHOR (grey) MoRFpred (brown) and mean (black). 
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red and orange residues, as well as being identified by white arrows. As seen in Figure 14, 
CALR wt random coil region within the C-terminal domain is mostly formed by acidic amino 
acids. In contrast, within the same structural region of CALR type 1 and type 2 mutants there 
is a switch from acidic to basic amino acids (Figure 14).  
 
 
 
 
 
 
Moreover, analysis using the Scripps Institute’s on-line Protein calculator v.3.3 showed that 
CALR wt C-terminal domain Isoelectric point (pI) is highly acidic compared with type 1 and 
type 2 mutants, which are highly basic (Table 14). Therefore, change in amino acid charge 
Figure 14. Analysis of acidic and basic residues location within the 3D structural models of CALR WT, type 
1 and type 2 mutations. 
Visualisation of acid and basic residues within the best predicted structural models of CALR by I-TASSER 
software. White arrows indicate the C-terminal region of the protein 
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within this region could affect the Ca2+ binding capacity of CALR mutants and consequently 
lead to abnormal ER Ca2+ buffering activity.  
 
Table 14. Isoelectric points for WT and mutant CALR peptides used during this study derived from the C-
terminus. 
Calculations were performed using the Scripps Institute’s on-line Protein Calculator v.3.3 
(http://www.scripps.edu/Bcdputnam/protcalc.html) 
CALR Sequence Ip 
wt QDEEQRLKEEEEDKKRKEEEEAEDKEDDEDKDEDEEDEEDKEEDEEEDVPGQAKDEL 
 
3.96 
Type 1 QDEE-QRTRRMMRTKMRMRRMRRTRRKMRRKMSPARPRTSCREACLQGWTEA 
 
12 
Type2 QDEEQRLKEEEEDKKRKEEEEAEDRRMMRTKMRMRRMRRTRRKMRRKMSPARPRTSCREACLQGWTEA 
 
10.30 
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3.3. Discussion 
 
CALR C-terminal domain is a functionally important region, as it binds to 50% of ER Ca2+ and 
contains the ER retention motif. Nevertheless, the secondary structural characterisation of 
this region has not yet been detailed due to its high instability. Novel advances in 
bioinformatic tools aiming to predict protein secondary structure and stability have recently 
helped to understand the nature of CALR C-domain (Migliaccio and Uversky, 2017). However, 
further characterisation of this region could play an important role in deciphering the 
malignant role of the novel CALR mutant C-terminal domains (Nangalia et al., 2013; Klampfl 
et al., 2013). 
This study reports a deep structural in silico based analysis of the C-terminal region of human 
CALR and the two most common CALR mutations described in MPNs patients. The initial 
analysis based in the disorder probability of CALR C-terminal domain showed that CALR type 
1 and type 2 mutations display an intrinsic disorder state in most of the domain, although 
there are some regions that reach or trend to a more stable status. This multiparametric study 
corroborates previous published results using single in silico predictors (Eder-Azanza et al., 
2014, Varricchio et al., 2017). The intrinsic disordered state of CALR wt C-terminal domain 
could be essential for the functionality of the region as it could provide functional advantages, 
such as further interface area during protein interactions (Gunasekaran et al., 2003). Also, it 
has been suggested that IDPR containing high specificity and low affinity binding properties, 
as seen in CALR C-terminal domain and Ca2+ binding sites, allow a rapid and easy dissociation 
of interactions within these regions (Wright and Dyson, 2009).  Therefore, the disordered 
structural state of CALR C-terminal domain could allow to have more functional efficiency 
during the Ca2+ buffering activity of CALR within the ER and increase interface Ca2+  interaction 
areas. Hence, it could be speculated that CALR mutations, which decrease the number of 
amino acid Ca2+ binding sites and also decrease the disorder probability of the C-terminal 
domain, could lead to an impaired Ca2+ buffering activity of CALR mutant proteins.   
Additionally, the C-terminal domain of CALR wt is characterised by a coil-coil structure and 
minimal α-helical content (Migliaccio and Uversky, 2017, Varricchio et al., 2017). However, 
both CALR mutations analysed in this study showed changes in the structural characteristics 
of the C-terminal tail, leading to a small change of the α -helical content.  These local 
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conformational changes could impact protein behaviour and may cause abnormal protein-
protein interactions. Interestingly, further analysis of MoRFs within the mutant C-terminal 
tails showed an increased probability of a potential binding site within this region of CALR 
type 1 and type 2 mutants, as previously described (Varricchio et al., 2017). In addition, these 
results agree with the described presence of LCR within these protein domains (Eder-Azanza 
et al., 2014).  This data could explain the molecular basis of previous studies which revealed 
the novel interaction between CALR mutant and MPL receptor, which is dependent on C-
terminal domain (Elf et al., 2016; Araki et al., 2016; Chachoua et al., 2016).   
However, it is important to bear in mind that the structural models estimated in this study 
using I-TASSER software do not ensure total accuracy and reliability, as the best predicted 
models obtained during our study did show residues within the not allowed region in the 
Ramachandran plots. Given these mutant areas do not have any structural template of a 
homologous protein that could be used by structural prediction servers to obtain higher 
reliability models, these results could be considered as a good approximation of CALR 
mutants’ secondary structure. Moreover, in order to gain further details of the secondary 
structure of these regions of interest an additional predictor was used, known as s2D method, 
which combines the disorder state and the secondary structure prediction of each amino acid. 
Results provided further evidence of a decrease in the random coil-coil population within the 
C-terminal domain in both CALR mutants compared with CALR wt. Furthermore, s2D method 
showed an increase in α-helix population. However, the α-helix population predicted by s2D 
server did not agree with the population predicted by I-TASSER. Both servers showed changes 
in the structural state within these regions but in different amino acid sequences. Therefore, 
CALR type 1 and type 2 mutations lead to changes in the α-helical content within the C-
terminal domain, as previously suggested (Eder-Azanza et al., 2014), however the localisation 
of this novel structured regions remains unclear.  
CALR C-terminal domain contains the basic lysine and arginine residues interspersed in large 
clusters of acidic residues of aspartic and glutamic acid (Coe and Michalak, 2009). This 
characteristic amino acid composition leads to the appearance of low affinity and high 
capacity Ca2+ binding residues (Nakamura et al., 2001; Coe and Michalak, 2009).  Interestingly, 
deletion of the interspersed basic amino acids leads to a disruption of Ca2+ binding activity of 
this residue (Breier and Michalak, 1994). Therefore, not only are the acidic regions important 
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but the complete amino acid sequence of this domain is essential for the correct activity of 
CALR as a Ca2+ buffering protein. In this study, the 3D structural models of CALR wt, type 1 
and type 2 mutants obtained using the I-TASSER software were used as templates to visualise 
the different positions of acidic and basic residues within the novel mutant regions. Both CALR 
mutations lead to a significant decrease of acidic amino acids and increase in basic residues 
in both CALR mutants structure. Decrease of acidic residues match with the Ip of each region 
described here and in previous publications (Shivarov et al., 2014). Importantly, these results 
suggest that both, changes in the acidity and the amino acid sequence within CALR type 1 and 
type 2, could impair the Ca2+ buffering activity of CALR within the ER.  
Overall these results confirm the initial speculations about the effects of CALR C-terminal 
domain mutations leading to changes in the physical characteristics of the novel mutant 
regions.  CALR mutations found in MPN decrease the disorder probability of the C-terminal 
domain and could lead to the emergence of α-helix structure within this region, as well as 
changes in the domain´s acidity. These structural changes in CALR C-terminal domain could 
change CALR cellular behaviour by leading to inefficient Ca2+ buffering activity and also 
promote novel protein-protein interactions.  
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3.3.2. Conclusion 
 
This in silico study describes in detail the structural characteristics of the novel C-terminal 
domain of CALR type 1 and type 2 mutants and provides more insights into the potential of 
these regions to establish novel protein interactions. In summary, the major conclusions of 
this study are: 
I. This multiparametric study shows similar results than the previously obtained 
using single disorder predictors (Varricchio et al., 2017). CALR type 1 and type 2 
mutations affect the intrinsic disorder state of the C-terminal domain. Although 
these regions display an overall disordered status, there is a tendency of decrease 
towards a stable structure, mostly at the end of the domain. 
 
II. Both analyses of secondary structure using I-TASSER and S2D servers predict the 
appearance of an α-helix content within CALR type 1 and type 2 C-terminal 
domains. 
  
III. Changes in the molecular properties of type 1 and type2 C-terminal domains lead 
to the emergence of potential novel MoRFs regions, as previously described 
(Varricchio et al., 2017). 
 
IV. CALR mutations change the amino acid charge of the novel C-terminal domains 
from acidic to basic.  
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3.3.4. Future work 
 
This preliminary study sets the basis for further experimental analysis of CALR mutants in 
MPNs. As predictions suggest that CALR mutations lead to a decrease in the disorder state of 
C-terminal domain, it is possible that CALR mutants could be crystallised and analysed further 
in detail. Additionally, PDB files obtained of each predicted model could be used to perform 
further molecular dynamics to obtain more reliable models and to estimate Ca2+ binding 
affinity under the simulation of physiological ER conditions.  
Additionally, as previously discussed, increase in MoRFs regions within type 1 and type 2 C-
terminal domains could increase the binding protein interactions. Binding between mutant 
CALR and MPL have been described, however it would be of interest to analyse other 
potential binding partners by using pull-down assay and mass spectrophotometry in order to 
understand the role of CALR mutant within the aberrant signalling network described in CALR 
mutant MPNS.  
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Chapter 4: MARIMO cell line, a new 
model to study megakaryopoiesis with 
CALR mutations  
 
 
4.1 Introduction  
 
Hematopoiesis is a complex and highly regulated process in which specific cell-type gene 
expression signatures lead to the differentiation of pluripotent stem cells into mature blood 
cells. The study of molecular events during hematopoietic commitment in disease is hindered 
by the access to purified primary progenitor cells. Thus, the use of leukemic cell lines as 
models for the study of cell lineage commitment has increased greatly during last two 
decades (Kang et al., 1996; Smithgall, 1998; Zhang et al., 2007; Hirose et al., 2013; Huang et 
al., 2014). In vitro cellular differentiation using cytokines is a commonly used to study cell 
commitment under physiological conditions (Syme and Gluck, 2001; Flores-Guzman et al., 
2002). However, the use of the pharmacological agents as differentiation inducers is a 
technique that has shown strong differentiation effects in multiple myeloid leukemia cells 
(Smithgall, 1998). Classic examples of differentiation inducing agents are phorbol esters or 
retinoic acids, which have been widely used for the investigation of the differentiation block 
characteristic of leukemic blasts as well as for the discovery of signalling cascades associated 
with cellular commitment (Smithgall, 1998; Huo et al., 2006; Hirose et al., 2013; Huang et al., 
2014).  
Phorbol 12-myristate 13-acetate (PMA) is a phorbol ester commonly used to induce lineage 
differentiation of several myeloid leukemia cell lines. Previous research demonstrated that 
the monocytic U-937 and THP-1 and the promyelocitic leukemia HL-60 cell lines differentiate 
into macrophages under PMA treatment (Huberman and Callaham, 1979; Ways et al., 1987). 
Also, the erythroleukemia cell lines K562 and HEL differentiate into megakaryocytes in 
response to PMA induction (Long et al., 1990; Tabilio et al., 1983).  PMA megakaryocytic 
induction is accompanied by the acquisition of the megakaryocyte phenotype, such as 
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increase cell size and cell adhesion, increase expression of megakaryocyte cell surface 
antigens (CD41, CD61 and CD110), acquisition of DMS, as well as arrest in cell cycle and 
endomitosis. 
PMA is known to mimic the activity of diacylglycerol. Downstream signalling of this molecule 
leads to the activation of protein kinase C (PKC) family, which comprises 11 different 
members. PKC is involved in the intracellular signalling mechanism inducing megakaryocyte 
commitment (Racke et al., 2001). Previous work demonstrated the cooperation of PKC with 
GATA-1 during the transcriptional activation of megakaryocyte promoters (Racke et al., 2001). 
Also, PKC is involved in the activation of Raf-MEK-ERK cascade during megakaryocyte 
commitment (Ueda et al., 1996; Schonwasser et al., 1998) 
The recent finding where a previously established AML-M2 cell line, known as MARIMO 
(Yoshida et al., 1998), harbors a CALR mutation has revealed the importance of this cellular 
model for the study of the molecular pathogenesis of CALR mutant in MPNs (Kollmann et al., 
2015). These cells carry a 61-bp deletion in CALR exon 9 (L367fs*43). As all CALR mutations 
found in MPNs, this mutation leads to a +1- bp shift in the reading frame and therefore the 
formation of a novel C-terminal region. Importantly, JAK2 and c-MPL mutations have not been 
identified in MARIMO cells (Kollmann et al., 2015). 
 
Since the discovery of CALR mutation in MARIMO cells, research using this cell line has been 
focused in deciphering the signaling profile characteristic of these cells, to shed light in the 
pathogenesis of CALR mutant MPNs. Interestingly, MARIMO cells’ growth do not show 
dependence on JAK/STAT signaling. These cells are resistant to JAK inhibitors and JAK/STAT 
downstream JAK2 and STAT5/1/3 proteins show low levels of phosphorylation (Kollmann et 
al., 2015). This previous publication suggested that CALR mutations could induce activation 
of different signalling cascades other than JAK/STAT signalling during disease (Kollmann et al., 
2015).  Surprisingly, a recent investigation showed that CALR mutant MARIMO cells display a 
significant dependence on MAPK pathway compared to other myeloid leukemia cell lines 
(Kollmann et al., 2016).  These cells showed high sensitivity to MAPK inhibitors and displayed 
high phosphorylation levels of downstream components of this cascade such as MEK1 and 
ERK1 (Kollmann et al., 2016).  
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Further research analysing the phenotype of these leukemic blasts revealed that MARIMO 
cells do not express MPL cytokine receptor, neither in mRNA nor protein levels (Kollmann et 
al., 2016). As previous research demonstrated, CALR mutant protein binds to MPL receptor 
(Araki et al., 2016; Elf et al., 2016) and this novel protein binding could possibly induce the 
activation of JAK/STAT pathway during disease (Chachoua et al., 2016; Marty et al., 2016). 
The fact that MARIMO cells do not express MPL receptor opens the possibility that CALR 
mutations activate MAPK pathway through other mechanisms in these cells, and that 
JAK/STAT signalling might not be active due to the absence of expression of this cytokine 
receptor.  
 
MARIMO cell line was established from a secondary AML patient that evolved from ET 
treatment (Yoshida et al., 1998). This cell line has been reported to be negative for 
megakaryocyte (CD61, CD41, CD42) and erythrocyte (CD235a) cell surface markers but 
positive for CD15 (Kollmann et al., 2015), a marker characteristic of myeloid progenitor cells 
(Lee et al., 2001).  Therefore, this cell surface antigens phenotype suggests a block in 
differentiation in early stages of the myeloid cell linage in MARIMO cell line.    
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4.1.1. Aim and hypothesis 
 
As recent data show that the MARIMO leukemic cell line expresses a myeloblast cell surface 
antigen, lacks any cell surface markers characteristic of cell lineage commitment and does not 
express MPL, it is therefore possible that these cells could display a block in early stages of 
myeloid differentiation. Therefore, MARIMO cell line could have the potential to commit into 
specific cell lineages under the exposure of differentiation inducing agents.  
The main aim of this study is to characterise the potential of MARIMO cells to differentiate 
into the megakaryocyte lineage under PMA treatment, as previously reported with other AML 
cell lines. The purpose of analysing MARIMO megakaryocyte induction is to establish a cellular 
model that could be used for the analysis of megakaryopoiesis characteristic of ET and PMF 
harbouring CALR mutations and to study the behaviour of CALR mutant within megakaryocyte 
differentiated cells. Therefore, in order to assess the megakaryocytic potential of MARIMO 
cells, four major objectives will be addressed: 
 
I. Analysis of expression of CD41a megakaryocyte cell surface marker after 
incubation of MARIMO cells under different PMA concentrations.   
 
II. Study of the effects of PMA treatment on the cell cycle and replicative potential of 
MARIMO cells. 
 
III. Analysis of the emergence of megakaryocyte morphological characteristics, 
including polyploidy, increase cell size, adhesion and the emergence of DMS.   
 
IV. Characterisation of JAK/STAT signalling status after PMA treatment.   
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4.2. Results 
 
4.2.1 Analysis of CD41a expression in MARIMO cells after PMA induction 
The potential of in vitro megakaryocytic differentiation of MARIMO leukemia cell line was 
tested by using PMA treatment as a cell commitment inducer. MARIMO cells were seeded at 
a concentration of 3x105 cells/ml and cells were incubated with different PMA concentrations 
(0 nM, 2 nM, 5 nM, 10 nM, 20 nM). After 72 hours incubation presence of the megakaryocyte 
cell surface marker CD41a was analysed by immunostaining and flow cytometry.  
As previously reported, MARIMO control cells showed no expression of CD41a under normal 
conditions. However, MARIMO cells under PMA treatment showed an overall increase in 
CD41a expression within the cell membrane after 72 hours of PMA incubation, suggesting the 
potential of megakaryocytic differentiation of MARIMO cells. The obtained contour plots of 
the different PMA treatment showed a major shift in CD41a fluorescence within the cell 
population under 5 nM PMA treatment (Figure 15). Moreover, 10 nM and 20 nM PMA 
concentrations did not show a significant increase in CD41a expression compared to 5 nM 
PMA (Figure 15).  Therefore, in order to avoid cellular toxicity under PMA treatment 5 nM 
PMA was used for further experiments as an optimal concentration for PMA megakaryocytic 
induced differentiation of MARIMO cells.  
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Figure 15. Optimization of MARIMO PMA treatment. 
Representative counter plots of flow cytometry analysis measuring CD41a antigen expression in MARIMO 
cell population after treatment of different concentrations of PMA (2 nM, 5 nM, 10 nM, 20 nM) during 72 
hours. Cells were stained with CD41a-APC antibody.  
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Quantification of CD41a fluorescence of MARIMO cells after 5 nM PMA treatment during 72 
hours incubation showed a significant increase in CD41a cell surface expression compared to 
the control (Figure 16 A, B). Moreover, percentage of cellular events registered to express 
CD41a antigen within the cell surface increased from 13.41% to 72.8% suggesting that PMA 
induced megakaryocyte differentiation in the majority of MARIMO cell population (Figure 16 
B).  
Finally, the toxic effects of 5nM PMA treatment after 72 hours in MARIMO cell line were 
analysed. Trypan blue was used as an indicator of cell death within the culture. Results 
showed that PMA induced cell death in about 24% of cells within the culture (Figure 16).  
These results demonstrated that PMA treatment induce the expression of a megakaryocytic 
cell surface marker in MARIMO cells, suggesting a possible differentiation towards the 
megakaryocytic lineage of this AML-2 cell line. 
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Figure 16. CD41a quantification and cell death induction after MARIMO PMA induction. 
A, B) MARIMO cells were subjected to 5 nM PMA treatment during 72 hours and then CD41a expression was 
analysed and quantified by flow cytometry. C) Quantification of CD41a positive cells. D) Analysis of cell death 
after PMA treatment. Values represent mean ± SEM for each group. n=3. **P<0.01, *P<0.05. Student T.test  
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4.2.2. MARIMO cell cycle analysis after PMA treatment 
As MARIMO cells express a megakaryocyte cell surface marker after exposure to PMA, the 
effects of this inducer in the DNA replication potential of these cells were further examined.  
In order to study the cellular distribution along the cell cycle, propidium Iodide staining and 
flow cytometry analysis were used after 72 hours incubation.  
Results showed that MARIMO cells under PMA treatment reduced their replication potential 
(Figure 17). The number of cells found in S phase dropped from 23% in the control group to 
6% in the PMA induced cells. Additionally, the number of cells in G2/M also decreased from 
15% to 10%. On the contrary, the obtained results displayed an accumulation of cells in G0/G1 
phase, increasing from 61% in the control cells to 84% in the PMA treated cells (Figure 17 B).  
These observations suggested that PMA-megakaryocytic induced differentiation in MARIMO 
cells leads to an arrest in cell cycle, accumulating cells in G0/G1 phase. The loss of replicative 
potential is a characteristic of cell terminal differentiation, and therefore these results 
corroborated the effect of megakaryocytic induction of MARIMO cells under PMA treatment.  
Moreover, during megakaryopoiesis cells exhibited increase nuclei size and then enter in 
endomitosis during final megakaryocyte maturation. Propidium iodide staining showed an 
increase in 2N and 4N fluorescence intensity, suggesting an initial increase in nuclear size 
(Figure 17 A). However, no signs of an overall cellular polyploidy (8N, 16N) were found after 
72 hours of PMA induction in MARIMO cells  
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Figure 17. Analysis of cell cycle in PMA induced MARIMO cells.  
MARIMO cells were subjected to 5 nM PMA treatment during 72 hours and propidium iodide staining 
was performed and samples were analysed by flow cytometry. A) Representative histogram of cell cycle 
analysis of MARIMO cells after PMA treatment. B) Quantification of number of cells in each cell cycle 
step. Values represent mean ± SEM for each group. n=3. **P<0.01, *P<0.05. Student T.test 
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4.2.3. Proliferation assay of MARIMO cells under PMA treatment 
A reduction of S phase in MARIMO cells under PMA treatment after 72 hours suggested a 
decrease in the proliferation capacity of these cells, as expected for induced differentiation 
cells. To analyse the division capacity of these cells under 5 nM PMA treatment, MTS assay 
was performed over 72 hours.  
Control MARIMO cells increased 4 fold during 3 days of culture (Figure 18).  However, PMA 
induced cells showed a decreased in their rate of proliferation (Figure 18). Inhibition of 
proliferation after PMA induction was significantly decreased between 24 and 48 hours. After, 
no further cellular proliferation was detected. These results indicated that 5 nm PMA treated 
MARIMO cells progressed to only one cycle of cell division before their arrest in cell cycle.  
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Figure 18. Proliferation analysis during PMA megakaryocytic induction of MARIMO cells. 
MARIMO cells were subjected to 5 nM PMA treatment during 0, 24, 48 and 72 hours. Then, MTS assay 
was performed in order to test cell viability.  Values represent mean ± SEM for each group. n=2 
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4.2.4. Morphological analysis of MARIMO cells under PMA treatment 
Megakaryocyte characteristics such as increase cell size or cell adhesion can be easily 
described in cell cultures under light microscopy (Huang et al., 2014). After describing an 
increase of CD41a megakaryocyte antigen and an arrest in cell cycle characteristic of cell 
differentiation, the morphological characteristics of MARIMO cells after PMA induction were 
analysed.   
Initial morphological analysis under light microscopy showed differences between the control 
and the PMA induced MARIMO cells. In control, cultured MARIMO cells show normal 
leukemic blast characteristics (Figure 19).  MARIMO cells cultured for 72 hours in the presence 
of 5 nM PMA acquired a megakaryocyte-like phenotype. Overall, MARIMO cells displayed 
differences in cell morphology after PMA-induced differentiation. Cells show a slight increase 
in cell size compared to the control group. Also, MARIMO differentiated cells displayed 
cytoplasmic projections characteristic of DMS for platelet production (Figure 19, black 
arrows).  Moreover, PMA treatment induced an increase in the adhesive capacities of 
MARIMO cells.  
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MARIMO control 
MARIMO 5nM PMA  
Figure 19. Representative images of MARIMO live cells under PMA treatment. 
MARIMO cells were subjected to 5 nM PMA treatment during 72 hours. Then, samples were used 
for light microscopy. Images were captured using 40x objective. Black arrow: DMS. Scale bars =50µm 
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MARIMO morphology was analysed in more in detail using Wright-Giemsa staining.  In control 
cells MARIMO displayed a typical basophilic cytoplasm containing abundant lipid vacuoles 
(Figure 20, black arrows) and   rounded nuclei with numerous basophilic nucleoli (Figure 20A, 
blue arrow). Moreover, cells showed a high nuclear-to-cytoplasm ratio, characteristic of 
leukemic blasts (Figure 20).  
MARIMO cells under PMA megakaryocytic induction showed an overall increase in cell size 
and fragmented cytoplasm (Figure 20).  The cytoplasm was less basophilic, azurophilic 
granules were occasionally found and extensive DMS were identified (Figure 20 D, orange 
arrows) as sign of cytoplasm maturation. Moreover, nuclei increased size and displayed oval 
or kidney shapes, corroborating previous data obtained where there was an increase in 2N 
and 4N signal in these cells (Figure 20 A). Furthermore, occasional multilobulated nuclear cells 
were found, suggesting that MARIMO cells undergo endomitosis under PMA treatment after 
72 hours. Different cellular stages of megakaryocytic maturation were described according to 
the number of nuclei and cell size: megakaryoblast with a single oval nucleus and a diameter 
between 20-30 µM (Figure 20 B), pro-megakaryocyte with 2-4 nuclei (Figure 20 C) and mature 
megakaryocytes which display 4-16 nuclei and diameter ranges between 30-90 µM (Figure 20 
D).   
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Figure 20. MARIMO cytological changes under PMA treatment. 
MARIMO control cells slides were prepared using the Cytospin and cells treated with 5 nM PMA for 72 
hours were grown in coverslips. Both groups were subsequently subjected to Wright-Giemmsa 
staining. Representative images of MARIMO A) control and B, C, D) PMA treated cytological 
characteristics are shown. Images were capture using  X100 objective. Scale bars = 10 µm. 
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4.2.5. Analysis of MPL expression in MARIMO cells after PMA treatment 
Megakaryocyte maturational process includes the expression and activation of specific 
proteins and cellular signals. c-MPL gene is highly expressed in megakaryocytes and its 
expression is essential for megakaryocyte formation (Methia et al., 1993, Nagata et al., 1995). 
Although MARIMO leukemic blasts have been described not to express MPL (Kollmann et al., 
2016), the previously described MARIMO megakaryocyte like transformation could lead to an 
induced expression of c-MPL.  
To examine the effects of PMA treatment in the expression of MPL, cMPL mRNA levels were 
quantified using qRT-PCR analysis. Results showed a significant upregulation of c-MPL gene 
expression when cells treated with PMA (Figure 21 A). Moreover, MPL protein levels within 
the cell surface were quantified by flow cytometry and results showed a significant increase 
of this antigen after PMA induction (Figure 21 B, C). Quantification of MPL positive events 
estimated that approximately 60% of cells in the culture expressed this receptor within the 
cell surface (Figure 21 D).  
Overall these interesting results showed that PMA megakaryocyte induction in MARIMO cell 
line leads to an expression of MPL receptor, in both mRNA and protein levels, suggesting a 
possible activation of JAK/STAT pathway when these cells acquire megakaryocyte 
characteristics.  
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Figure 21. MPL expression in MARIMO cells after PMA megakaryocytic induction. 
MARIMO cells were subjected to 5 nM PMA treatment for 72 hours. A) mRNA was extracted and converted 
into cDNA and finally subjected RT-qPCR using primers against c-MPL. B, C) MPL (CD110) expression was 
analysed and quantified by flow cytometry. D) Quantification of CD41a positive cells. Values represent mean 
± SEM for each group. n=3. **P<0.01, *P<0.05. Student T. test.  
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4.2.6. Study of the expression of STAT5 gene signature in MARIMO cells after PMA 
treatment. 
Detection of JAK/STAT cascade activation by measuring the phosphorylation status of STAT 
proteins is possible by directly analysing the gene signature of these transcription factors 
(Sonkin et al., 2015). To study the consequences of the megakaryocyte induction in the 
signalling signature of MARIMO cells qRT-PCR was used to study the status of STAT5.  Four 
known STAT5 target genes, PIM1, CISH, ID1 and SOCS2, were selected as targets for this 
analysis. Previous research reported that this gene signature is highly correlated with the 
phosphorylation status of STAT5 during haematological malignancies (Sonkin et al., 2015). 
qRT-PCR analysis showed that MARIMO PMA induction leads to an overall increase of mRNA 
expression of the gene signature of STAT5 (Figure 22).  Although not statistically significant, 
mRNA expression of PIM1 and ID1, two oncogenes linked with the development of 
haematological malignancies (Suh et al., 2008; Brault et al., 2010), showed an overall 
upregulation in MARIMO PMA treated cells. However, CISH and SOCS2, which are involved in 
the negative regulation of JAK/STAT pathway (Quentmeier et al., 2008; Borges et al., 2008), 
displayed a statistical significant upregulation of mRNA expression compared with the control 
(Figure 22 C, D) displaying a 6.5 and 9 fold increase respectively.  
Thus, MARIMO PMA treatment resulted in a trend for upregulation of the STAT5 gene 
signature. This, in combination with the previous findings showing an upregulation of MPL 
expression, suggests an activation of the JAK/STAT signalling within MARIMO PMA treated 
cells 
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Figure 22. Expression of STAT5 gene signature in MARIMO cells after PMA treatment. 
MARIMO cells were subjected to 5 nM PMA treatment during 72 hours. mRNA was extracted, converted 
into cDNA and finally subjected RT-qPCR using primers against PIM1, CISH, ID1 and SOCS2 genes. Values 
represent mean ± SEM for each group. n=3. **P<0.01, *P<0.05. Student T.test 
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4.3. Discussion 
 
CALR mutant MARIMO AML-2 cell line displays a primitive hematopoietic phenotype, 
expressing an early cell surface myeloblast marker and lacking any cell lineage commitment 
antigens (Kollmann et al., 2015; Yoshida et al., 1998) (Figure 23). Together with the 
publication of the establishment of MARIMO cell line, it was reported that these cells only 
differentiated into granulocytes under all-trans retinoic acid (ATRA) treatment, however, the 
conditions and results of experiments using phorbol esters were not described (Yoshida et al., 
1998). This study demonstrates that the treatment of MARIMO cells with 5 nM of the phorbol 
ester PMA during 72 hours leads to an induced megakaryocytic lineage commitment of these 
cells. Analysis of MARIMO cells under PMA treatment revealed that these cells significantly 
express the megakaryocyte antigen CD41a. Morphologically, PMA induced MARIMO cells 
showed an increase in cell size as well as cytoplasmic and nuclear megakaryocyte maturation 
(Figure 23). These structural changes under PMA induction are also accompanied with a cease 
of cellular proliferation and increase in DNA content.  
Detailed morphological analysis of PMA induced MARIMO cells showed a clear increase in cell 
size and nuclear content, presence of DMS, as well as a decrease in basophilia within the 
cytoplasm. This phenotype is consistent with the previously described megakaryocyte stages 
of megakaryoblast and pro-megakaryocyte (Hattori et al., 1987; Long and Williams, 1981). 
However, a relatively reduced number of mature megakaryocytes was found in the culture, 
with an extensive DMS and high polyploidy (8N-16N), although no alpha-granules and no 
cytoplasmic division into platelets were identified in culture. The reduced ability of MARIMO 
cells to commit into final mature megakaryocytes is not surprising, as in vitro terminal 
differentiation of haematopoietic cell lines commonly fails, such as megakaryocyte and 
erythrocyte maturation of HEL cells (Long et al., 1990; Papayannopoulou et al., 1987) or HL-
60 granulocyte maturation (Collins, 1987). Therefore, these results suggest that either PMA 
does not entirely induce the final megakaryocyte maturation or that MARIMO cells do not 
have the capacity to fully differentiate into mature megakaryocytes due to the leukemic 
transformation of this cell line or the culture conditions.  
Endomitosis is a process by which megakaryocytes replicate their DNA without cytoplasmic 
division, leading to the characteristic polypoid state of these cells. Firstly, megakaryocyte 
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commitment is accompanied by changes in the cell cycle, reducing the proliferation potential 
of these cells. Then, megakaryoblasts begin endomitosis reaching 4n-64n DNA content during 
maturation (Zimmet and Ravid, 2000; Wen et al., 2011).  These results show that PMA induced 
MARIMO cells proliferation potential ceases and cells consequently continue undergoing 
endomitosis, reaching 2 to 4 times of their baseline DNA content after 72 hours. However, it 
is possible that increase of PMA incubation time could lead to a continuation of the 
endomitotic process, reaching higher DNA content in these committed cells. Nevertheless, 
MARIMO cells displayed a reduction in capacity to synthesise DNA content compared to 
primary megakaryocytes, as previously seen with other cell lines, such as HEL cells under PMA 
induction (Long et al., 1990). Although the process of endomitosis is not complete during 
MARIMO megakaryocyte commitment, the technical problems of studying this process using 
primary immature megakaryocytes leads to increase interest in using this cell line as a novel 
model to study the initiation of the endomitotic process.  
TPO, the major cytokine regulating megakaryocyte maturation and platelet formation, acts 
via its MPL receptor. MPL receptor is essential for megakaryopoiesis and its expression is also 
essential to have a tight control of myeloproliferation (Besancenot et al., 2014). MPL and 
deregulated JAK/STAT signalling cascade are commonly linked with the pathogenesis of ET 
and PMF (Kilpivaara and Levine, 2008; Kralovics et al., 2005; Pardanani et al., 2006). CALR 
mutant MARIMO cell line does not express MPL receptor in its blast stage and consequently 
JAK/STAT signalling is not activated in these cells (Kollmann et al., 2015; Kollmann et al., 
2016). Interestingly, this study has shown that the commitment of MARIMO cells into the 
megakaryocytic lineage is accompanied by an increased expression of MPL receptor, in mRNA 
and protein levels. Also, results provided further evidence that STAT5 gene signature (PIM1, 
CISH, ID1 and SOCS2) is expressed after MARIMO PMA treatment, suggesting an activation of 
JAK/STAT pathway in these cells, possibly as a consequence of MPL expression (Figure 23).  
MARIMO cells carry L367fs*43 CALR mutation which leads to 1+ base pair shift in the reading 
frame in CALR exon 9 fragment. Therefore, CALR 61 bp del mutation found in MARIMO cells  
generates a novel C-terminal domain, as described in the common mutations type 1 and type 
2 (Kollmann et al., 2015). Type 1 and type 2 CALR mutations have been described to interact 
with the extracellular domain of MPL receptor leading to its oncogenic activation in ET and 
PMF (Elf et al., 2016; Araki et al., 2016). However, this interaction has been described using 
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artificial models, such as retrovirally transduced murine Baf3 and transfected human HEK-
293T cells. Because MARIMO megakaryocyte like cells increase MPL receptor expression, the 
interaction of CALR mutant and MPL receptor could be possible in these cells after PMA 
megakaryocyte induction. Therefore, MARIMO cells could be used as a model to study the 
binding of the intrinsic CALR mutant and MPL in vitro, thus avoiding any artificial effects 
caused by protein overexpression in specific cellular models.  
The JAK/STAT signalling cascade has been linked with cell survival and cancer progression 
(Kisseleva et al., 2002; Ihle and Gilliland, 2007; Wierenga et al., 2008). Aberrant JAK/STAT 
signalling pathway in MPNs has accelerated the use of JAK inhibitors for the treatment of this 
group of diseases, such as Ruxolitinib, a potent JAK1/2 inhibitor used in clinic (Harrison et al., 
2012). The understanding of CALR mutations and their link with aberrant cellular signalling is 
a controversial topic.  Some studies directly correlate the presence of CALR mutations with 
an overactivated downstream JAK/STAT cascade (Araki et al., 2016; Chachoua et al., 2016; Elf 
et al., 2016) and other suggests that CALR mutant lead to a deregulated MAPK activation and 
that this is the major cause of pathogenesis in this group of patients (Kollmann et al., 2016). 
However, it is important to bear in mind that CALR mutant MPN patients respond well to 
Ruxolitinib treatment (Harrison et al., 2012; Patel et al., 2015), therefore aberrant JAK1/2 
activity is possible in this group of patients. MARIMO cell line was used as a model to 
demonstrate that CALR mutant cells aberrantly activate MAPK signalling rather than JAK/STAT 
(Kollmann et al., 2016). However, results in this thesis suggested that the reason why 
JAK/STAT signalling was not active in this AML-2 cell line was due to a block in the leukemic 
blast stage.  However, further studies are essential to test whether this cascade is active due 
to a direct interaction of CALR mutant and MPL or other molecular pathologies lead to an 
activation of this cascade. 
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Taken together, the current data highlights the importance of MARIMO cell line as a model 
to study CALR mutations. The findings of this investigation reveal a novel cellular model with 
potential to differentiate into the megakaryocyte lineage and propose its relevance to study 
CALR mutations effects in the physiological process of megakaryocyte formation 
characteristic of the myeloid neoplasms harboring this driver mutation.  
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Figure 23. Schematic representation of MARIMO megakaryocyte like cells model based in the results obtained 
in this study. 
114 
 
4.3.1. Conclusions 
 
The novel megakaryocyte commitment capacity of MARIMO cells described during this study 
provides new insights into the biology of this newly characterised CALR mutant cell line. In 
summary, the major conclusions of this study are: 
I. MARIMO cell line has the potential to commit into the megakaryocytic lineage under 
5 nM PMA treatment during 72 hours 
II. PMA MARIMO induction leads to the expression of the megakaryocyte antigen 
CD41a, megakaryocytic-like morphological characteristics, lose the replicative 
potential and increase nuclear content. 
III. MARIMO cells have the capacity to initiate the endomitotic process, although after 
72 hr it is mostly incomplete.  
IV. PMA treatment decreases the cell proliferation capacity of MARIMO cells after 24 
to 48 hours.  
V. MARIMO megakaryocyte committed cells express MPL receptor.  
VI. STAT5 gene expression signature (PIM1, CISH, ID1 and SOCS2) is expressed after 
MARIMO PMA treatment.  
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4.3.2. Future directions 
 
Additional studies are needed to further characterise the megakaryocyte commitment 
potential of MARIMO cells. Analysis of cell surface expression of the megakaryocyte antigen 
CD41a could be completed with the further study the expression of other megakaryocyte-
platelet proteins such as CD61 or CD42. Moreover, a few mature megakaryocytes like cells 
with clear endomitosis process (8n-16n) were identified. To further understand the complete 
capacity of MARIMO cells to commit into mature megakaryocytes, analysis of longer 
incubation of cells with PMA could be essential for the identification of a complete 
megakaryocyte differentiation process in these cells. Moreover, addition of TPO within the 
cell media could improve this commitment.  
The obtained satisfactory results demonstrating an increase expression of MPL opens the 
possibility of using this cell line to analyse CALR mutant and MPL binding and the 
consequently pathogenic downstream signalling. The initial analysis of this novel protein 
interaction could be addressed by protein pull-down assay and western blot.  Additionally, 
further experiments will be essential to understand which molecular pathogenesis leads to 
an active status of STAT5 transcription factor, by analysing the quantification of 
phosphorylated JAK and STATs proteins, as well as downstream MAPK proteins. These 
molecular analyses will help to shed light into the cellular signalling characteristic of CALR 
mutant ET and PMF.  
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CHAPTER 5: Analysis of CALR mutant sub-
cellular localisation 
 
 
5.1. Introduction 
 
Ca2+ binding protein CALR contains the KDEL region, a C-terminal ER retrieval signal. However, 
in many occasions this protein has been found to be localised outside the ER (Johnson et al., 
2001). Mechanisms by which CALR evades ER retention remain elusive, yet the important role 
of this protein outside the ER is currently unclear (see section 1.6.3) (Coppolino et al., 1997; 
Gold et al., 2010; Dedhar et al., 1994; Holaska et al., 2001). Regardless of the essential roles 
of CALR undertaken outside the ER, the major characterised functions of this protein are 
carried out within the ER lumen, such as Ca2+ homeostasis and chaperone activity (Michalak 
et al., 2009). Therefore, there is no doubt of the importance of controlled subcellular 
compartmentalisation of CALR for correct functioning of many cellular processes.  
CALR protein can escape from the ER to the Golgi apparatus, where it is recognised by the 
KDEL-receptors and is subsequently recycled back to the ER (Sonnichsen et al., 1994). Previous 
study has shown that deletion of the KDEL sequence within the C-terminal domain leads to 
an increased exit of CALR protein from the ER (Sonnichsen et al., 1994). This escape of 
proteins from the ER was linked with the inability of the KDEL-receptors to recognise CALR for 
retrieval (Sonnichsen et al., 1994). Interestingly, CALR mutations described in MPNs delete 
the KDEL sequence within the C-terminal domain (Klampfl et al., 2013; Nangalia et al., 2013). 
Although some previous studies have attempted to analyse the cellular localisation of CALR 
mutant, a full understanding of the effects of KDEL deletion for the subcellular localisation of 
this mutant protein in megakaryocytes remains elusive. Recent research revealed by 
fluorescent microscopy that both type 1 and type 2 CALR mutants do not co-localise with the 
ER marker CNX, therefore suggesting that CALR mutants might not reside within the ER 
(Chachoua et al., 2016). This study also described that type 1 and type 2 mutants co-localise 
with the Golgi marker ERGIC53 (Chachoua et al., 2016). Hence, it could be suggested that 
deletion of KDEL region does not ensure the retrotranslocation of CALR into the ER 
117 
 
(Sonnichsen et al., 1994), and therefore these proteins escape from the ER through the Golgi 
apparatus, possibly reaching other areas within the cell.  
As previously described, CALR mutants directly interact with MPL receptor within the cell 
surface (Araki et al., 2016; Chachoua et al., 2016; Elf et al., 2016). Therefore, this suggests that 
CALR mutant cell surface localisation increases upon MPL binding.   Previous research aiming 
to understand the cellular localisation of CALR mutations demonstrated an increase of CALR 
type 2 mutant protein within the cell membrane using UT-7 cell line (Araki et al., 2016). 
However, there is no analysis aiming to understand possible differences between the 
quantification of CALR type1 and CALR type 2 within the cell surface. Interestingly, previous 
publication agreed that CALR mutants are not retained within the lumen of the ER, although 
it was published a personal communication from Prof. Tony Green (Cambridge University, UK) 
who suggested a partial retention of CALR mutants within the ER by an unknown mechanism 
(Wiersma et al., 2015).  
CALR mutants are less stable than CALR wt, and therefore its cellular detection is more 
complex than long-lived proteins (Han et al., 2016; Kollmann et al., 2016). Their instability has 
been suggested to be linked with possible changes in protein structure and therefore mutant 
protein undergo quick proteosomal degradation (Kollmann et al., 2016). Despite CALR 
mutants are short-lived proteins, these proteins are still able to activate aberrant cellular 
signalling (Kollmann et al., 2016). It is important to note that the CALR-Flag tagged within the 
C-terminal domain commonly used in research increases the stability of the protein, possibly 
increasing artificial effects within the cells (Kollmann et al., 2016).   An additional study 
reported that CALR mutant proteins are secreted to the extracellular medium and more 
interestingly, there is an increase of CALR mutant protein content when MPL is expressed 
within the cells (Han et al., 2016). Therefore, this suggests that MPL interaction could 
decrease the degradation rate of CALR mutant proteins and consequently increase the 
protein levels of CALR mutant within the cells. Hence, it is possible that CALR mutants’ stability 
and localisation change during megakaryocyte differentiation stages as a result of an increase 
c-MPL expression during megakaryopoiesis.  
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5.1.1. Aims and hypothesis 
 
Overall the limited available information regarding CALR mutant cellular localisation proposes 
a sub-cellular mislocalisation of CALR mutants. This study aims to further investigate the 
localisation of CALR mutants within the cell.  Moreover, it is hypothesised that as 
megakaryocyte maturation entails an increase expression of MPL, it is therefore expected 
that CALR mutants cell surface localisation could increase after megakaryocyte maturation.  
Hence, during this investigation three major objectives will be addressed: 
I. Analysis of CALR mutant localisation within the ER and further areas of the cell.  
 
II. Visualisation by immunofluorescence of its interaction with MPL receptor on the cell 
surface. 
 
III. Analysis of differences of CALR levels on the cell surface between different stages of 
megakaryocyte maturation.  
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5.2. Results 
 
5.2.1. Sub-cellular localisation of CALR mutant 
To define whether CALR mutations lead to an escape of the protein from the ER and reach a 
different subcellular localisation of CALR, transfected HEK 293T cells with CALR-wt-GFP and 
CALR-type2-GFP plasmids were used. Cells were subjected to immunostaining and high 
resolution confocal microscopy. ERP57, an ER chaperone (Bedard et al., 2005), was used as 
an ER marker during immunostaining.  
Firstly, the cellular localisation of CALR wt was analysed. As expected, results showed a higher 
expression of CALR wt around the cellular nucleus and this expression co-localised with ERp57 
immunostaining (Figure 24 A), suggesting a high expression of CALR wt within the cellular ER. 
Moreover, some signal was registered within the cell nucleus (Figure 24).  
Further analysis of CALR type 2 cellular localisation showed that CALR mutant is around the 
nucleus co-localising with ERp57, although its expression was also diffused within the 
cytoplasm (Figure 24 B). CALR type 2 mutant expression was disseminated around the cellular 
cytoplasm and did not display a clear cellular localisation of expression. Interestingly, its 
expression was also highly diffused within the cellular nucleus compared with CALR wt (Figure 
24 B).  
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Figure 24. CALR WT and CALR type 2 mutant cellular localisation. 
HEK 293T cells were transfected with CALR-WT-GFP and CALR-type 2 mutant-GFP vectors. 48 hr after 
transfection cells were fixed and were subjected to immunostaining using mouse anti-ERp57 and anti-mouse. 
A) Representative images for CALR WT-GFP co-localization with ERp57 in transfected HEK 293T cells. B) 
Representative images of CALR type 2 mutant –GFP expression in transfected HEK 293T cells.  Scale bars = 5 µM 
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5.2.2. CALR mutant co-localisation with MPL receptor at the cell surface  
Recent investigations have examined the contribution of CALR mutants to the development 
of MPN by studying the direct interaction between CALR and MPL receptor (Araki et al., 2016; 
Chachoua et al., 2016; Elf et al., 2016). These studies have addressed and analysed this 
interaction by using co-immunoprecipitation and western blot analyses, however there was 
no evidence of this interaction when using immunofluorescence and cell microscopy. Here, 
this issue is addressed by using HEK 293T cells transfected with CALR-Flag and MPL-HA 
vectors. Cells were subjected to immunofluorescence staining and finally high resolution 
confocal microscopy.  
As seen in the previous analyses, CALR wt is mostly localised around the cellular nucleus. 
Moreover, this analysis showed MPL receptor expression within the cell membrane and 
intracellularly. The intracellular fraction corresponds to the ER, as this receptor is synthesised 
within this cellular organelle. Therefore, it is not surprising to visualise an intracellular co-
localisation of CALR WT and MPL; however, there is not a co-localisation of these proteins 
within the cell membrane (Figure 25 A).  
In contrast, CALR type 2 mutant is highly expressed through all the cytoplasmic area and the 
cell membrane. Results showed co-localisation of MPL and CALR mutant within the cell 
surface (Figure 25 B). Overall, these results proved an interaction between CALR Type 2 
mutant and MPL at the cell membrane and support previous immunohistochemical analyses 
proving this interaction.  
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Figure 25. CALR mutant co-localises with MPL within the cell membrane. 
HEK 293T cells were transfected with CALR-WT-Flag, CALR-type 2 mutant-Flag and TPO-R-HA vectors. 48 hr 
after transfection cells were fixed and were subjected to immunostaining using mouse anti-HA, rabbit anti-
Flag, anti-rabbit Cys3 and anti-mouse 647. A) Representative images for CALR WT-Flag and MPL-HA transfected 
HEK 293T cells. B) Representative images of co-localization of CALR type 2 mutant –Flag and MPL-HA in 
transfected HEK 293T cells. C) Zoomed images showing co-localisation. White squares indicate areas of co-
localisation.  Scale bars = 5 µM 
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5.2.3. Analysis of CALR cell surface localisation in leukemic blast cells 
Previous study reported that CALR mutations increase its cell surface localisation upon MPL 
receptor binding (Han et al., 2016). In order to analyse whether increased expression of CALR 
on the cell surface is totally dependent on this interaction, CALR cell surface levels in MARIMO 
cell line, which does not express MPL receptor in its leukemic blast stage (Kollmann et al., 
2016), were quantified. CALR cell surface analysis was performed by immunostaining and 
quantified by flow cytometry.  
Surprisingly, this study revealed that MARIMO cells displayed a significant increase of CALR 
cell surface compared with other leukemic cell line negative for CALR mutation; K562 cells 
(Figure 26). Therefore, this result suggests that CALR mutants might be localised into the cell 
membrane independently of MPL interaction in early stages of megakaryocyte development.  
 
 
 
 
 
 
 
 
 
 
 
 
To extend the analysis of CALR localisation, CALR cell surface localisation was further 
quantified in DAMI cells, a megakaryocyte cell line that constitutively express MPL receptor 
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Figure 26. CALR cell surface expression in K562 and MARIMO cells. 
Cells were subjected to immunostaining and were further analysed by flow cytometry. A) Average quantification 
of CALR cell surface. B) Representative histogram of CALR-PE fluorescence in both samples. Values represent 
mean ± SEM for each group. n=3. **P<0.01, *P<0.05. Student T.test 
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(Pang et al., 2009; Greenberg et al., 1988). CALR wt, CALR type 1 and CALR type 2 constructs 
were expressed using a lentiviral vector and transduced into DAMI cells. Empty GFP vector 
was used as a control for transduction. During the experiment, two clones of each condition 
were used, and the experiment was performed in triplicates in each clone. Total CALR levels 
were analysed to ensure equal CALR protein levels and GFP expression of the control group 
was analysed to ensure transfection efficiency (see Appendix 3).  
CALR cell surface quantification using flow cytometry revealed that, CALR type 1 DAMI cells 
showed a significant increase of CALR expression within the cell surface compared with the 
control (Figure 27). In contrast, CALR type 2 cells did not show any difference of CALR cell 
surface expression relative to CALR wt (Figure 27).  
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Figure 27. CALR cell surface levels in DAMI cells overexpressing CALR wt, type 1 and type 2 mutations. 
Cells were subjected to immunostaining and were further analysed by flow cytometry. A) Average 
quantification of CALR cell surface B) Representative histogram of CALR-PE fluorescence. Representative 
example of fluorescent measurements of a single clone per condition are shown. Values represent mean ± 
SEM for each group. n=3. **P<0.01, *P<0.05. Student T.test 
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5.2.4. Analysis of differences of CALR levels within the cell surface between blast and 
megakaryocyte like cells  
Expression of MPL during megakaryocyte differentiation might lead to a consecutive increase 
of mutant CALR on the cell surface (Han et al., 2016). Therefore, to explore the consequences 
of megakaryocyte differentiation in CALR cell surface localisation, CALR levels were quantified 
after megakaryocyte differentiation. This study was performed using DAMI, MARIMO and 
K562 cellular models. Hence, before analysing CALR cell surface protein levels, the 
megakaryocyte differentiation potential of these cell lines was tested.  
 
Chemical induction of K562 megakaryocyte differentiation 
 
K562 cells are a known established model used to study megakaryocyte differentiation. In 
order to analyse CALR protein levels on the cell surface in megakaryocyte like cells, the 
optimal conditions to induce K562 cell differentiation into the megakaryocyte lineage in vitro 
were established.   For this purpose, cells were differentiated into megakaryocytes with 5nM 
PMA during 72 hours, as shown previously (Koeffler et al., 1981; Huo et al., 2006; Zhang et 
al., 2007; Huang et al., 2014). To corroborate cell differentiation, expression of the 
megakaryocyte cell surface marker CD41a was analysed by flow cytometry.  
Consistent with previous research, results showed that in vitro megakaryopoiesis of K562 cells 
was induced under 5nM PMA treatment over 72 hours. PMA treatment resulted in a 
significant increase in CD41a expression and 90% of the cells expressed this marker (Figure 
28). Additionally, microscopic examination revealed that cells showed megakaryocyte 
phenotypic characteristics, such as increase in cell size, adherence and cytoplasmic 
projections (Figure 28 A).   
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Figure 28. K562 cells under PMA treatment display megakaryocytic characteristics. 
A, B) Increase expression of CD41a marker in the cell surface after 72 hr of PMA treatment. C)  Live cells show 
changes in cell morphology and increase cell adherence. Images were captured using 40x objective. Values 
represent mean ± SEM for each group. n=3. **P<0.01, *P<0.05. Student T.test. Error bars = 50µm 
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Chemical induction of DAMI megakaryocyte differentiation 
 
DAMI cell line is also a model to study megakaryocyte differentiation (Greenberg et al., 1988). 
DAMI clones overexpressing CALR WT, CALR type 1 and type 2 mutants were differentiated 
towards mature megakaryocytes to further analyse CALR cell surface population within the 
cell surface. DAMI cells were incubated under PMA treatment for 72 hours, as previously 
described in the literature (Greenberg et al., 1988). Then, CD41a expression on the cell surface 
was analysed by flow cytometry.  
Results showed that in vitro megakaryocyte formation of the DAMI clones was induced under 
5nM PMA treatment over 72 hours. Overall, PMA treatment resulted in a significant increase 
of CD41a expression in all samples (Figure 29).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Finally, phenotypic characterisation revealed that DAMI cells under PMA treatment displayed 
the morphological characteristics of megakaryocyte maturation (Figure 30). Interestingly, 
CALR mutant cells showed increased cell adhesion within the culture, and in addition, CALR 
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Figure 29. DAMI cells under PMA treatment increase CD41a expression. 
Increase expression of CD41a marker in the cell surface after 72 hr of PMA treatment. Results were averaged 
between three independent experiments. Results were averaged between six independent experiments using two 
different clones per condition. Values represent mean ± SEM for each group. **P<0.01, *P<0.05. Student T.test.  
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type 1 cells after PMA treatment displayed an increased size compared with the controls and 
CALR type 2 cells.  
 
 
 
 
 
 
 
 
Figure 30. DAMI cells under PMA treatment display megakaryocytic phenotypic characteristics. 
DAMI cells were subjected to 5 nM PMA treatment during 72 hours and were subsequently used for 
light microscopy. Live cells showed changes in cell morphology and increased cell adherence. Images 
were captured using 40x objective. Error bars = 50µm. 
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5.2.5. CALR quantification within the cell surface after megakaryocyte differentiation 
 
Once K562, MARIMO and DAMI cells were differentiated towards the megakaryocytic lineage, 
CALR cell surface expression within these cells was analysed before and after megakaryocyte 
induction.  
Firstly, CALR cell surface expression in K562 and MARIMO cells was quantified in their blast 
and megakaryocyte stage. K562 and MARIMO cells were differentiated towards 
megakaryocyte using PMA as previously described. Surprisingly, when K562 cells were 
differentiated towards mature megakaryocytes, there was a significant increase of CALR on 
the cell surface compared with its basal levels during the blast stage (Figure 31). Interestingly, 
when MARIMO cells were induced with PMA, results also showed an increase of CALR on the 
cell surface compared to its basal control (3.6 fold), however this relative increase was lower 
than the rise detected in K562 cells (5 fold) (Figure 31). Although the fold increase was smaller 
in MARIMO cells, the total CALR cell surface quantified in MARIMO megakaryocyte like cells 
was higher than the control cells. However, this difference was not statistically significant 
(Figure 31 C).  
Next, this study proceeded to analyse CALR cell surface using DAMI cells overexpressing CALR 
wt, CALR type 1 and CALR type 2. After PMA induction, all samples showed an overall increase 
of CALR on the cell surface (Figure 32). However, CALR type 1 cells showed a higher increase 
of cell surface CALR compared with the control (Figure 32). In this case, differences were not 
statistically significant. CALR type 2 cells showed a similar increase of CALR cell surface after 
megakaryocyte induction compared with the control cells (Figure 32).  
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Figure 31. CALR cell surface levels in K562 and MARIMO cells after PMA induction. 
Cells were exposed to PMA treatment during 72 hours. Then, cells were used for CALR immunostaining and CALR 
levels were quantified by flow cytometry. A) Average quantification of CALR cell surface. B) Representative 
histogram of CALR-PE fluorescence. C) Total CALR-PE fluorescence. Values represent mean ± SEM for each group. 
n=3. **P<0.01, *P<0.05. Student T.test. 
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Figure 32. CALR cell surface levels in DAMI cells overexpressing CALR wt, type 1 and type 2 mutations after PMA 
induction. 
DAMI cells were exposed to PMA treatment during 72 hours. Then, cells were used for CALR immunostaining and 
CALR levels were quantified by flow cytometry. A) Average quantification of CALR cell surface. B) Representative 
histogram of CALR-PE fluorescence. Example of fluorescent measurements of a single clone per condition are shown. 
Results were averaged between six independent experiments using two different clones per condition. Values 
represent mean ± SEM for each group. **P<0.01, *P<0.05. Student T.test.  
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5.3. Discussion  
 
CALR protein has been described to be present in multiple localisations inside the cell 
(Michalak et al., 2009) and therefore alterations of expression levels within different cellular 
compartments could be key to understand the pathogenesis of CALR driver mutations.  This 
study has demonstrated that CALR mutant proteins characteristic of MPNs display an 
abnormal cellular localisation and thus, CALR normal cellular functions might be disrupted 
within these abnormal cells.  
The ER is the cellular compartment that contains the major amount of CALR within the cell. 
The immunofluorescence assay performed in this study suggested that CALR mutant is 
localised within the ER and its expression is also diffused through the cytoplasm and nucleus. 
As mentioned in the literature, CALR mutant is present within the Golgi apparatus (Chachoua 
et al., 2016). Therefore, loss of KDEL region could be the cause of a deregulated 
retrotranslocation of CALR from the Golgi into the ER, and therefore this mutant protein is 
transported through the Golgi into different cellular compartments. Of note, CALR has been 
described to be present within the cellular nucleus in primary megakaryocytes (Iborra and 
Papadopoulos, 2017) and there have been previous reports about the potential 
transcriptional activity of CALR (Holaska et al., 2001).  
Major interest has been raised by the novel finding of CALR mutant interaction with MPL 
receptor (Araki et al., 2016; Chachoua et al., 2016; Elf et al., 2016). Therefore, its increase 
expression within the cell surface is expected. This study shows a co-localisation of CALR type 
2 with MPL receptor within the cell surface of HEK 293T cells using microscopy. In addition, 
DAMI cells overexpressing CALR type 1 and type 2 mutants showed an increase of CALR within 
the cell surface only in CALR type 1 cells.  Although both mutants have been described to 
directly interact with MPL receptor (Araki et al., 2016), the different quantification levels at 
the cell surface in DAMI cells between CALR mutant clones described in this study could be 
linked with the different pathogenic role of both mutations, as CALR type 1 is associated with 
a more malignant disease phenotype.  
One interesting finding is that quantification of CALR cell surface in CALR mutant MARIMO 
cell line is significantly increased compared with K562 cells. According to previous research 
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(Kollmann et al., 2016) and this study (see chapter 4), MARIMO cells in their blast stage do 
not express MPL receptor, and therefore, CALR increase on the cell surface might be caused 
by independent pathways of the MPL-CALR binding. However, a note of caution is due here 
as only one leukemic cell line has been used as a control in comparison to MARIMO cell line, 
and therefore it could be possible that the differences described in this study are due to 
intrinsic differences between these cell lines. Thus, this study should be completed with the 
comparison of other leukemic blasts such as HEL, HL-60 or UKE-1.  
During megakaryocyte differentiation there is a profound reorganisation of the ER (Ru et al., 
2016), towards a complex DMS which is highly dependent on ER activity (Eckly et al., 2014). 
Therefore, it is possible that there are differences in expression of the ER proteins during 
megakaryopoiesis. One unanticipated finding in this study was that megakaryocyte 
differentiation induced by PMA leads to an overall increase of CALR cell surface expression in 
CALR wt cells. These results are likely to be related to changes within the ER nature during 
megakaryocyte formation, however this data might be interpreted with caution as 
megakaryopoiesis was induced in this case by pharmacological treatment and there is no 
known links between the possible effects of this phorbol treatment into the ER or CALR 
localisation. In addition, it is interesting to note that CALR mutant cells displayed a higher 
increase of CALR within the cell surface during megakaryopoiesis, suggesting further 
abnormal regulation of CALR cellular localisation during megakaryocyte differentiation.  
In the current years, an increase in the use of immunotherapy for treatment of neoplastic 
diseases has been witnessed (Gattinoni et al., 2006). A previous study evaluated the 
possibility of using CALR mutants within the cell surface of neoplastic cells as targets of 
immunogenic cell death (Holmstrom et al., 2017). Promising results displayed the possibility 
of using peptide vaccinations for CALR mutant MPN patients (Holmstrom et al., 2017). 
Therefore, this novel investigation together with the initial data obtained in this study, where 
it is demonstrated an increase of CALR within the cell surface during megakaryopoiesis, raise 
the necessity of further analysis aiming to target this CALR cell surface population as a novel 
MPN treatment.  
The present study makes several noteworthy contributions to the understanding of CALR 
mutant cellular localisation. It is important to bear in mind that CALR functions are highly 
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correlated with its cellular compartmentalisation, and therefore an abnormal localisation of 
this protein could lead to aberrant cell functioning with altered Ca2+ buffering activity, change 
its protein folding capacity or as previously described, lead to changes in cell signalling (Araki 
et al., 2016; Chachoua et al., 2016; Elf et al., 2016; Han et al., 2016; Kollmann et al., 2016). 
There is, therefore, a definitive need to further study the link of abnormal CALR mutant sub-
cellular localisation and changes in its cellular roles to deeply understand the nature of CALR 
mutant MPNs.  
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5.3.1. Conclusions  
The data described in this study reveals that mutant CALR is abnormally localised within the 
cell. Overall, the major conclusions of this study are:  
i. CALR mutations known to delete the KDEL region within the C-terminal domain lead 
to a different localisation of CALR in the cell.  Even though CALR mutant is localised 
within the ER, it is also mislocalised around the cytoplasm.  
 
ii. CALR co-localizes with MPL receptor on the cell surface in CALR mutant expressing 
cells. 
 
iii. CALR mutant blast cells display an increased expression of mutant CALR at the cell 
surface, independently of MPL receptor.  
 
iv. Megakaryocyte differentiation leads to an increase of CALR within the cell surface. 
However, CALR mutant cells display a major increase of this protein in the cell surface 
during megakaryocyte differentiation.  
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5.3.2. Future directions  
Future research should concentrate on the investigation of CALR mutant protein 
quantification within the ER, nucleus, Golgi and cytoplasm. This investigation could be carried 
out by protein purification using different density gradients purification and western blot 
analysis.  
Moreover, the analysis of CALR cell surface increase in MARIMO cells during its blast stage 
raises new questions of other possible mechanisms of CALR escaping towards the cells 
surface. It would be of much interest to analyse the possible mechanisms that increase CALR 
within the cell surface in CALR mutant blast cells to finally understand whether in this case it 
works as an ER stress marker. However, it would be important to perform this initial 
experiment using further leukemic cell lines and primary patient samples as control, to avoid 
intrinsic differences between them.  
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Chapter 6: Analysing the importance of 
calcium during megakariopoiesis and the 
effects of CALR mutations in calcium 
homeostasis.  
 
6.1. Introduction 
 
The Ca2+ ion is an essential intracellular molecule required for many cellular functions such as 
cell proliferation, metabolism, trafficking, apoptosis and differentiation (Berridge et al., 2000; 
Carafoli, 2002). A tight control of cellular signalling relays on oscillations of the intracellular 
Ca2+ concentration ([Ca2+i]) which are regulated by intracellular and extracellular Ca2+ sources.  
Ca2+ channels, Ca2+ buffering proteins or Ca2+ pumps move this molecule between the ER, the 
cytosol and the extracellular space in a highly controlled manner to transmit the required cell 
signals.   
 
6.1.2. Calcium cellular dynamics  
In a basal cellular state, the plasma membrane Ca2+ ATPase (PMCA) and the 
sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) pumps mostly control the cellular [Ca2+i]. 
However, when a cell is stimulated and the signal is transmitted, the [Ca2+i] increases due to 
mobilisation of intracellular Ca2+ storages or Ca2+ influx from the extracellular environment 
into the cytosol (Berridge et al., 2003). 
The ER is the major Ca2+ store within the cell. However, it has been reported that other 
organelles such as mitochondria or the Golgi apparatus can contribute to the Ca2+ cellular 
homeostasis (Berridge et al., 2003). Within the ER, Ca2+ is buffered by Ca2+ binding proteins 
such as Protein Disulphide Isomerases (PDI), CNX or CALR, which not only act as buffering 
proteins but also as chaperones and regulators of Ca2+ ER channels (Berridge, 2002; Coe and 
Michalak, 2009). The ER Ca2+ is released into the cytoplasm in response to specific intracellular 
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signals. Activation of the phospholipase-C (PLC) by many cell surface receptors leads to the 
production of Inositol 1,4,5-trisphosphate (IP3), which will subsequently lead to the activation 
of Inositol 1,4,5-trisphosphate receptor (IP3-R)/ Ca2+ channel. Finally, active IP3-R leads to the 
ER Ca2+ release into the cytosol (Mikoshiba, 2007). In excitable cells, ryanodine receptors 
(RYRs) are responsible for the Ca2+ ER release rather than IP3-R (Lanner et al., 2010). 
SERCA is an ER pump that actively transports Ca2+ ions from the cytoplasm into the ER lumen, 
tightly regulating the [Ca2+i] (Periasamy and Kalyanasundaram, 2007). SERCA presence is 
ubiquitous and it is the only ER Ca2+ pump known to maintain the ER Ca2+ stores within the 
cell (Figure 33).  In vitro inhibition of SERCA pump is a common routine to study cellular ER 
Ca2+ buffering capacity. For that, Thapsigargin, a well-known strong SERCA inhibitor, is 
commonly used in research (Lytton et al., 1991).  
Cells display the store-operated Ca2+ entry (SOCE) mechanism to avoid ER Ca2+ depletion. 
SOCE leads to Ca2+ influx through the cell membrane and it is activated as a response of ER 
Ca2+ store depletion (Smyth et al., 2010). During this process, Stromal interaction molecule 
(STIM) proteins, which are located within the ER membrane, act as Ca2+ ER sensors 
(Stathopulos et al., 2008). Upon ER Ca2+ decrease, STIM molecules are placed near the cell 
membrane and then interact with the SOCE channels, formed by the Orai proteins. Next, SOCE 
channels allow the influx of extracellular Ca2+ inside the cell to finally restore the optimal ER 
Ca2+ levels (Figure 33) (Cahalan, 2009; Deng et al., 2009; Schindl et al., 2009).  
Extracellular Ca2+ enters the cell through the activation of various Ca2+ channels and pumps 
within the cell membrane with widely different characteristics. For example, voltage-
operated calcium channels (VOCs), which include L-, P/Q-, N-, R-, and T-type channels, 
generate fast extracellular Ca2+ fluxes in order to modulate rapid intracellular processes 
(Catterall, 2011). These channels are broadly known to regulate extracellular Ca2+ entry in 
excitable cells like neurons, cardiac and pancreatic-β cells (Yang and Berggren, 2006; Bean, 
1991), although L-type channels also have been proved to be relevant in non-excitable cells, 
such as human T-cells (Stokes et al., 2004). Moreover, further cell membrane Ca2+ entry 
channels regulate the optimal cellular [Ca2+i] within the cell, such as the Second-messenger-
operated channels (SMOCs), which are regulated by internal messengers. Additionally, there 
also are the Receptor-Operated channels (ROCs), including the N-methyl-D-aspartate 
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receptors (NMDARs) which activate in response to extracellular glutamate (Vyklicky et al., 
2014).  
6.1.2. Intracellular calcium oscillations  
The ability of Ca2+ to regulate cell physiological processes relies on the cellular capacity to 
control [Ca2+i] in space and time. Oscillations in [Ca2+i] can be propagated from microseconds 
to hours and could be described as spontaneous events or derived from downstream cellular 
cascades. As a consequence of these Ca2+ transient oscillations, the course of cellular 
physiology is determined (Pinto et al., 2016; Putney and Bird, 2008).  
The spatial and temporal pattern of Ca2+ oscillations can be regulated by internal Ca2+ stores, 
such as ER or Golgi, as well as by the Ca2+ channels and pumps within the cell membrane. 
Moreover, intracellular Ca2+ oscillations can be produced as a response of external ligands 
and can be manipulated in vitro by drug treatments (Pinto et al., 2016). Intracellular Ca2+ 
signalling can lead to rapid rise in [Ca2+i], within microseconds to second ranges, in local areas 
or promote global increase of [Ca2+i] levels within the cell. Prolonged Ca2+ oscillations that tent 
to last longer (hours) have been implicated with several cellular processes, such as 
differentiation (Sun et al., 2007), cytokines production (Uhlen et al., 2000), neuronal growth 
(Hutchins and Kalil, 2008) and cell migration (Giannone et al., 2002).   
Cells are able to interpret changes in the frequency of intracellular Ca2+ oscillations using 
sophisticated systems. For example, PKC and CaMKII have been shown to play pivotal roles in 
the decoding the frequency of intracellular Ca2+ oscillations frequency (Oancea and Meyer, 
1998; Dupont et al., 2003).  
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Figure 33. Cellular Ca2+ signalling dynamics.   
Cells display a widely specialised protein toolkit to control Ca
2+
signalling and to maintain specific [Ca
2+
i] within the cell. 
Majority Ca
2+   is bound to buffering proteins, although a small proportion binds to effectors, leading to the activation of 
many cellular processes.  Black arrows show the direction of movement of Ca
2+
 ions. [Ca
2+
i]: intracellular Ca
2+    
concentrations. SERCA: sarcoendoplasmic reticulum Ca
2+
-ATPase, IP3R: inositol 1,4,5-triphosphate receptor, PMCA: plasma 
membrane Ca
2+ 
ATPase 
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6.1.3. Calcium and its role in cellular differentiation 
Emergent research has been focused in elucidating the role of intracellular Ca2+ signalling 
during cell differentiation. A recent systematic literature review suggested that stem cell 
differentiation is triggered by transient oscillations of [Ca2+i], and the different nature of these 
oscillations could determinate specific cell fates (Pinto et al., 2016). This statement was based 
in previous published data where it was demonstrated that erythrocyte, neurons and muscles 
cells differentiation are initiated by global increases of [Ca2+i] (Gu et al., 1994; Miller et al., 
1988; Miller et al., 1989).  Moreover, it has been observed that physical manipulation of 
intracellular Ca2+ oscillations of mesenchymal cells (MSC) can lead to cell commitment into 
the osteoblast lineage (Sun et al., 2007). Therefore, there is a growing body of literature that 
recognises the importance of intracellular Ca2+ oscillations during the initiation of cell 
commitment into specific cell fates.  
Intracellular Ca2+ oscillations play a critical role in the control of gene expression.  Previous 
studies have demonstrated a direct link between activation of Ca2+ signalling pathways and 
activity of specific transcription factors (Dolmetsch, 2003; West et al., 2002). Changes in 
amplitude, spatial and temporal features of [Ca2+i] could lead to the activation of different 
transcriptional signatures (Dolmetsch et al., 1997; Dolmetsch et al., 1998). Although growing 
evidences prove the importance of [Ca2+i], the link between intracellular Ca2+ oscillations and 
gene transcription during cell differentiation is still poorly understood. However, a previous 
research reported a link between Ca2+ signalling and gene expression during neural 
differentiation (Chang and Spitzer, 2009). Therefore, there is a growing need of shedding light 
into this area of investigation to unravel the complex mechanisms of cellular differentiation.  
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6.1.4. Megakaryocytes and calcium 
During early megakaryocyte maturation stages, cells display few undeveloped membranous 
organelles, such as the Golgi apparatus and ER. However, it is characteristic of megakaryocyte 
maturation an increase of the cytoplasmic area, which is accompanied by an expansion of ER, 
essential for the DMS (Eckly et al., 2014; Ru et al., 2016).  During this process there is profound 
reorganisation of ER Ca2+ pumps and channels that lead to a tight control of [Ca2+i] during 
megakaryopoiesis (Lacabaratz-Porret et al., 2000; Nurden et al., 2006). Previous research 
demonstrated that SERCA3 expression increases in the latest stages of megakaryocyte 
differentiation, as well as IP3RI/II (Lacabaratz-Porret et al., 2000). Further evidence suggests 
the important role of Ca2+ during this process. For example, TPO signalling leads to a change 
of cellular Ca2+ in megakaryocytes (den Dekker et al., 2001). Thus, reorganisation of Ca2+ ER 
storage and Ca2+ signalling could be key elements to maintain a tight control of 
megakaryopoiesis.  
Of note, NMDARs have been described to be highly expressed in megakaryocytes (Genever 
et al., 1999) and also, these receptors could have a pivotal role in regulating megakaryocyte 
functions (Hitchcock et al., 2003). A recent publication demonstrated that leukemic blasts 
treated with NMDARs antagonist such as Nemamtine or Riluzole, reduced proliferation and 
increased megakaryocyte-like characteristics, such as polyploidy and cell morphology (Kamal 
et al., 2015). Hence, it is possible that changes in the [Ca2+i] caused by NMDARs inhibition 
could activate megakaryocyte commitment, as previously described with other cell types (Sun 
et al., 2007).  
Although much research has been focused in the understanding of the role of intracellular 
Ca2+ during megakaryocyte differentiation, a recent publication revealed that Ca2+ is also 
essential for the regulation of megakaryocyte physiological functions (Di Buduo et al., 2014). 
This previous investigation demonstrated that Ca2+ mobilisation from the ER and extracellular 
Ca2+ entry by SOCE machinery in human megakaryocytes directly regulate important cellular 
functions, such as megakaryocyte adhesion to the extracellular matrix, megakaryocyte 
motility and proplatelet formation (Di Buduo et al., 2014). However, further investigation is 
needed to help to understand the complex functions of Ca2+ during megakaryocyte 
differentiation, survival and correct cellular functions.  
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6.1.5. Calcium and pathological megakaryocyte production 
Megakaryocyte hyperplasia has been previously linked with abnormal Ca2+ homeostatic 
regulation (Di Buduo et al., 2016). Interestingly, mice expressing an activated form of STIM1 
which results in an increase of [Ca2+ I], displayed megakaryocyte hyperplasia (Grosse et al., 
2007). Noteworthy, after 6 months, these mice showed bone marrow fibrosis and 
splenomegaly, both pathological characteristics of PMF (Grosse et al., 2007). Therefore, a 
tight control of [Ca2+i] by cell membrane Ca2+ channels and the ER in megakaryocytes could 
be a key element to maintain a tight balance of megakaryocyte production. However, to 
which extent Ca2+ homeostasis contributes to MPNs development remains to be clarified.   
Based on the current information about the role of intracellular Ca2+ in megakaryocytes, 
previous publication hypothesised that rise in [Ca2+i] could promote megakaryocyte 
proliferation, motility and increased platelet production (Di Buduo et al., 2016) (Figure 34). 
Coincidently these characteristics are pathological features in ET and PMF.  
CALR mutations described in PMF and ET are thought to influence Ca2+ buffering capacity of 
this protein during megakaryocyte hyperplasia.  To this regard, previous research using 
primary mature megakaryocytes harbouring CALR type 1 and type 2 mutations demonstrated 
that these mutations enhanced ER Ca2+ release under cyclopiazonic acid (CPA) treatment. Of 
note, CALR type 1 showed significant higher ER Ca2+ release values than CALR type 2 mutant 
cells (Pietra et al., 2015).  Interestingly, CALR type 1 is associated with worst disease prognosis 
than type 2 (Cabagnols et al., 2015). To this extent it could be possible that differences in Ca2+ 
homeostasis caused by these mutations could lead to the different disease phenotype, 
although more data is essential to understand the link between abnormal Ca2+ homeostasis 
and the different subtypes of CALR mutations. Moreover, analysis of MARIMO cells in 
response to thapsigargin have also showed deregulated ER Ca2+ buffering activity (Kollmann 
et al., 2015). However, the registered ER Ca2+ homeostasis shown in this previous study was 
opposite to the results published in primary megakaryocytes (Pietra et al., 2015), therefore 
showing discrepancies in our understanding of CALR mutant ER Ca2+ buffering activity.  
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6.1.6. Methods to study intracellular calcium 
Considering the relevance of Ca2+ signalling for many cellular processes, the development of 
techniques to measure intracellular Ca2+ levels has been a major focus of research for many 
years. Nowadays, the use of fluorescent Ca2+ indicators is a common and successful technique 
to study intracellular Ca2+ processes (Paredes et al., 2008). Currently, there are two different 
types of Ca2+ indicators: genetically modified proteins or chemically engineered fluorophores. 
Figure 34. Proposed model of megakaryocyte hyperplasia induced by increase [Ca2+I]. 
A) Physiological megakaryocyte formation. B) Pathological megakaryocyte formation occasioned by abnormal Ca2+ 
homeostasis during the differentiation of megakaryocytes. Previous data showed the relevance of SOCE machinery 
during MPNs development, however further analysis need to be completed to fit the role of CALR mutant within 
this model. Figure reproduced from (Di Buduo et al., 2016). 
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However, chemical indicators offer major advantages, such as their easy manipulation, the 
availability of many well established loading protocols (Takahashi et al., 1999; Paredes et al., 
2008) and importantly, these dyes do not require to be transfected or overexpressed within 
cells.  
Chemical intracellular Ca2+ indicators are classified in three different groups according with 
their chemical forms: salts, dextran conjugates or acetoxymethyl (AM) esters (Paredes et al., 
2008). The salt Ca2+ indicators require invasive cell loading techniques, such as 
microinjections, due to their membrane impermeability characteristic. Also, once these 
indicators cross the membrane could be compartmentalised in vacuoles within the cytosol 
and are consequently degraded within 30 minutes to an hour. Dextran conjugates show no 
compartmentalisation issues although they still require invasive cell loading procedures 
(Paredes et al., 2008).  Finally, AM indicators offer easier cell loading methods, as AM dyes 
are membrane permeable and can cross the cellular membrane passively. Once the dye 
reaches the cytoplasm, cellular esterases cleave the AM group and the fluorescent dye is 
trapped inside the cell (Paredes et al., 2008; Tsien, 1981).   
Once optimal Ca2+ indicators are selected for the experimentation, multiples techniques are 
used to study the Ca2+ buffering capacity and Ca2+ dynamics within the cell. Ca2+channel 
blockers (CCBs) are widely used to manipulate in vitro the cellular Ca2+ dynamics. Therefore, 
CCBs could be widely used to analyse the effects of inhibiting specific Ca2+ channels within the 
cell. Although a variety of CCBs are commonly used in clinic to treat many different disorders, 
such as vascular diseases or migraines, (Olson et al., 2005) these drugs are extremely useful 
in research. For example, BTP-2 and Riluzole, inhibitors of SOCE and NMDR receptors 
respectively, were used in previous research to demonstrate the role of both Ca2+  channels 
in megakaryocytes (Di Buduo et al., 2014; Kamal et al., 2015). As well as Fendiline, an L-Type 
Ca2+ channel and calmodulin antagonist, which has been used to prove the importance of Ca2+ 
dynamics on platelet aggregation (Luckhoff et al., 1991) 
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6.1.7. Aims of the study 
 
The existing body of research suggests a central role of [Ca2+i] during cell fate differentiation. 
However, the link between [Ca2+i] and megakaryocyte differentiation remains poorly 
understood. Intriguingly, CALR mutations described in MPNs raise new questions about the 
importance of this ion during abnormal megakaryocyte maturation in ET and PMF. Therefore, 
the analysis of Ca2+ dynamics during megakaryocyte formation is a major step that will lead 
to a better understanding of megakaryocyte cell fate differentiation in physiological 
conditions and disease. Thus, during this investigation, three major aims were addressed:  
I. Determine the existence of [Ca2+i] oscillations during megakaryocyte cell 
commitment in physiological conditions.  
 
II. Characterisation of the effects of CALR mutations in Ca2+ dynamics by analysing 
[Ca2+I], cellular ER Ca2+ buffering activity and quantification of the stored ER Ca2+ in 
different megakaryocyte differentiation stages.  
 
III. Study the effects of physical manipulation of [Ca2+i] by using different CCBs as 
inductors of megakaryocyte like phenotype in leukemic blasts.   
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6.2. Results 
 
6.2.1. Building a model of [Ca2+i] oscillations during megakaryocyte differentiation.  
[Ca2+i] oscillations have been described to be essential in many cell fate differentiation (Sun 
et al., 2007; Gu et al., 1994). One purpose of this study was to analyse whether there are 
transient oscillations of [Ca2+i] that could determinate the nature of megakaryocyte cell fate 
in physiological conditions. For that, [Ca2+i] was measured during megakaryopoiesis using 
three different cellular models, two leukemic cell lines with potential to differentiate into 
megakaryocytes, K562 and DAMI cells, as well as primary mouse bone marrow cells. To 
measure [Ca2+i] an intracellular Ca2+ indicator known as Fluo-8-AM was used during this study. 
Fluorescence intensity was quantified with flow cytometry at different time points during 
megakaryocyte maturation.  
Analysis of [Ca2+i] oscillations during K562 induced megakaryopoiesis 
 
K562 cells are characterised as highly undifferentiated cells. However, as previously 
described; these cells differentiate into megakaryocytes after 72 hours of 5 nM PMA 
incubation (See section 5.2.4) (Kang et al., 1996; Hirose et al., 2013; Huang et al., 2014). 
Analysis of [Ca2+i] during the in vitro megakaryopoiesis of K562 cells could allow to determine 
[Ca2+i] levels, since early differentiation stages until megakaryocyte like cells.  
Results showed that during the first stages of megakaryocyte commitment [Ca2+i] raised 
significantly in a 6 ~ fold ratio compared with the control during the first 24 hours. Afterwards, 
[Ca2+i] showed a gradual decrease over time (Figure 35). 72 hours after PMA megakaryocyte 
induction, mature cells displayed a significant increase of [Ca2+i] of 3 ~ fold compared with the 
initial K562 cells (Figure 35 A).  
Overall, these results showed that [Ca2+i] oscillate over time, in hours scale, during 
megakaryocyte cell fate differentiation of K562 cells. Additionally, it showed a significant 
increase in [Ca2+i] which could be required for the commitment into the megakaryocyte 
lineage.  
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Analysis of [Ca2+i] oscillations in mouse bone marrow cells during in vitro megakaryopoiesis 
 
Further analysis aiming to study [Ca2+i] oscillations during megakaryocyte formation were 
performed. Mouse bone marrow cells were induced to differentiate toward the 
megakaryocyte lineage and [Ca2+i] was subsequently analysed in different maturation stages. 
To induce differentiation, bone marrow cells were incubated with TPO (10 µg/ml) over 10 
days. To select three different populations with different maturation status along the 
megakaryocyte lineage, CD117 (cKIT) and CD41a cell surface markers were used for the flow 
cytometry gating strategy based on previous publication (Hunt et al., 1992). HSC/Early 
Figure 35. [Ca2+i] oscillations during K562 megakaryocyte formation. 
K562 cells were subjected to 5 nM PMA treatment for 72 hours and then Fluo-8 fluorescence was quantified 
by flow cytometry A) Average quantification of [Ca2+i] over time during K562 megakaryopoiesis. B) 
Representative histogram of [Ca2+i] oscillations over 72 hours.  Results were averaged between three 
independent experiments. Values represent mean ± SEM for each group. n=3. **P<0.01, *P<0.05. Student 
T.test 
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progenitors (CD117+, CD41a-), megakaryocyte progenitors/early mature megakaryocyte 
(CD117+, CD41a+) and mature megakaryocytes (CD117-, CD41a+) were gated in order to 
analyse the [Ca2+i] levels within these three different populations (Figure 36). The [Ca2+i] of 
each cellular population was measured using Fluo-8-AM staining together with CD117 and 
CD41a markers. Measurements were taken at day 1, day 5 and day 10 during this process.  
Optimal gating of the three cellular populations of interest was firstly established. Then, 
further analysis to decipher the [Ca2+i] of these populations was carried out. As expected, over 
the 10 days since the exposure of cells to TPO, the fluorescent intensity of CD117 decreased 
and CD41a increased gradually, together with changes in the number of HSC/progenitors, 
megakaryocyte progenitors and mature megakaryocytes (Figure 36). First day after TPO 
treatment, HSC/progenitors population had a significant higher number of events compared 
to the following 10 days (Figure 36 C). At day 5, the number of megakaryocyte progenitors 
increased (Figure 36 D) and finally, after 10 days, the events of mature megakaryocytes 
increased significantly (Figure 36 E). Therefore, changes in the number of events of each cell 
population suggested an efficient cell differentiation towards the megakaryocyte lineage 
within the culture.  
Once it was corroborated that megakaryopoiesis was taking place within the culture, the 
[Ca2+i] of these three cellular populations was analysed to obtain levels of [Ca2+i] during 
dynamic conditions of differentiation, rather than in static cellular differentiation stages 
within the culture. Results showed significant differences of [Ca2+i] between the different 
stages of maturation. Interestingly, HSC/early progenitors showed significant lower levels of 
[Ca2+i] compared with megakaryocyte progenitors and mature megakaryocytes. Early 
megakaryocyte progenitors rise [Ca2+i] compared with HSC/progenitors population and 
finally, mature megakaryocytes displayed a reduction of [Ca2+i] compared with 
megakaryocyte progenitors (Figure 37).  
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Therefore, different megakaryocyte maturation stages display differences in [Ca2+i] which 
could be directly linked with the functionality of these cells. [Ca2+i] levels of primary 
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Figure 36. In vitro megakaryopoiesis of mouse bone marrow cells. 
Purified mouse bone marrow cells were incubated with TPO (10 µg/ml) for 10 days. A) Changes in cell populations 
within the 10 days. B) CD117 and CD41 fluorescent fluctuations during 10 days of treatment. C) Quantification of 
number of events within each population during the 10 days of incubation.  Values represent mean ± SEM for each 
group. n=3 
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HSC/progenitors, megakaryocyte progenitors and megakaryocytes agreed with the previously 
oscillations described during K562 megakaryocyte induction. Overall, megakaryocyte 
commitment displays an increase in [Ca2+i] which is maintained in early megakaryocyte 
progenitors. Then during final maturation this [Ca2+i] decreases until reaching the required 
levels for mature megakaryocytes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Analysis of [Ca2+i] oscillations in DAMI cells during induced megakaryopoiesis 
 
Final analysis aiming to investigate the link between the last stage of megakaryocyte 
maturation and decrease of [Ca2+i] was performed. DAMI cell line, which is known to 
differentiate from megakaryoblast to megakaryocyte, when exposed to PMA, was used for 
this experiment (Greenberg et al., 1988).  (See section 5.2.4). [Ca2+i] was quantified after the 
maturation of DAMI cells into mature megakaryocytes to verify the decrease of [Ca2+i] during 
this last stage of megakaryocyte differentiation.  
0
2
4
6
HSC/Progenitors Megakaryocyte
Progenitors
Megakaryocytes
Fl
u
o
-8
 a
ve
ra
ge
 f
lu
o
re
sc
ec
e
[Ca2+i] in mouse bone marrow cells during 
megakaryopoiesis
 **  
 **  HSC/Progenitors 
Megakaryocyte 
progenitors 
Megakaryocytes 
Figure 37.  [Ca2+i] levels of HSC/Progenitors, megakaryocyte progenitors and megakaryocytes during in vitro 
megakaryopoiesis of mouse bone marrow cells. 
Purified mouse bone marrow cells were incubated with TPO (10 µg/ml) for 10 days and [Ca2+i] levels of selected 
cellular populations were analysed using Fluo-8 staining and flow cytometry. Figure shows average quantification of 
[Ca2+i] levels of HSC/Progenitors, megakaryocyte progenitors and megakaryocytes and a representative histogram of 
[Ca2+i] oscillations.   Values represent mean ± SEM for each group. n=3. **P<0.01, *P<0.05. Student T.test 
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As expected, megakaryocyte maturation of DAMI cells showed a decrease in [Ca2+i] after PMA 
treatment (Figure 38). DAMI mature megakaryocytes displayed a decrease of 0.6 ~ fold 
compared to the control (Figure 38). Therefore, these results agreed and validated the 
previous statement where it is proposed a decrease in [Ca2+i] during final mature 
megakaryocyte differentiation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Overall these experiments showed a rather remarkable result. Analysis of [Ca2+i] during 
megakaryocyte formation of three different cellular models revealed novel insights of Ca2+ 
dynamics during megakaryopoiesis. Together, these results demonstrate that there are 
intracellular Ca2+ oscillations during megakaryocyte cell fate differentiation. The model 
described here showed that initial megakaryocyte commitment displays an increase of [Ca2+i] 
followed by a decrease of this ion within the cytoplasm during the last stages of 
megakaryocyte maturation (Figure 39). These intracellular changes could be essential for 
initial megakaryocyte commitment and further functionality of mature megakaryocytes and 
platelets.  
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Figure 38. [Ca2+i] oscillations during DAMI megakaryocyte formation. 
DAMI cells were subjected to 5 nM PMA treatment for 72 hours and then Fluo-8 fluorescence was quantified 
by flow cytometry A) Average quantification of [Ca2+i] over time during DAMI megakaryocypoiesis. B) 
Representative histogram of [Ca2+i] oscillations.  Results were averaged between three independent 
experiments. Values represent mean ± SEM for each group. n=3. **P<0.01, *P<0.05. Student T.test 
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6.2.2. Analysis of the specificity of [Ca2+i] oscillations during cell differentiation of 
different blood lineages 
 The previous experiments do not determinate whether the established model of [Ca2+i] 
oscillations is only characteristic for megakaryocyte differentiation or it is common during cell 
fate determination in the haematopoietic lineage. Therefore, to unravel the pattern of [Ca2+i] 
oscillations during different cell fate commitment, this investigation further analysed [Ca2+i] 
during erythropoiesis.  
K562 cells are a known established model to study megakaryocyte and erythrocyte formation 
(Huo et al., 2006). Therefore, K562 cells were selected as a model to analyse the differences 
of [Ca2+i] oscillations between erythropoiesis and megakaryopoiesis. Hence, optimal 
conditions for K562 erythrocyte commitment in vitro were stablished. [Ca2+i] levels were 
measured and consequently compared with K562 megakaryopoiesis [Ca2+i] data.  
K562 erythropoiesis was induced with 50 µM Hemin treatment for 72 hours and erythrocyte 
induction was tested using CD235 erythrocyte cell surface marker and flow cytometry. K562 
50 µM Hemin treatment resulted in a significant increase in CD235a expression within the cell 
surface in almost 80% of these cells (Figure 40 A, B). Moreover, haemoglobin production was 
visualised by an increased red cell pellet compared with the control (Figure 40 C), as 
Figure 39. Model proposed in this study of [Ca2+i] oscillations during megakaryocyte formation in physiological 
conditions 
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previously described (Zhang et al., 2007). Cell death assay showed that Hemin treatment 
induced ~30% cell death (Figure 40 D).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Once K562 erythropoiesis was confirmed, [Ca2+i] was analysed during this process. 
Surprisingly, K562 treatment with Hemin and PMA led to a significant difference in [Ca2+i] 
oscillations during cell fate differentiation (Figure 41). K562 incubated with Hemin displayed 
a gradual increase of [Ca2+i], reaching a significant increase of 3 ~ fold compared with the 
control at 72 hours incubation (Figure 41).  
 
0
10
20
30
40
50
Control  Hemin
%
 c
e
ll 
d
ea
th
% Cell death
0
1
2
3
Control  Hemin
C
D
23
5a
  m
ea
n
 f
lu
o
re
sc
e
n
ce
(F
o
ld
 c
h
an
ge
)
CD235a expression during K562 erythropoiesis
0
20
40
60
80
100
 Control  Hemin%
 C
el
ls
 iw
th
 C
D
23
5a
  f
lu
o
re
sc
e
n
ce
% Cells expressing  CD235a 
Hemin     -               +  
 *  
*  
A.  B.  
C.  D.  
Figure 40. K562 cells under Hemin treatment display erythrocyte characteristics. 
A, B) Increase expression of CD235 marker in the cell surface after 72 hr of Hemin treatment.C) Change of color 
after Hemin treatment. Results were averaged between three independent experiments. Values represent mean ± 
SEM for each group. n=3. **P<0.01, *P<0.05. Student T.test 
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Taken together, the data emerged from this study show a specific pattern of Ca2+ oscillation 
on a temporal scale during cell differentiation, therefore, suggesting an important role of this 
molecule during the haematopoietic commitment.  
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Figure 41. [Ca2+i] fluctuations during K562 erythropoiesis and megakaryopoiesis. 
A) Representative histogram showing the difference of basal calcium over time during K562 erythropoiesis 
and megakaryopoiesis. B) Results were averaged between three independent experiments. Values 
represent mean ± SEM for each group. n=3. **P<0.01, *P<0.05. Student T.test 
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6.2.3. Ca2+ dynamics in CALR mutant cells: an integrative analysis of different 
megakaryocyte differentiation stages.  
  
CALR mutations lead to a deletion of the majority of Ca2+ binding sites and reduce the acidity 
of this C-terminal domain. Therefore, CALR mutations described in MPNs might affect the 
intracellular Ca2+ dynamics during megakaryocyte hyperplasia. This study aimed to analyse 
the Ca2+ dynamics in CALR mutant cells in two different stages of megakaryocyte 
differentiation: early blast stage and mature megakaryocytes. In order to analyse Ca2+ 
dynamics within these cells the [Ca2+i], the ER Ca2+ buffering activity and the amount of Ca2+ 
stored within the ER were analysed.  
 
6.2.3.1. Basal [Ca2+i] of leukemia blasts harbouring CALR mutations  
 
To understand how CALR mutations affect Ca2+ dynamics within the cell, initial experiments were 
focussed on analysing [Ca2+i] in CALR mutant cells during early stages of cell differentiation.  
Firstly, [Ca2+i] of MARIMO cells were analysed and compared to K562 [Ca2+i]. Interestingly, 
results showed a significant difference of [Ca2+i] between the two cell lines (Figure 42). 
MARIMO cells displayed a decrease in [Ca2+i] compared with K562 level (Figure 42). These 
results suggested that CALR mutation L367fs*43 could affect Ca2+ homeostasis of CALR 
mutant cells. 
Next, further analysis of basal [Ca2+i] within the megakaryoblast stage were performed. DAMI 
cells overexpressing CALR wt, CALR type 1 and CALR type 2 were used for this experiment. 
Results showed a significant decrease in [Ca2+i] in CALR type 2 cells compared with the control 
(Figure 43). Additionally, a small decrease in the [Ca2+i] of CALR type 1 cells was described, 
although results were not significant (Figure 43). These results demonstrated that CALR 
mutations lead to an overall decrease in [Ca2+i] during early stages of differentiation and this 
could have an impact in the Ca2+ signalling during initial megakaryopoiesis in ET and PMF. 
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Figure 42. [Ca2+i] levels in leukemic blasts. 
Cells were stained using FLUO-8-AM and basal intracellular Ca2+ levels were quantified by flow cytometry. 
Results were averaged between three independent experiments. Values represent mean ± SEM for each 
group. n=3. **P<0.01, *P<0.05. Student T.test 
 
 
Figure 43. [Ca2+i] levels in DAMI cells overexpressing CALR wt, type 1 and type 2 mutations. 
Cells were stained using FLUO-8-AM and basal intracellular Ca2+ levels were quantified by flow cytometry. 
Results were averaged between six independent experiments. Values represent mean ± SEM for each 
group. **P<0.01, *P<0.05. Student T.test. 
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6.2.3.2. ER Ca2+ buffering activity of leukemic blasts harbouring CALR mutations 
 
CALR mutations are described to be present from early stages of cellular differentiation. As 
previously described, CALR mutant cells in blast stages display lower [Ca2+i]. Cellular [Ca2+i] is 
highly regulated by the ER Ca2+ buffering activity. Therefore, to further characterise the effects 
of CALR mutations, the ER Ca2+ buffering activity of cells in early stages of differentiation were 
analysed. To evaluate cytoplasmic Ca2+ mobilisation from the ER, cells were exposed to 
thapsigargin (1 µM). Thapsigargin is a SERCA inhibitor which treatment results in an increase 
of [Ca2+i] as a consequence of preventing ER Ca2+ sequestration and finally leading to ER Ca2+ 
depletion. This technique is commonly used to study the ER Ca2+ levels within the cells. During 
this experiment cells were stained with Fluo-8-AM and [Ca2+i] were registered up to 15 
minutes after thapsigargin treatment using flow cytometry.  
Initial analysis was carried out using MARIMO and K562 cell lines. As expected, thapsigargin 
ER Ca2+ depletion induced an increase of [Ca2+i] due to passive release of the ER Ca2+ storage 
into the cytoplasm (Figure 44 A). Afterwards, [Ca2+i] decreased to the baselines levels of Ca2+ 
registered in both cell lines (Figure 44 A) as the cellular membrane Ca2+ channels extruded to 
the extracellular medium this excess of Ca2+.  
Analysis of ER Ca2+ buffering activity in MARIMO leukemic blasts, showed a slower release of 
Ca2+ upon thapsigargin treatment, compared with the control (Figure 44 A).  Moreover, 
quantification of the total ER Ca2+ released during ER depletion revealed that MARIMO cells 
displayed a significant lower amount of stored ER Ca2+ compared with K562 cells (Figure 44 
B).  
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Figure 44. Fluorescence-based analysis of ER Ca2+ flow in K562 and MARIMO cells. 
A) Cells were stained using Fluo-8-AM and were subsequently resuspended in PBS.  Once 1 µM thapsigargin 
was added to the cells, fluorescence measurements were registered using flow cytometry for 15 minutes. B) 
Measurements of ER Ca2+ release in K562 and MARIMO cells. Values represent mean ± SEM for each group. 
n=3. **P<0.01, *P<0.05. Student T.test 
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Following the same experimental procedure, the cytoplasmic Ca2+ mobilisation from the ER 
of DAMI cells overexpressing CALR wt, CALR type 1 and type 2 mutants upon thapsigargin 
treatment was analysed. The experiment was performed using two different DAMI clones of 
each condition in triplicates.  
Results showed that DAMI cells exposed to thapsigargin displayed ER Ca2+ depletion following 
the same dynamics as described with MARIMO and K562 cells (Figure 45). Interestingly, DAMI 
cells harbouring both CALR mutations, type 1 and type 2, showed a decrease of cytosolic Ca2+ 
oscillation after thapsigargin treatment (Figure 45 A). A slightly decrease in the rate of ER Ca2+ 
release was found in both mutants compared with the control (Figure 45 A). Additionally, 
CALR mutant cells showed a significant lower amount of stored ER Ca2+ compared with CALR 
wt DAMI cells (Figure 45 B).  
Overall, there results prove that the three CALR mutations used during this study type 1 and 
type 2 together with L367fs*43 affect cytoplasmic Ca2+ mobilisation from the ER in cells 
blocked in early stages of megakaryocyte differentiation. CALR mutations, indistinctively of 
the CALR type of mutation, lead to a significant decrease of ER Ca2+ storage as well as decrease 
of Ca2+ mobilisation the cytoplasm from the ER in leukemic blasts.   
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Figure 45. Fluorescence-based analysis of ER Ca2+ flow in DAMI cells overexpressing CALR WT, type 1 
and type 2 mutations. 
A) Cells were stained using Fluo-8-AM and were subsequently resuspended in PBS.  Once 1 µM 
thapsigargin was added to the cells, fluorescence measurements were registered using flow cytometry 
for 15 minutes. Representative example of fluorescent measurements of a single clone per condition 
are shown. B) Measurements of ER Ca2+ release in DAMI cells. Results were averaged between six 
independent experiments using two different clones per condition. Values represent mean ± SEM for 
each group. n=3. **P<0.01, *P<0.05. Student T.test 
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6.2.3.3. Analysis of [Ca2+i] in megakaryocyte like cells harbouring CALR mutations 
 
To further explore the effects of CALR mutations in the Ca2+ dynamics during megakaryocyte 
maturation, basal [Ca2+i] in DAMI cells overexpressing CALR wt, type1 and type 2 cells after 
PMA megakaryocyte induction were analysed. Experiments were performed in triplicates 
using two different clones for each condition.  
As previously described, DAMI cells significantly decreased their [Ca2+i] from the 
megakaryoblast to the mature megakaryocyte stages after PMA induction. Interestingly, none 
of the PMA-megakaryocyte induced CALR mutant DAMI cells showed a significant decrease 
of [Ca2+i]. Surprisingly, CALR type 1 cells showed a slight increase in [Ca2+i] compared with its 
correspondent basal control, although this difference was not statistically significant (Figure 
46). Moreover, DAMI CALR type 2 did not show any difference in [Ca2+i] after PMA 
megakaryocyte induction (Figure 46).  
Overall, these results proved that CALR mutations affect the [Ca2+i] during the last stages of 
megakaryocyte commitment. Surprisingly, analysis of the [Ca2+i] of the matured 
megakaryocytes showed significant differences between CALR wt and CALR mutant cells. 
Both mutants displayed a significant increase in [Ca2+i] at the final mature megakaryocyte 
stage, compared with CALR wt (Figure 46 B). Interestingly, CALR type 1 megakaryocytes 
displayed higher [Ca2+i] levels compared with CALR type 2 megakaryocytes (Figure 46 B).   
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Figure 46.  [Ca2+i] levels in DAMI cells overexpressing CALR wt, type 1 and type 2 mutations after PMA 
induction.  
DAMI cells were exposed to PMA treatment for 72 hours. Cells were stained using FLUO-8-AM and basal 
intracellular Ca2+ levels and quantified by flow cytometry. A) [Ca2+i] before and after DAMI megakaryocyte 
induction. B) [Ca2+i] of DAMI megakaryocyte cells. C) Representative histogram of the [Ca2+i] of one clone 
per condition.  Results were averaged between six independent experiments using two different clones per 
condition. Values represent mean ± SEM for each group. **P<0.01, *P<0.05. Student T.test 
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6.2.3.4. ER Ca2+ buffering activity of megakaryocyte like cells harbouring CALR mutations 
 
Previous analyses demonstrated that CALR mutations lead to a decrease of basal [Ca2+i], drop 
cytoplasmic Ca2+ mobilisation from the ER as well as decrease the ER Ca2+ storage during early 
stages of megakaryocyte differentiation (blast and megakaryoblast stages). However, CALR 
type 1 and type 2 mutations seem to lead to a final increase in the basal [Ca2+i] in DAMI mature 
megakaryocytes. Therefore, to further understand the effects of CALR mutations in the Ca2+ 
dynamics of mature megakaryocytes, this study further analysed whether CALR mutations 
affect the cytoplasmic Ca2+ mobilisation from the ER at this differentiation stage. For this, 
DAMI cells overexpressing CALR wt, CALR type 1 and CALR type 2 were treated with PMA 
during 72 hours. Then, Fluo-8 stained megakaryocytes were treated with thapsigargin, and 
intracellular Ca2+ levels were recorded as previous experiments.  
DAMI PMA induced cells exposed to thapsigargin displayed ER Ca2+ depletion (Figure 47). 
Interestingly, DAMI cells harbouring both CALR mutations, type 1 and type 2, showed an 
increase of cytosolic Ca2+ oscillation after thapsigargin treatment compared to the control 
(Figure 47 A). Additionally, a slightly increase in the rate of ER Ca2+ release was found in both 
mutants (Figure 47 B). Finally, both mutants showed an increase of ER Ca2+ storage, although 
differences were not statistically significant (Figure 47 B).  
Comparison of the ER Ca2+ mobilisation between CALR mutant DAMI cells in their 
megakaryoblast and megakaryocyte stage showed surprising results.  Both CALR mutations 
increase the rate of Ca2+ release after megakaryocyte maturation (Figure 48 B, C).  
Furthermore, megakaryocyte differentiation in both mutants leads to a significant increase of 
ER Ca2+ storage (Figure 49). In contrast CALR wt DAMI cells did not show any differences 
between both differentiation stages.  
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Figure 47. Fluorescence-based analysis of ER Ca2+ flow in DAMI PMA induced  cells overexpressing CALR 
WT, type 1 and type 2 mutations. 
A) DAMI cells were differentiated into megakaryocytes under PMA treatment for 72 hours. Then, cells were 
stained using Fluo-8-AM and were subsequently resuspended in PBS.  Once 1 µM thapsigargin was added 
to the cells, fluorescence measurements were registered using flow cytometry for 15 minutes. 
Representative example of fluorescent measurements of a single clone per condition are shown. B) 
Measurements of ER Ca2+ release in DAMI megakaryocyte cells. Results were averaged between six 
independent experiments using two different clones per condition. Values represent mean ± SEM for each 
group. n=3. **P<0.01, *P<0.05. Student T.test 
 
166 
 
 
  
Figure 48. Comparison of the fluorescence-based analysis of ER Ca2+ flow between DAMI cells 
overexpressing CALR wt, type 1 and type 2 mutations before and after PMA megakaryocyte 
induction. 
Representative example of fluorescent measurements of a single clone per condition are shown. Values 
represent mean ± SEM for each group.  
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Together these results provide novel insights into the nature of CALR mutations. CALR mutant 
cells display abnormal Ca2+ dynamics through the megakaryocyte maturational process. These 
cells show different patterns of ER Ca2+ release during different stages of megakaryocyte 
differentiation. In contrast CALR wt cells do not show any alteration of this activity during 
megakaryopoiesis.  
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Figure 49. Comparison of the ER Ca2+ release between DAMI cells overexpressing CALR wt, type 1 and 
type 2 mutations before and after PMA megakaryocyte induction. 
Results were averaged between six independent experiments using two different clones per condition. Values 
represent mean ± SEM for each group. **P<0.01, *P<0.05. Student T.test 
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6.2.4. Ca2+ channel blockers as inducers of megakaryocytic differentiation 
 
Physical manipulation of intracellular Ca2+ has shown to induce differentiation of specific 
cellular lineages (Sun et al., 2007; Pinto et al., 2016). This study has demonstrated that [Ca2+i] 
could play an essential role during megakaryocyte formation. Additionally, CALR mutations 
characteristic of megakaryocytic neoplastic cells change the Ca2+ dynamics during 
megakaryocyte differentiation. All these results together with the recent published study 
showing that treatment with Riluzole, a CCB specific of NMDAR, induces megakaryocytic 
characteristics in leukemic blast (Kamal et al., 2015), suggest that changes in Ca2+ dynamics 
within the cells could induce megakaryocyte cell fate. To evaluate whether physical 
manipulation of [Ca2+i] could induce megakaryocyte characteristics, we exposed leukemic 
blast cells were exposed to three CCBs. BTP-2 is an inhibitor of SOCE machinery and Fendiline 
an inhibitor of L-type channels. Furthermore, Riluzole treatment was also used to test further 
megakaryocyte characteristics under its treatment than the previously published data (Kamal 
et al., 2015). 
CD41a expression under BTP-2 and Fendiline treatment 
 
CD41a cell surface marker was used to test the induction of megakaryocytic differentiation 
under BTP-2 and Fendiline treatment. Firstly, K562 and MARIMO cells were incubated with 
BTP-2 under different concentrations (0, 20, 25, 50 µM) over 72 hours and cell surface 
expression of CD41a marker was analysed. Results showed an increase in CD41a expression 
in a BTP-2 dose dependant manner (Figures 50 and 51). The major shift in CD41a fluorescence 
in both cell lines, was found with 50 µM BTP-2 treatment after 72 hours. Then, cells were 
incubated with 50 µM BTP-2 and CD41a cell surface expression was recorder every 24 hours 
over 72 hours. Results showed the major increase in cell surface expression after 72 hours 
(Figures 50 and 51). Therefore, 50 µM BTP-2 treatment over 72 hours was selected as optimal 
condition for further experiments.  
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Figure 50. Analysis of CD41a cell surface marker expression in K562 cells after BTP-2 treatment. 
Representative counter plots of flow cytometry analysis measuring CD41a antigen expression in K562 cell 
population after treatment of different concentrations of BTP-2 (20, 25, 50 µM) and times of incubation (24, 48 
and 72 hours). Cells were stained with CD41a-APC antibody.  
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CD41a fluorescence was quantified in both cell lines after 50 µM BTP-2 treatment for 72 
hours. K562 and MARIMO cells showed a significant increase in CD41a marker compared with 
the untreated control, suggesting an induction of megakaryocyte characteristics under these 
Figure 51. Analysis of CD41a cell surface marker expression in MARIMO cells after BTP-2 treatment. 
Representative counter plots of flow cytometry analysis measuring CD41a antigen expression in MARIMO 
cell population after treatment of varying concentrations of BTP-2 (20, 25, 50 µM) and different times of 
incubation (24, 48 and 72 hours). Cells were stained with CD41a-APC antibody. 
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conditions (Figure 52 A, B). Almost 100% of events displayed CD41a expression in both cell 
lines (Figure 52 C). 
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Figure 52. CD41a quantification and cell death induction after 50 µM BTP-2 treatment. 
A, B) K562 and MARIMO cells were subjected to 50 µM BTP-2 treatment for 72 hours and CD41a expression was 
analysed and quantified by flow cytometry. C) Quantification of CD41a positive cells. Values represent mean ± 
SEM for each group. n=3. **P<0.01, *P<0.05. Student T.test  
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After SOCE machinery inhibition, the effects of non-voltage-gated L-type channels inhibition 
was analysed by using Fendiline treatment. K562 and MARIMO cells CD41a cell surface 
expression was analysed after cell incubation with different Fendiline concentrations (0, 5, 
10, 20 µM) over 72 hours. Results showed a shift in CD41a fluorescence under 20 µM 
concentration in both cell lines (Figures 53 and 54). Moreover, measurements every 24 hours 
under 20 µM showed that cells under this treatment display CD41a within the cell surface 
after 72 hours (Figures 53 and 54) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 53. Analysis of CD41a cell surface marker expression in K562 cells after Fendiline treatment. 
Representative counter plots of flow cytometry analysis measuring CD41a antigen expression in K562 
cell population after treatment of different concentrations of Fendiline (5, 10, 20 µM) and different 
times of incubation (24, 48 and 72 hours). Cells were stained with CD41a-APC antibody. 
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Figure 54. Analysis of CD41a cell surface marker expression in MARIMO cells after Fendiline treatment. 
Representative counter plots of flow cytometry analysis measuring CD41a antigen expression in MARIMO cell 
population after treatment of different concentrations of Fendiline (5, 10, 20 µM) and different times of 
incubation (24, 48 and 72 hours). Cells were stained with CD41a-APC antibody 
 
 Finally, CD41a fluorescence was quantified in K562 and MARIMO after 20 µM Fendiline 
treatment for 72 hours. Both cell lines showed an increase in CD41a expression compared 
with control (Figure 55 A, B). Moreover, almost 100% of events displayed CD41a expression 
in K562 and 80 % in MARIMO cells (Figure 55 C). 
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Figure 55. CD41a quantification and cell death induction after 20 µM Fendiline treatment. 
A, B) K562 and MARIMO cells were subjected to 20 µM Fendiline for 72 hours and then CD41a expression was 
analysed and quantified by flow cytometry. C) Quantification of CD41a positive cells. Values represent mean ± 
SEM for each group. n=3. **P<0.01, *P<0.05. Student T.test  
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MTS analysis after BTP-2 and Fendiline treatment 
 
Cell exposure to CCBs could induce high cytotoxicity within the cell culture. Therefore, before 
carrying out further molecular analysis using BTP-2 and Fendiline treatment the cytotoxic 
effect of these CCBs were investigated by MTS assay. Cells were cultured under different drug 
concentrations (0, 5, 10, 20, 50, 100 µM) for 72 hours.  
MTS results showed that BTP-2 and Fendiline treatment provided a strong decrease of cell 
growth in both cell lines in a dose dependent manner (Figure 56 A). 50 µM of BTP-2 treatment, 
the optimal concentration where CD41a was expressed in both cell lines, reduced K562 cell 
number to 62 ± 10 % (Figure 56 A). Moreover, MARIMO cells were more sensitive to the 
exposure to this CCB, as cell viability was reduced to 48 ± 13 % (Figure 56 A).  
Fendiline showed a higher inhibitory effect compared with BTP-2. MARIMO cells exposed to 
20 µM Fendiline displayed a decrease in cell viability to 34.19 ± 2.3 % (Figure 56 B). K562 
showed a slightly higher sensitivity under these conditions, and their cell growth rate 
decrease to 26.36 ± 8.7 % (Figure 56 B).  
Overall, MTS results showed that optimal BTP-2 and Fendiline concentrations for induction of 
megakaryocyte like characteristics chosen above provided a strong decrease of cell growth in 
both, K562 and MARIMO cell lines.  
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Figure 56. Cell proliferation analysis of MARIMO and K562 cells exposed to BTP-2 and Fendiline 
treatment. 
MARIMO and K562 cells were subjected to 0, 5, 10, 20, 50, 100 µM treatment of A) BTP-2 and B) Fendiline 
for 72 hours. Then, MTS assay performed to test cell viability.  Values represent mean ± SEM for each 
group. n=3. 
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MPL expression under BTP-2, Fendiline and Riluzole treatment.  
 
During megakaryocyte formation, the expression of c-MPL is essential for a correct cellular 
function. In order to study whether intracellular Ca2+ manipulation can induce highly 
important events such as c-MPL expression, MARIMO cells, which have been shown to be 
negative for this receptor (Kollmann et al., 2016) were exposed to BTP-2, Fendiline and 
Riluzole during 72 hours.  
Initially, c-MPL mRNA levels were tested using qRT-PCR analysis. Surprisingly, results showed 
a significant upregulation of c-MPL gene expression after treatment with the three CCBs 
(Figure 57). Additionally, flow cytometry analysis revealed a significant increase of MPL 
protein levels within the cell surface of MARIMO cells after BTP-2, Fendiline and Riluzole 
treatment (Figure 57).  Quantification of MPL positive events estimated about 100% of cells 
under Riluzole and BTP-2 treatment and 75% of cells treated with Fendiline to express this 
protein within the cell surface.  
Therefore, physical intracellular Ca2+ manipulation by blocking NMDR, SOCE or L-type 
channels independently by using CCBs led to a significant expression of MPL receptor, in both 
mRNA and protein levels.  
 
 
 
 
 
 
 
 
 
178 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
25
50
75
100
Control Riluzole BTP-2 Fendiline
%
 c
e
lls
% Cells expressing MPL
** 
** 
* 
0
20
40
60
80
100
120
140
Control Riluzole BTP-2 Fendiline
R
el
at
iv
e 
ex
p
re
ss
io
n
 t
o
 g
ap
d
h
c-MPL mRNA levels
** 
** 
0
5
10
15
20
Control Riluzole BTP-2 Fendiline
M
P
L 
fl
u
o
re
ce
n
ct
m
ea
n
 
(F
o
ld
 c
h
an
ge
)
MPL cell surface expression
 MPL-APC 
 
A. 
B. C. 
D. 
Control 
Riluzole 
BTP-2 
Fendiline 
** 
 
* 
Figure 57. MPL expression in MARIMO cells after Riluzole, BTP-2 and Fendiline treatment. 
MARIMO cells were subjected to 100 µM Riluzole, 50 µM BTP-2 or 20µM Fendiline treatment for 72 hours. A) RNA 
was extracted and converted into cDNA and finally subjected qRT-PCR using primers against c-MPL. B, C) MPL 
(CD110) expression was analysed and quantified by flow cytometry. D) Quantification of CD41a positive cells. Values 
represent mean ± SEM for each group. n=3. **P<0.01, *P<0.05. Student T. test.  
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Expression of STAT5 target genes after BTP-2, Fendiline and Riluzole treatment 
 
Previous results clearly stated an important role of intracellular Ca2+ during megakaryocyte 
formation. However, there is no previous evidence suggesting whether Ca2+ signalling has any 
directly link with JAK/STAT cascade, which is known to be essential for correct 
megakaryopoiesis. For that reason, the activation status of STAT5 after exposure to Riluzole, 
Fendiline and BTP-2 was further studied. MARIMO cells were used in this experiment, as this 
cell line has been previously reported to display an inactive JAK/STAT cascade (Kollmann et 
al., 2016; Kollmann et al., 2015). Expression of four known STAT5 target genes PIM1, CISH, 
ID1 and SOCS2 (Sonkin et al., 2015) was analysed after 72 hours of drug incubation.  
Interestingly, qRT-PCR analysis showed that MARIMO cells exposed to CCB display a 
significant increase of mRNA of the four gene signature of STAT5 (Figure 58).  Although some 
samples did not show a statistically significant increase due to higher variability between the 
experiments, an overall increase of expression was found. Thus, MARIMO cells exposed to 
CCBs resulted in a trend for upregulation of the mRNA expression of the STAT5 gene 
signature. These results together with the previous findings showing an upregulation of MPL 
expression after intracellular Ca2+ manipulation by using CCBs, suggested a direct link 
between Ca2+ dynamics and JAK/STAT signalling.  
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Figure 58. Expression of STAT5 gene signature in MARIMO cells after Riluzole, BTP-2 and Fendiline treatment. 
MARIMO cells were subjected to 100 µM Riluzole, 50 µM BTP-2 or 20µM Fendiline treatment for 72 hours. RNA 
was extracted and converted into cDNA and finally subjected RT-qPCR using primers against PIM1, CISH, ID1 and 
SOCS2 genes. Values represent mean ± SEM for each group. n=3. **P<0.01, *P<0.05. Student T.test 
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6.3. Discussion 
 
Cell differentiation is directly controlled by long term transient oscillations of [Ca2+i] (Pinto et 
al., 2016). A strong relationship between [Ca2+i] oscillations and specific cell differentiation 
lineages has been previously established. However, although Ca2+ dynamics seem to play a 
pivotal role in megakaryocyte differentiation and functions, the temporal changes of [Ca2+i] 
during the differentiation of this lineage have not been described. This study demonstrates 
that [Ca2+i] oscillate between different megakaryocyte maturational stages in a highly 
controlled manner during megakaryocyte commitment. In this investigation, three in vitro 
cellular models showed that megakaryocyte commitment is accompanied by highly regulated 
transient Ca2+ oscillations in hours scale.   
During the analysis of [Ca2+i] oscillations, two different megakaryocyte inducers where used, 
PMA and TPO. Hence, the [Ca2+i] oscillations observed in this study were not an artificial 
product based on a specific drug treatment. Interestingly, previous research aiming to 
decipher the role of mitochondrial function during megakaryocyte commitment, described 
the same Ca2+ oscillations during K562 megakaryopoiesis, and they considered this transient 
Ca2+ changes to be consequence of transitional changes in reactive oxygen species (ROS) 
during cell differentiation (Huang et al., 2014). However further evidence is needed to 
understand the molecular basis of these specific [Ca2+i] oscillations and their repercussions 
during megakaryocyte commitment. 
Erythrocyte cell differentiation is highly dependent on [Ca2+i] (Schaefer et al., 1997). Previous 
analysis demonstrated that EPO induces increases of [Ca2+i] (Miller et al., 1989). Thus, [Ca2+i] 
is suggested to be an important intracellular signal during erythrocyte differentiation. Results 
measuring the [Ca2+i] of K562 under Hemin erythrocyte induction displays an increase of 
[Ca2+i] over time. Therefore, the Ca2+ oscillations during K562 erythropoiesis described here 
agrees with previous statements suggesting an increase of [Ca2+i] during erythrocyte cell 
commitment (Miller et al., 1988; Miller et al., 1989). These results, together with previous 
studies that reported a rise in [Ca2+i] for neurons and muscles cells differentiation, suggest 
that increase in [Ca2+i] is an initiating event for cellular differentiation.  Interestingly, K562 
Ca2+ oscillations differ in space and time depending on erythrocyte/megakaryocyte 
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commitment. Hence, the frequency of these transient [Ca2+i] oscillations could be a key signal 
for cell differentiation fate during haematopoiesis.  
Cytosolic Ca2+ dynamics directly depends on the ER Ca2+ and its constant flow towards the 
cytoplasm. Previous investigations targeting the analysis of intracellular Ca2+ dynamics in CALR 
mutant cells showed contradictory results regarding the ER Ca2+ release capacity of these 
cells. Interestingly, the ER Ca2+ release of MARIMO cells in response to thapsigargin treatment 
shows a decreased capacity of ER Ca2+ release (Kollmann et al., 2015). On the contrary, 
primary megakaryocytes from MPN patients harbouring CALR type 1 and type 2 mutations 
treated with CPA displayed a significant increase of ER Ca2+ release compared with JAK2 
mutants or healthy subjects (Pietra et al., 2015). Initially, results using MARIMO and DAMI 
cells overexpressing CALR type 1 and type 2 cells in their blast stage showed a decrease 
capacity of ER Ca2+ release in response to thapsigargin compared to the control, as previously 
described (Kollmann et al., 2015). Unexpectedly, when DAMI cells were differentiated 
towards megakaryocyte under PMA treatment, both CALR mutant cells increased their ER 
Ca2+ release rate, as seen in primary megakaryocytes (Pietra et al., 2015). Therefore, this study 
demonstrates that the previously registered discrepancies are due to differences in the 
differentiation stage of the cellular models used in these studies. DAMI CALR type 1 showed 
a tendency to a slightly higher increase rate of ER Ca2+ release compared with CALR type 2. 
These observations are consistent with previous studies where primary patient 
megakaryocytes CALR type 1 subjects displayed a significant higher capacity of ER Ca2+ release 
(Pietra et al., 2015), which is known to have more pronounce pathological effects than CALR 
type 2.  
However, not only the ER Ca2+ release capacity fluctuates in CALR mutant cells, but the basal 
[Ca2+i] differ as well during different stages of differentiation within these cells. MARIMO cells 
and DAMI cells overexpressing CALR mutations displayed a significant decrease of [Ca2+i] in 
their blast stage compared with CALR wt cells. However, when cells were differentiated 
towards mature megakaryocytes, the basal [Ca2+i] raised, reaching a significant difference 
compared with the control. Importantly, Ca2+ has been proved to be a key element for normal 
megakaryocyte and platelet function (Di Buduo et al., 2014, Di Buduo et al., 2016), hence 
changes in [Ca2+i] could directly affect megakaryocyte functions during disease.  
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CALR mutations affect intracellular Ca2+ in a cell differentiation stage manner during 
megakaryopoiesis, and it is possible that transient changes of Ca2+ buffering activity 
contribute to the pathogenesis of megakaryocyte hyperplasia. Of note, a recent publication 
suggested that there are quantitative changes at the protein level of CALR mutants during 
megakaryopoiesis (Iborra and Papadopoulos, 2017). CALR mutant proteins undergo rapid 
degradation when overexpressed in DAMI and HEL cell lines (Kollmann et al., 2016). In 
contrast, significantly higher CALR mutant protein levels were described in platelets from 
MPN patients (Kollmann et al., 2016).  Therefore, it has been proposed that during early 
stages of megakaryocyte maturation cells undergo a process of readjustment of CALR mutant 
protein levels to achieve cell survival (Iborra and Papadopoulos, 2017).  Changes in ER Ca2+ 
buffering activity and basal [Ca2+i] during megakaryocyte differentiation described in this 
study could be directly linked with the protein levels of CALR mutants within the cell during 
the different megakaryocyte maturational stages.  However, further analysis is needed to 
corroborate the transitions of CALR mutant protein levels within the megakaryocyte lineage 
in order to link this with changes of the Ca2+ buffering activity within CALR mutant cells during 
megakaryopoiesis.  
Increase of [Ca2+i] in megakaryocytes has been previously linked with the development of 
megakaryocyte hyperplasia in mice expressing an activated form of STIM protein (Grosse et 
al., 2007). According to the results showed in this study, CALR mutations, which are restricted 
to MPNs displaying megakaryocyte hyperplasia, lead to an increase of [Ca2+i] in mature 
megakaryocyte cells.  Therefore, it could be suggested that changes in the [Ca2+i] caused by 
CALR mutants could be the driving force of megakaryocyte hyperplasia during ET and PMF, 
together with an active JAK/STAT and MAPK pathway. Therefore, this study extends our 
knowledge of the effects of CALR mutations into megakaryocytes and it increases the possible 
oncogenic roles of this mutation in MPNs.  
Furthermore, this study reveals that leukemic cell lines with potential to commit into the 
megakaryocytic lineage express megakaryocyte like molecular characteristics when exposed 
to different CCBs. NMDARs, SOCE and L-type channels facilitate extracellular Ca2+ flow into 
the cytoplasm, helping to maintain high [Ca2+i] in response to specific stimuli. This study 
demonstrates that the following NMDARs, SOCE and L-type antagonist known as Riluzole, 
BTP-2 and Fendiline respectively, increase the expression of CD41a and MPL megakaryocyte 
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cell surface markers, as well as induction of STAT5 transcriptional activity. To our knowledge, 
this is the first study to report that inhibition of overall extracellular Ca2+ entry in leukemic 
cells induces megakaryocyte features, suggesting that physical manipulation of intracellular 
Ca2+ facilitates megakaryocyte differentiation as previously reported in other cell types (Sun 
et al., 2007).  
NMDARs have been previously described to be active in human platelets (Kalev-Zylinska et 
al., 2014) as well as to regulate megakaryocyte formation in vitro (Hitchcock et al., 2003). 
Moreover, it was shown that NMDARs inhibition leads to expression of CD41a, CD61 and 
induce polyploidy in leukemic blasts (Kamal et al., 2015). This thesis supports this previous 
study by adding novel data proving that NMDARs inhibition increases MPL cell surface 
expression and induces expression of PIM1, CISH, SOCS2 and ID1 genes, showing the 
relevance of NMDAR for megakaryocyte maturation. Moreover, SOCE machinery actively 
regulates human megakaryocyte functions (Di Buduo et al., 2014). This investigation 
demonstrates that SOCE machinery could regulate, together with NMDARs receptors, Ca2+ 
homeostasis during megakaryopoiesis, as BTP-2 treatment leads to expression of the same 
megakaryocytic characteristics as Riluzole treatment (Kamal et al., 2015). In contrast L-type 
channels have not been shown to have any direct link with megakaryocyte formation. 
However, this study indicates that the use of antagonists of these channels leads to induction 
of megakaryocytic characteristics. Though, further studies regarding the expression of L-type 
channels and their activity in these cells is necessary to fully understand their functional role 
in megakaryocyte formation.  
Additionally, it is important to note the high cytotoxicity of the described optimal 
concentrations of Fendiline and BTP-2 for the induction of megakaryocyte characteristics in 
comparison to the previously reported Riluzole (Kamal et al., 2015). Consequently, 
characterisation of cell morphology of the live cells within the culture was not doable and 
therefore further analysis of megakaryocyte characteristics were not completed, such as 
analysis of polyploidy. Therefore, the test of other SOCE inhibitors, such as CRAC or 2-APB and 
L-type channel inhibitors like A5605 and A7232 will be essential to identify optimal drug 
treatment to reduce cytotoxicity and induce megakaryocyte characteristics in leukemic blasts.  
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Leukaemia cells are characterised by a blockage in early stages of differentiation and fail to 
differentiate into fully mature cells (Sell, 2005).  Differentiation therapy has shown promising 
results in the treatment of acute promyelocytic leukaemia (APL) by using the differentiation 
agent ATRA (Degos and Wang, 2001).  ATRA treatment has improved greatly the prognosis of 
APL patients, therefore much of today’s research is focussed on the identification of further 
differentiating agents for the treatment of myeloid leukaemia’s. These findings provide 
further depth to the current understanding of the relevance of intracellular Ca2+ in cell 
differentiation and open the possibility that Ca2+ might be an important target for the 
development of novel differentiation inducing agents for leukemic differentiation therapy.  
In summary, this investigation reveals that Ca2+ oscillations could be the driving force of 
megakaryocyte differentiation. CALR mutations lead to changes in Ca2+ dynamics during the 
process of megakaryocyte formation, and therefore these changes could favour the 
megakaryocyte cell differentiation during the process of hyperplasia in disease and 
consequently alter megakaryocyte and platelet functions in ET and PMF.  
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6.3.1. Conclusions 
 
The novel data presented in this study showing the correlation between Ca2+ and 
megakaryocyte formation in physiological conditions and disease reveals new insights into 
the important role of Ca2+ dynamics and megakaryocyte cell commitment. The major 
conclusions of this study are:  
I. Megakaryocyte differentiation displays a characteristic pattern of [Ca2+i] oscillations 
in hours scale, which could induce specific signalling necessary for the initiation of 
megakaryocyte differentiation.  
 
II. Differentiation towards megakaryocyte or erythrocyte cell commitment show 
differential frequency of [Ca2+i] oscillations, suggesting a direct correlation between 
[Ca2+i] and cell commitment during haematopoiesis. 
 
III. Presence of CALR mutations in early stages of megakaryocyte commitment leads to a 
decrease of basal [Ca2+i] as well as decreased ER Ca2+ flow towards the cytoplasm and 
total ER Ca2+stored. 
 
IV. Mature megakaryocytes harbouring CALR mutations display higher [Ca2+i] in their 
megakaryocyte stage compared with CALR wt cells. Moreover, megakaryocyte 
commitment in these mutant cells lead to an increase of ER Ca2+ flow towards the 
cytoplasm and total ER Ca2+stored.  
 
V. Intracellular Ca2+ manipulation by CCB treatment leads to the appearance of 
megakaryocyte like characteristics in leukemic cells, such as CD41a, MPL expression 
or activation of STAT5 transcriptional activity.  
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6.3.2. Future directions  
 
To obtain more results regarding human megakaryocyte Ca2+ physiology in health and 
disease, further analysis using the same experimental procedures used during this study will 
be required using human megakaryocyte cultures from CD34+ progenitor cells of healthy 
subjects and CALR mutant MPN patients. It will be of much interest the analysis of the effects 
of a decrease of [Ca2+i] during early stages of development and an increase of [Ca2+i] in final 
mature megakaryocytes and its effect for the correct physiology of these cells and final 
platelet production rate and function. Moreover, analysis of CALR protein levels during 
megakaryopoiesis by western blot analysis could help to shed light into the different effects 
of CALR mutants during this process.  
Analysis of physical manipulation of [Ca2+i] as a driving force for megakaryocyte 
differentiation provided highly interesting results. The use of CCBs for inhibition of SOCE, L-
type and NMDR receptors, showed the capacity of these drugs to induce megakaryocyte 
differentiation, although with high cytotoxicity. Therefore, investigation of the use of other L-
type and SOCE antagonist to reduce cytotoxicity could help to understand the role of Ca2+ 
during megakaryopoiesis in more reliable cell conditions. Additionally, analysis of inhibition 
of other Ca2+ channels within the membrane, such as Na+/Ca2+ exchangers or PMCA pump, 
could provide more data to reach a broader knowledge of the important role of the 
membrane Ca2+ channels and megakaryocyte formation.  
Moreover, this study hinted that L-type channels could have a key role for megakaryocyte 
formation. However, the role of L-Type channels has not been clearly described in 
megakaryocytes; therefore, further studies targeting the understanding of these channels 
within these cells could reveal important information of the Ca2+ dynamics of 
megakaryocytes.  
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CHAPTER 7: General Discussion 
 
7.1. Discussion  
 
ET, PV and PMF are rare myeloproliferative malignancies characterised by a neoplastic 
proliferation of mature myeloid cells (Rumi and Cazzola, 2017). These diseases are associated 
with an increased risk of mortality and a decrease quality of life in these patients (Mesa et al., 
2016).  Identification of the MPNs driver mutations in JAK2, c-MPL and CALR genes has led to 
an advance in our knowledge about the development of these malignancies. However, there 
is a clear need for a better understanding of the molecular and cellular pathology of these 
mutations to further improve individual patient outcome.  
The discovery of CALR mutations in ET and PMF has opened a new paradigm in the biology of 
MPNs (Klampfl et al., 2013; Nangalia et al., 2013).  Constitutive activation of MPL receptor 
driven by CALR mutant proteins is a novel mechanism of oncogenic transformation in MPNs 
(Araki et al., 2016; Chachoua et al., 2016; Elf et al., 2016). Despite the large body of research 
aiming to decipher the oncogenicity of CALR mutant proteins, very little is known about the 
effects of these mutations on the multiple CALR cellular functions. Therefore, this 
investigation has worked under the hypothesis that CALR mutations alter the physical 
characteristics of CALR C-terminal domain, and this not only leads to deregulated signalling 
cascades, but there is also a modification of CALR normal cellular behaviour, such as changes 
in its cellular compartmentalisation and its intracellular Ca2+ buffering activity during 
megakaryocyte hyperplasia.  
Structural analyses have been used to predict the molecular pathogenesis of mutations in 
disease (Khan and Vihinen, 2007). Minor variations in the amino acid sequence within a 
protein can result in  major consequences, including modifying or preventing the cellular 
function of the protein (Choi et al., 2012). To understand the molecular pathogenesis of 
MPNs, a particular focus has been placed on the analysis of the physical alterations within 
CALR C-terminal domain caused by CALR type 1 and type 2 mutations. Chapter 3 described in 
detail an in silico structural analysis of the C-terminal region of CALR wt, CALR type 1 and type 
2 mutants. This study has shown that CALR mutations lead to i) a decrease in the disorder 
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state, hence increasing the stability of C-terminal region, ii) an increase in the α-helix content, 
which are known to be interactive regions in other proteins, iii) an appearance of potential 
novel MoRFs regions, thus potentially modifying the function or interactions of CALR and iv) 
changes in the pI within C-terminal domain. The current data highlight the need to understand 
the changes in the structure-function relationship within these mutant proteins in order to 
decipher the genotype-phenotype correlation in ET and PMF. 
Sub-cellular mislocalisation of proteins can lead to their loss of function, deregulation of their 
activity or lead to a damaging activity within the wrong cellular compartment. Hence, 
abnormalities in the sub-cellular compartmentalisation of specific proteins can cause diseases 
that involve aberrant cell signalling or protein aggregation (Hung and Link, 2011). Several 
cancer types have been linked with abnormal protein localisation, such as breast (Xia et al., 
2004) and colon (Ogino et al., 2009) cancer, however in the pathogenesis of MPNs no driver 
mutations were known to lead to an oncogenic phenotype due to protein sub-cellular 
mislocalisation until CALR was found to be mutated in this type of myeloid neoplasms. CALR 
is a multi-compartment protein and the localisation of it highly correlates with its cellular 
functions (Michalak et al., 2009). Results within Chapter 5 suggested an escape of CALR from 
the ER and described an increase of CALR protein within the cell surface in CALR mutant cells. 
This change in localisation leads to a gain of function phenotype, as microscopy analyses 
revealed a co-localisation of CALR and MPL within the cell membrane, in accordance with 
previous publications (Araki et al., 2016; Chachoua et al., 2016; Elf et al., 2016).  These results 
led to the hypothesis that the described structural changes and the emergence of potential 
MoRFs regions within CALR C-terminal domain could be the direct cause of CALR-MPL binding, 
as this protein interaction is dependent only on this domain (Elf et al., 2016). Also, these 
structural and localisation alterations caused by CALR mutations could lead to a novel 
network of protein interactions, such as the previously proposed interactions with cellular 
kinases, including PKC, PKA or CDK5 (Eder-Azanza et al., 2014), which activation could 
potentially contribute to ET and PMF phenotype.   
Therapeutic treatment targeting protein mislocalisation has been proposed as a promising 
strategy in many human disorders, such as cancer or neurodegenerative diseases (Hung and 
Link, 2011).  Identification of CALR mutant in MPNs as a mislocalised protein with gain of 
function within the wrong cellular compartment is a novel example of how deregulated 
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protein localisation can lead to an oncogenic transformation. Understanding whether 
therapeutic treatment could reverse this mislocalisation and therefore its oncogenic 
interaction network could be a potent area of investigation to improve the treatment of CALR 
mutant ET and PMF. However, it is important to analyse further effects of CALR mutations on 
the functional roles of this protein, such as its Ca2+ buffering activity, to gain a broader 
understanding of the pathogenesis of CALR mutations for the development of novel 
therapeutic agents.  
During recent years there has been a growing interest of how deregulated components of 
Ca2+ signalling pathways contribute to an oncogenic transformation (Roderick and Cook, 
2008). However, whether the abnormal Ca2+ homeostasis is needed to sustain the oncogenic 
process remains to be established. There is very little published data about the effects of CALR 
mutations on the Ca2+ homeostasis in megakaryocyte cells during MPNs progression (Pietra 
et al., 2015). The present study makes several noteworthy contributions regarding CALR 
mutations and Ca2+. Chapter 6 describes an overall abnormal ER Ca2+ buffering activity and 
changes in [Ca2+i] in CALR mutant cells. It can thus be suggested that changes in the pI of CALR 
C-terminal domain and changes in the localisation of CALR mutant could be the direct cause 
of deregulated Ca2+ homeostasis during ET and PMF oncogenesis. Interestingly, differences in 
CALR expression levels have been linked with the development of many cancer types (Lu et 
al., 2015). For example, increased CALR expression enhances cell migration in bladder cancer 
cells (Lu et al., 2011) and squamous cell carcinoma (Chiang et al., 2013) by unknown 
mechanisms. However, this study shows evidences that deregulation CALR Ca2+ buffering 
activity could be a novel oncogenic mechanism of CALR during disease.  Moreover, results 
shown in this thesis contribute to the hypothesis that changes in [Ca2+i] are associated with 
pathological thrombopoiesis as previously described (Grosse et al., 2007). However, to 
develop a full picture of the role of CALR mutants and abnormal Ca2+ homeostasis in 
megakaryocyte hyperplasia, further work within this thesis aimed to gain a broader picture 
about the importance of [Ca2+i] during physiological megakaryocyte differentiation.  
Studies demonstrating an essential role of [Ca2+i] oscillations during erythrocyte, neuronal, 
osteocyte cell fate differentiation showed the relevance of Ca2+ homeostasis for a correct 
developmental process (Miller et al., 1988; Bikle et al., 2004; Sun et al., 2007; Gu et al., 1994). 
Several components of the regulatory network of Ca2+ signalling have proven to be necessary 
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for megakaryopoiesis and megakaryocyte function (Hitchcock et al., 2003, Di Buduo et al., 
2014, Kamal et al., 2015). However, there is no previous knowledge about the spatial and 
temporal dynamics of [Ca2+i] during megakaryocyte differentiation. Chapter 6 revealed a 
specific temporal pattern of [Ca2+i] oscillations during megakaryopoiesis. This study is pioneer 
in the description of Ca2+ dynamics during the megakaryocyte differentiation process; 
however, the molecular mechanism that leads to these [Ca2+i] oscillations remains unknown. 
Interestingly, alterations in the regulation of [Ca2+i] by ER Ca2+ proteins have been linked with 
a carcinogenic phenotype, such as altered IP3R expression (Mound et al., 2017; Singh et al., 
2017). Therefore, a tight control of [Ca2+i] by ER Ca2+ proteins during megakaryopoiesis could 
be key to suppress megakaryocyte hyperplasia.  
Understanding the regulatory mechanisms of Ca2+ dynamics is a major step to further improve 
our knowledge of the remodelling of Ca2+ during oncogenesis of CALR mutant MPNs. 
Intracellular Ca2+ regulation during megakaryopoiesis seems to be rather complex (Di Buduo 
et al., 2016). SOCE machinery, NMDAR and L-type channels have been described to be key 
cell membrane Ca2+ channels involved in megakaryocyte and platelet function (Di Buduo et 
al., 2014; Kamal et al., 2015; Hitchcock et al., 2003; Luckhoff et al., 1991). This study 
demonstrates that the use of CCBs targeting these three main channels leads to the 
emergence of megakaryocyte like characteristics in leukemic cells, such as expression of 
CD41a marker and upregulation of megakaryocyte like genes. Therefore, this investigation 
suggests that several Ca2+ entry pathways are involved in the regulation of megakaryocytic 
differentiation. In addition, these results propose that SOCE, NMDAR and L-type channel’s 
activity could support the leukemic phenotype, as their inhibition leads to an unblock of the 
blast undifferentiated phenotype. This hypothesis is supported by recent reports where Ca2+ 
signalling has been shown to play key roles in carcinogenesis (Prevarskaya et al., 2014; Wen 
et al., 2016), in addition to the previous data linking abnormal Ca2+ dynamics in CALR mutant 
cells.  Therefore, this study could have future clinical implications, suggesting the Ca2+ 
regulatory components as potential therapeutic targets in megakaryocytic pathologies.  
Analysis of megakaryocyte differentiation in ET and PMF is a major challenge in the 
understanding of MPNs pathologies (Balduini et al., 2011; Mondet et al., 2015). Previous 
investigations have studied the role of CALR mutations in megakaryocyte like cells (Pietra et 
al., 2015; Kollmann et al., 2016); however, there are no previous analysis of megakaryocyte 
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maturation in ET and PMF harbouring CALR mutation. This work has demonstrated the 
importance of studying the process of megakaryopoiesis in presence of CALR mutations, as 
the results presented here revealed that CALR mutant functions could differ between 
different megakaryocyte stages. This study has identified an overall increase of CALR cell 
surface population during induced megakaryocyte differentiation, suggesting that CALR 
cellular distribution might vary during megakaryopoiesis. Thus, as CALR mutant sub-cellular 
mislocalisation significantly differs between different stages of development, its functional 
role could also be altered following the megakaryocyte maturation process, such as its Ca2+ 
buffering activity. Moreover, this study demonstrated that Ca2+ dynamics significantly differ 
between different megakaryocyte differentiation stages in CALR mutant cells. Therefore, this 
investigation highlights the need of studying MPN driver mutations in the dynamic process of 
megakaryocyte differentiation in order to reach a better understanding of megakaryocyte 
hyperplasia and the defects of megakaryocyte maturation characteristic of ET and PMF 
positive for CALR mutations (Balduini et al., 2011; Loghavi et al., 2016).   
Myeloid leukemic cell lines have been widely used for the understanding of megakaryocyte 
differentiation (Tan et al., 2010; Datta and Long, 2002; Wang et al., 2016). However, there 
has been a lack of cellular models harbouring CALR driver mutations with capacity to 
differentiate into the megakaryocyte lineage that could be used to study megakaryocyte 
maturation in MPNs. Importantly; in this study MARIMO cell line has been proposed as a novel 
megakaryocyte differentiation model, which harbours CALR mutation (Kollmann et al., 2015). 
MARIMO cells, in response to PMA treatment displayed megakaryocyte like characteristics, 
such as increase in size, cell adherence, polyploidy and expression of megakaryocytic genes. 
This finding opens the possibility of studying the process of megakaryocyte differentiation 
under the presence of CALR mutations using basic cell culture techniques. 
The results of this thesis targeting the analysis of CALR mutant localisation and Ca2+ dynamics 
have been performed using cell lines with megakaryocyte-like characteristics or during the 
process of megakaryocyte differentiation. Additionally, this study is pioneer in using MARIMO 
cell line as a model of megakaryocyte differentiation in the study of CALR mutations. 
However, the use of cell lines has disadvantages when extrapolating the results to the MPN 
disease pathology (Iborra and Papadopoulos, 2017). Therefore, future work analysing the 
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effects of CALR mutations presented in this thesis should be cautious, as the studies displayed 
here need to be continued with human primary megakaryocytes from ET and PMF patients. 
 
7.2. Concluding remarks 
 
Structural characteristics of CALR C-terminal domain are affected by CALR exon 9 mutations 
found in MPNs. Changes in the physical properties of this mutant domain, together with the 
abnormal CALR mutant sub-cellular localisation described in this study, could be the base for 
the molecular and cellular understanding of novel protein interactions, such as MPL binding, 
and abnormal Ca2+ buffering activity during megakaryocyte hyperplasia.  
Intracellular Ca2+ regulation is highly important for megakaryocytic differentiation in 
physiological conditions and disease. CALR mutations affect this highly controlled regulation 
during megakaryocyte formation, by altering [Ca2+i] and ER Ca2+ buffering activity, suggesting 
that intracellular Ca2+ homeostasis plays an important role during the pathogenesis of MPNs 
harbouring CALR mutations.  
Establishment of MARIMO cell line as a novel model to study megakaryopoiesis in presence 
of CALR mutations opens the possibility of an easy accessible cellular model to study the 
pathogenesis of CALR mutant cellular functions during the process of megakaryocyte 
formation characteristic of ET and PMF. These results, together with the data shown in this 
thesis revealing the importance of analysing the different effects of CALR mutations during 
the process of megakaryocyte formation, lead to an innovative approach to study the 
pathogenic role of these driver mutations described in MPNs.  
Overall, these findings shed light into the effects of CALR mutations in the physical and 
functional characteristics of CALR in MPNs, describing new aspects of the oncogenic capacity 
of this driver mutation. This thesis helps to complete our understanding of CALR mutant 
cellular pathogenesis, which will be essential to reach a full interpretation of the clinical 
manifestations of ET and PMF patients harbouring CALR mutations.  
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7.3. Research limitations 
 
Although this study has achieved its aims, there were some technical limitations and 
shortcomings that should be highlighted. The study was conducted using several cell lines and 
therefore, the extrapolation of the obtained results to primary human megakaryocytes would 
be important for a correct interpretation of the effects shown in this study.  
The laboratory techniques used during this investigation displayed some limitations that 
should be taken into consideration. Cellular Ca2+ quantification was performed using flow 
cytometry. This technique is valid and has been used for this purpose (Kollmann et al., 2015), 
however, the use of fluorescent microscopy to register Ca2+ fluctuations in a continuous time 
frame could provide more detailed results than flow cytometry. During this project, several 
attempts were performed to use microscopy to measure the Ca2+ fluctuations in response to 
thapsigargin treatment; however the use of this technique was not successful due to 
limitations of the equipment.  
SYBR green, used for RT-QPCR, is reported to give background signal and false positives. 
However, during this study we carefully analysed and optimised primer efficiency as well as 
melting curves to ensure the amplification of a single product (see appendix 2).  
The use of bioinformatic tools to analyse the secondary structure of mutant CALR C-terminal 
domain displayed some imprecisions between different prediction servers. Although the 
obtained models showed good predictive ratios, the discrepancies described between 
different predictor tools confirmed the limitations of using in silico techniques. Thus, the 
models described here should be taken as preliminary models which should be used to 
perform further structure modelling analyses, possibly adding further variants that could 
affect its structure, such as physiological Ca2+ concentrations. Such models should be 
confirmed using X-ray diffraction and NMR spectroscopy analysis which were beyond the 
scope of the current study.  
Finally, extrapolation of the experimental results obtained during this study into a 
phenomenon in vivo, such as animal or clinical models, is an important point that required 
consideration. This will be essential to understand the importance of single molecular effect 
in a more complex model. 
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Appendices 
 
 
1. Ramachandran plots  
Best predicted I-TASSER structural models of CALR wt, CALR type 1 and CALR type 2 mutants 
were validated using PROCHECK server. Analysis was performed in the C-terminal domain of 
these proteins and therefore, residues were selected from 316 to the end of the amino acid 
chain. Then, the percentage of residues within the allowed, generous and disallowed regions 
was calculated. The following images display the obtained Ramachandran plots of each C-
terminal domain of the predicted structural models. 
 
 
 
A. CALR wt C-terminal domain Ramachandran plot (residues number 316-417) 
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B. CALR type 1 mutant C-terminal domain Ramachandran plot (residues number 316-
410) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C. CALR type 2 mutant C-terminal domain Ramachandran plot of CALR type2 mutant 
predicted model (residues number 316-428) 
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2. qRT-PCR Melting curves  
 
During qRT-PCR analysis, melting curves were performed in order to corroborate the 
amplification of a single DNA product and eliminate the possibility of false positives and 
primer dimer signal. Following images show examples of the obtained melting curves of each 
primer reaction used during this study: 
 
 
A. GAPDH: Obtained melting curve during GAPDH amplification.   
 
 
 
 
 
 
 
 
B. PIM1: Obtained melting curve during PIM1  amplification 
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C. ID1: Obtained melting curve during ID1 amplification 
 
 
D. SOCS2: Obtained melting curve during SOCS2 amplification 
 
 
E. CISH: Obtained melting curve during CISH amplification 
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F. cMPL: Obtained melting curve during cMPL  amplification 
 
 
 
3. Control assays of DAMI clones overexpressing CALR wt, type 1 and type 2 mutants. 
 
DAMI cells used in this study were transduced to overexpress CALR wt, type 1 and type 2 
mutants. GFP empty vector was used as a control to test the efficiency of transduction. 
Therefore, GFP expression within these cells was assed by flow cytometry and results showed 
expression of GFP within the whole DAMI population.  
 
                        
A. GFP fluorescence in DAMI control cells used in this study.  
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Moreover, quantification of CALR protein amount in DAMI clones was assed by western blot 
analysis. Following images show examples of the obtained blots:   
 
B. Clones 1. 
 
 
 
 
 
 
C. Clones 2.  
 
 
 
  
 
 
 
 
 
 
